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Abstract
Autism spectrum disorder (ASD) is a complex and heterogeneous disorder, and in the
vast majority of cases the etiology is unknown. However, there are many syndromes of known
genetic origin that have a high incidence of autism. These highly penetrant syndromic forms of
autism offer a unique opportunity for the study of ASD because animal models can be readily
engineered to carry the same genetic disruption. Animal models are crucial for understanding
neurological disorders at the biological level, and while these monogenic disorders are relatively
rare, their animal models are likely to prove indispensable in identifying common pathogenic
pathways in ASD and associated intellectual disability (ID). As evidence accumulates from
genetic and molecular studies, autism is increasingly being regarded as a disease of the synapse.
In particular, a preponderance of genes associated with ASD appear to regulate the synaptic
signaling pathways necessary for the proper control of neuronal protein synthesis. Here, we test
the hypothesis that many ASDs may result from alterations in synaptic protein synthesis by
examining neuronal translation in the mouse models of fragile X (FX) and tuberous sclerosis
(TSC), the two leading inherited causes of ASD. Specifically, we determined if altered synaptic
protein synthesis downstream of metabotropic glutamate receptor 5 (mGluR5) is a shared
disruption in these disorders, and therefore may ultimately contribute to the pathophysiology of
ASD in general. First, we show that multiple aspects of mGluR-mediated protein synthesis are
altered in the mouse model of FX, suggesting that exaggeration of these processes may account
for the diverse phenotypes associated with the disorder. Next, we demonstrate that disruptions in
the mGluR pathway do not appear to be limited to this FX, as there is diminished synaptic
protein synthesis and mGluR-LTD in a mouse model of TSC as well. This suggests that
genetically heterogeneous causes of ASD and ID may produce similar deficits through
bidirectional deviations in mGluR-mediated protein synthesis. Finally, we address the
mechanisms by which mGluR activation is coupled to protein synthesis, which may elucidate
novel avenues for the next generation of mGluR-based therapies for the treatment of ASD.
Thesis Supervisor: Mark F. Bear, Ph. D.
Title: Picower Professor of Neuroscience
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Chapter 1 - Synaptic pathophysiology in autism
1.1 Introduction
Autism spectrum disorder (ASD) is a severe neurodevelopmental condition characterized
by social disability, communication impairment, and repetitive/restricted behavior. It is one of
the most common neurodevelopmental disorders, affecting up to 1 in 100 people (Baird et al.,
2006; Newschaffer et al., 2007), and the direct and indirect medical costs associated with autism
are estimated to be more than $35 billion per year and rising (Ganz, 2007). In spite of this high
prevalence and substantial societal cost, effective therapeutic interventions for autism are
woefully lacking. The most common pharmacological treatments include antidepressants,
stimulants, and antipsychotics (Oswald and Sonenklar, 2007). The main goal of these current
treatments is to alleviate behavioral symptoms that interfere with an individual's daily
functioning, such as seizures, sleep disturbances, irritability, and hyperactivity (Broadstock et al.,
2007). However, most of these treatments are associated with their own adverse side effects.
Educational and behavioral interventions are also commonly applied to ASD management
(Myers and Johnson, 2007), however the evidence for the effectiveness of these therapies is
currently lacking and more data from randomized controlled trials is needed to properly assess
their efficacy (Warren et al., 2011). Currently there are no treatments directed at the core
disturbances of the disorder.
Developing effective treatments for autism and other psychiatric illnesses requires
understanding of their underlying pathophysiology. At this time, there is no known unifying
mechanism for ASD at the molecular, cellular or systems level. There are no therapies that
address the core disturbances in autism because we do not understand the cause of these
disturbances; the complexity of the disorder makes it difficult to study. This largely stems from
the highly heterogeneous nature of autism with regards to both its genetic underpinnings and
behavioral manifestations.
1.1.1 Phenotypic diversity in autism and ASD
An individual is defined as having ASD if they meet the diagnostic criteria for a
combination of 2 or more of a triad of symptoms: social disability, communication impairment,
and repetitive/restricted behavior (American Psychiatric, 2003). However, beyond this broad
definition there is an extreme degree of clinical heterogeneity in ASD. There are striking
differences in the expression of these core symptoms across the autistic population-ranging from
17
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mild to severe (Bailey et al., 1996). Additionally, there is much variability in the severity of
impairment between core disturbances within in an individual with ASD. Hence, autism
represents a spectrum of disorders spanning a broad continuum of severity and heterogeneity in
regards to phenotype (Abrahams and Geschwind, 2008). Compounding this phenotypic
heterogeneity is the fact that these symptoms are not static, but emerge with development and
progressively change over time. Furthermore, ASD often co-occurs with other neurological
conditions, such as intellectual disability (ID) and seizure disorders, which affect up to 70% and
25% of individuals with autism, respectively (Tuchman and Rapin, 2002). Other common
comorbid conditions include obsessive-compulsive disorder, attention deficit or hyperactivity
disorder, or gait and motor disorders (Levy et al., 2009). Thus, the core symptoms of ASD are
variably expressed, change over development, and are compounded by other related
comorbidities.
This phenotypic complexity has not only impeded the diagnosis of ASD, but has raised
questions about the diagnosis itself. There is debate as to the degree to which different aspects of
ASD signify: (1) entirely distinct entities; (2) disorders that have overlapping foundations; or (3)
different variants of one underlying disease (Geschwind and Levitt, 2007). It is difficult to
define these diagnostic boundaries because the pathogenic mechanisms of ASD are largely
unknown. In order to address these fundamental questions, research has recently focused on
defining the genetic etiology of ASD in hopes of understanding the disorder at its core. With the
rapid advance in human genetics and gene sequencing technology, there is an increasing
availability of genome-wide data for ASD (Abrahams and Geschwind, 2008). This information
has greatly advanced our knowledge of the pathophysiology of autism and has allowed for this
disorder to be examined at a molecular level.
1.1.2 Genetics ofAutism and ASD
Genetic risk factors are important in the causation of all major psychiatric disorders
(Kendler, 2005). ASD is among the most highly heritable psychiatric disorders, with mono- and
dizygotic twin studies estimating the heritability of ASD at over 90% and high occurrence rates
among siblings and other relatives (Bailey et al., 1996; Risch et al., 1999). Despite this strong
heritability, the genetics underlying autism are astoundingly complex. Recent gene association
and whole-genome linkage studies have implicated over one hundred genes and genetic loci in
18
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autism and ASD (Abrahams and Geschwind, 2008; Betancur, 2011; Freitag et al., 2010).
Despite this strong genetic component, identifying causative genetic factors for ASD has
remained elusive. Microscopically visible chromosomal alterations have been reported in ~ 5%
of ASD cases; the most frequent abnormalities are 15ql l-qI 3 duplications, and deletions of
2q37, 22q1 1.2 and 22ql3.3 (Betancur, 2011). Recent whole-genome microarray analyses have
discovered submicroscopic deletions and duplications, called copy number variations (CNVs),
affecting many loci and including de novo events in 5%-i 0% of ASD cases (reviewed in
(Betancur, 2011)). ASD can also result from mutations of single genes involved in autosomal
dominant, autosomal recessive and X-linked disorders (Table 1.1). It is now known that defined
mutations, genetic syndromes, and de novo CNVs account for 10-20% of ASD cases, however
none of these known causes individually account for more than 1-2% of ASD cases (Abrahams
and Geschwind, 2008; Geschwind and Levitt, 2007). Indeed, in the vast majority of instances
the etiology of ASD remains unknown.
Broadly speaking, the genetic etiology of ASD can be delineated into two categories: (1)
rare, highly penetrant single gene mutations that have a large causal effect; or (2) common
inherited functional variants that individually present a small risk factor but cumulatively can
have profound impact (Campbell et al., 2009; Levitt and Campbell, 2009). While evidence
suggests this latter multifactorial etiology may account for the majority of cases of ASD, it is the
rare, highly penetrant mutations associated with autism that have provided the best experimental
platform for studying autism at the molecular and cellular levels. In particular, the study of
syndromic forms of ASD has been influential in our understanding of ASD pathophysiology.
Syndromic autism refers to genetically well-defined disorders in which ASD is observed
at higher than expected frequencies (Table 1.1). The most common of these syndromes (GENE)
associated with ASD is fragile X (FMR1), accounting for 2-5% of cases of ASD. Other
monogenic disorders associated with ASD include tuberous sclerosis (TSC1, TSC2),
neurofibromatosis (NF1), Angelman syndrome (UBE3A), Rett syndrome (MECP2) and PTEN
mutations in patients with macrocephaly and autism (Table 1.1) (Betancur, 2011). Syndromic
forms of autism with highly penetrant single-gene mutations offer a unique opportunity for the
study of ASD because animal models can be readily engineered to carry the same genetic
disruption. Animal models are crucial for understanding neurological disorders at the biological
level, and while these monogenic disorders are relatively rare, their animal models are likely to
19
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prove indispensable in identifying common pathogenic pathways in ASD. Although genetic
mutations associated with ASD will undoubtedly manifest differently at the behavioral level in
animals and humans, it is reasonable to assume that disruptions in elementary neuronal functions
are likely to be shared across species.
While animal models of syndromic autism have become a powerful tool for studying the
pathophysiology of ASD at a mechanistic level, it is important to realize that none of these
etiologies is specific to autism. Each syndrome encompasses a variable proportion of individuals
with and without autism, and each possesses their own unique physiological symptoms.
Therefore, it is critical to define similarities and differences across these syndromes in order to
determine which underlying disruptions are specific to ASD. Cross comparison of animal
models for syndromic disorders and rare mutations associated with autism has the potential to
uncover shared molecular pathways/processes that may be central to autism pathophysiology.
Specifically, if there is a shared pathogenesis between these disorders, then it is reasonable to
assume the same pathogenic mechanism may be associated with autism of unknown etiology.
Not only will this aid our understanding of how these diseases are, or are not, related to each
other, but it will help determine if treatments developed for one disease may also be effective for
others, including idiopathic autism. The studies in this thesis were designed to determine if there
is shared molecular dysfunction in the two leading inherited causes of ASD, fragile X (FX) and
tuberous sclerosis (TSC).
1.2 The pathophysiology of ASD
Studies from animal models of autism, combined with advances in human genetic
research, present the best approach to addressing fundamental questions about the nature of
ASD. Below, the current thinking about the pathophysiology of ASD is briefly reviewed.
1.2.1 Developmental verses ongoing pathology in ASD
The early onset of ASD symptoms highlights the importance of development in the
pathophysiology of autism. Changes in brain development are undoubtedly important in autism
etiology, exemplified by a high prevalence of macrocephaly in children with ASD (Courchesne
et al., 2004). However, in the majority of cases of ASD, neuropathological studies point to only
minor and inconsistent abnormalities in brain size (Schumann et al., 2004). The delayed post-
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natal onset of ASD symptoms may lend insight into how brain development is altered. The
period in which ASD symptoms present themselves typically coincides with the time in which
synaptic sculpting (i.e. synapse formation, synapse pruning and myelination) takes place. It has
been suggested that autism may arise from more subtle deficits in brain development required for
establishing proper synaptic connectivity, such as neuronal migration and axon pathfinding
(Geschwind and Levitt, 2007). In particular, alterations in postnatally-regulated features of
dendritic development may be central to the pathogenesis of ASD (Zoghbi and Bear, 2012).
Indeed, evidence from both human and animal studies have found that there is a preponderance
of long, thin, immature dendritic spines in many forms of autism, suggesting arrested synaptic
development (Minshew and Williams, 2007).
The developmental nature of ASD emphasizes the need for early treatment intervention.
However, recent studies in animal models has shown that postnatal genetic and/or
pharmacological manipulations can reverse many behavioral symptoms, even when treatment
begins in adulthood (Ehninger et al., 2008a; Ehninger et al., 2008b; Guy et al., 2007; Michalon et
al., 2012). This presents the exciting possibility that, with the proper interventions, both the
pathophysiological and accompanying cognitive deficits of ASD might be ameliorated even in
adulthood. Furthermore, it suggests that the underlying molecular perturbations in ASD not only
affect development but may continue to influence behavior throughout an individual's lifetime.
Therefore, it is important to not only understand how synaptic development is altered in ASD,
but by what molecular mechanisms, as this will provide therapeutic targets not only important
for early intervention but that may remain valuable throughout an individual's lifetime.
1.2.2 Synaptic dysfunction in ASD
As evidence accumulates from genetic and molecular studies, autism is increasingly
being regarded as a disease of the synapse (Gilman et al., 2011; Kelleher and Bear, 2008;
Zoghbi, 2003; Zoghbi and Bear, 2012). A preponderance of highly penetrant mutations
associated with autism are in genes that are critical regulators of synaptic structure and function
(Table 1.1). Correspondingly, one of the most consistent findings in animal models of ASD is
disrupted synaptic function. Common deficits include altered synapse number and strength,
aberrant dendritic size and shape, and disrupted synaptic plasticity (Zoghbi and Bear, 2012).
Furthermore, studies of post-mortem human brain tissue have found the presence of aberrant
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dendritic structure and/or number in the brains of autistic patients (Hinton et al., 1991; Minshew
and Williams, 2007; Purpura, 1974). Intriguingly, it seems that deficits in synaptic structure and
function can be related to higher-level phenotypes seen in ASD and related disorders. Disrupted
synaptic function may lead to altered plasticity, which in turn may underlie the cognitive deficits
seen in these disorders. Altered synaptic number and function will affect the balance between
excitatory and inhibitory connections, which may lead to seizures, hyperactivity, and disruptions
in sensory processing. As research continues on the human genetics and animal models of
autism, a picture is emerging where there is a convergence of diverse genetic and molecular
perturbations on a common dysfunction that may account for the numerous deficits seen in ASD.
For all the variability in its genetic origins and phenotypic expression, synaptic dysfunction
appears to be the bottleneck through which autism pathology runs.
1.2.3 Synaptic structural proteins associated with ASD
Some of the earliest clues linking ASD to synaptic function were the discovery of
mutations in cell adhesion molecules (CAMs) and scaffold proteins that are essential to synaptic
integrity. Neuroligins are postsynaptic CAMs that mediate synapse formation between neurons
by interacting with their presynaptic counterparts, neurexins. While rare, mutations in
neuroligin3 (NLGN3) and neuroligin4 (NLGN4) (Jamain et al., 2003; Laumonnier et al., 2004;
Lawson-Yuen et al., 2008), as well as neurexinl (NRXN1) and neurexin2 (NRXN2) have been
shown to be highly penetrant risk factors for autism (Table 1.1, Figure 1.1) (Kim et al., 2008;
Zahir et al., 2008; Zweier et al., 2009). The neurexin-neuroligin trans-synaptic complex
organizes the pre- and postsynaptic compartments through interactions with various synaptic
scaffolding molecules. A prominent family of synaptic scaffolding molecules are the SH and
Ankyrin-domain-containing proteins (Shanks) (Sheng and Kim, 2000).
Shanks interact with other scaffolding proteins at the synapse to link multiple receptors
and signaling pathways, thereby regulating synaptic structure and function (Sheng and Kim,
2000). Of particular interest is the finding that Shanks can specifically interact with neuroligins
via SAPAPs (Figure 1.1). Mutations in both SHANK2 and SHANK3 have also been implicated
in autism (Berkel et al., 2010; Durand et al., 2007; Kim et al., 2008; Yan et al., 2005). In
particular, haploid deficiency in SHANK3 has been consistently identified as a causative factor in
Phelan-McDermid syndrome (PMS) (Bonaglia et al., 2006; Wilson et al., 2003), a developmental
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disorder with high rates of autism resulting from a microdeletion of chromosome 22ql 3 (Table
1.1) (Phelan and McDermid, 2012). As more genome-wide association studies are performed for
ASD, several other genes encoding for synaptic adhesion and scaffolding proteins have been
shown to be associated with ASD (Table 1.1). This suggests that there is an interconnected
network of structural proteins that modulate synaptic signaling, and perturbations at many points
along this network can result in the disrupted synaptic function implicated in autism.
Genetic studies in mice demonstrate that neuroligns, neurexins and Shanks are integral
for proper synaptic function. Deletion of Nlgn1 or Nlgn2 respectively results in impairment of
excitatory or inhibitory synaptic transmission, consistent with their localization (Chubykin et al.,
2007). Studies have also shown that mice lacking neurexins have decreased spontaneous and
evoked neurotransmitter release (Missler et al., 2003). Interestingly, neither neuroligin or
neurexin deletion results in alterations of synaptic number or structure, suggesting that while
they are essential for synaptic function, they are not involved in the initial formation of synapses
-an interesting observation in light of the developmental context of ASD symptoms. In animal
models, overexpression of Shank] or 3 results in increased maturation and size of dendritic
spines and can even induce the formation of functional spines in neurons that typically do not
possess them (Roussignol et al., 2005; Sala et al., 2001). Conversely, deletion of Shank] or 3
results in reduced spine density and decreased synaptic transmission (Hung et al., 2008; Peca et
al., 2011). Thus, altered expression or function of these proteins consistently results in excessive
or diminished excitatory synaptic transmission, leading to subsequent alterations in the balance
of excitation and inhibition.
Behavioral studies in these mutant mice provide evidence for a relationship between
alterations in synaptic function and ASD pathogenesis. Nlgn3 and Nlgn4 knock out (KO) mice
display several autistic-like behaviors, including impaired ultrasonic vocalization, altered social
interactions and/or impaired social memory (Jamain et al., 2008; Radyushkin et al., 2009).
Several different mutations of Shank3 result in behavioral deficiencies relevant to ASD as well,
such as excessive grooming and stereotyped behaviors, increased anxiety, and decreased social
interactions (Bozdagi et al., 2010; Peca et al., 2011; Wang et al., 2011). Of particular interest,
mice engineered to carry a specific mutation of Nlgn3 associated with ASD display both altered
synaptic transmission and impaired social interactions, demonstrating that recapitulation of
mutations that cause autism in humans also disrupt synaptic function and behavior in mouse
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models (Tabuchi et al., 2007). This mutation appears to actually increase inhibitory synaptic
functions, suggesting that both loss-of-function and gain-of-function mutations in neuroligins
can result in autistic-like behaviors in mice. Consistent with this idea, both deletions and
duplications spanning SHANK3 have also been reported in patients with ASD or ID (Durand et
al., 2007; Okamoto et al., 2007). This suggests that bidirectional changes in synaptic function
may contribute to the ASD phenotype.
The notion that some ASDs may be regarded as a disease of the synapse is a major
conceptual advance in the understanding of autism pathophysiology (Zoghbi, 2003; Zoghbi and
Bear, 2012). Yet major questions remain regarding how synaptic dysfunction arises, and what
the nature of these disruptions are. Despite the fact that numerous genes implicated in ASD are
involved in synaptic function, there is much heterogeneity to their exact role at the synapse
(Table 1.1, Figure 1.1). While studies on synaptic adhesion and scaffolding proteins have been
influential in directing attention to the synapse as a common pathology in ASD, mutations in
genes directly involved in synaptic formation and stabilization are still exceedingly rare
(Abrahams and Geschwind, 2008). However, studies on these rare mutations have highlighted
the importance of activity-dependent synaptic signaling in the pathophysiology of ASD. In
particular, mutations in these scaffolding and adhesion molecules possess a commonality -
disruption in glutamatergic signaling.
1.2.4 Synaptic signaling is disrupted in ASD
A defining feature of synapses is their ability to undergo activity-dependent changes.
These changes are mediated by synaptic receptors that act on a complex array of signaling
cascades (Figure 1.1). At excitatory synapses, two glutamate receptors have been strongly
implicated: (1) the calcium-permeable N-methyl-D-aspartate ionotropic receptor (NMDARs);
and (2) the Gq-coupled (group 1) metabotropic glutamate receptor (mGluR1 and mGluR5).
Synaptic adhesion and structural proteins organize these glutamate receptors at the postsynaptic
density (PSD), thereby regulating synaptic transmission and signaling (Sudhof, 2008; Tu et al.,
1999). Deletion/mutation of Nlgn1 or Shank3 in mice not only alters synaptic strength, but
disrupt the function of NMDARs and mGluRs as well (Bangash et al., 2011; Baudouin et al.,
2012; Peca and Feng, 2012; Varoqueaux et al., 2006). Alterations in synaptic activity have also
been shown to rapidly change the composition of the PSD (Ehlers, 2003) and activation of the
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signaling cascades downstream of these glutamatergic receptors can directly influence synapse
strength, number, and development (Barnes and Slevin, 2003; Kelleher et al., 2004). Thus, there
is a reciprocal relationship between activity-dependent signaling and structure at the synapse.
Importantly, many genes characterized by high penetrance for ASD are involved in the
signaling pathways downstream of glutamate receptor activation (Table 1.1, Figure 1.1)
(Kelleher and Bear, 2008; Levitt and Campbell, 2009; Peca and Feng, 2012). In particular, the
synaptic signaling pathways necessary for the regulation of neuronal protein synthesis appear to
be regulated by genes associated with ASD (Table 1.1, Figure 1.1) (Kelleher and Bear, 2008).
As discussed below, activity-dependent synaptic mRNA translation is essential for normal
synaptic function and development (Kelleher et al., 2004). Thus, despite the heterogeneity in
their function, there may be a common thread amongst the genes implicated in ASD. We
propose that altered activity-dependent regulation of neuronal protein synthesis is a prominent
convergence point in the synaptic pathophysiology of ASD.
1.3 The role of protein synthesis in neurons
The ongoing synthesis of new proteins is a fundamental process essential for the function
and survival of all cells. The importance of proper translational regulation is underscored by the
high degree of conservation in the cellular pathways that govern protein synthesis across species
and cell types (Rhoads, 1999). While translational regulation is a ubiquitous process in all cells,
the functional consequences of this protein synthesis varies by cell type, as different cells
perform different functions. Neurons are a particularly distinctive type of cell and as such, the
requirements for and consequences of protein synthesis are unique in many respects. Aside from
their ability to propagate action potentials, two defining features of neurons are their inability to
undergo cell division and their dramatic compartmentalization. These features greatly define
how protein synthesis is regulated in neurons, and what functions it serves.
1.3.1 Translational regulation of synaptic plasticity
In the majority of cell types, stimulating protein synthesis is typically associated with the
regulation of cell division and growth (Mathews, 2000). However, aside from a few specific
areas within the brain, mature neurons are fully differentiated and no longer divide. Neurons
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therefore utilize protein synthesis for different processes essential for ongoing neuronal function.
One of the most important functions of neurons that requires translation is the maintenance of
long-lasting changes in synaptic efficacy, i.e. synaptic plasticity (Kelleher et al., 2004). Synaptic
plasticity is the ability of neurons to alter the strength and/or number of their synaptic
connections in an experience-dependent manner. These changes in synaptic efficacy are thought
to underlie long-term changes in neural circuits and thus modify behavior. In particular, synaptic
plasticity is thought to be the cellular/molecular correlate of learning and memory, as they share
many of the same mechanisms for expression, including the requirement of de novo protein
synthesis (Flexner et al., 1963; Gkogkas et al., 2010).
The hippocampus has long been implicated in playing an important role in memory
formation and has been used as a model system for the study of synaptic plasticity and its protein
synthesis-dependency (Morris et al., 2003). Although not limited to this structure, much of our
understanding of the mechanisms which support experience-dependent synaptic plasticity have
come from studies in the hippocampus. Long-term potentiation (LTP) and long-term depression
(LTD) are well-characterized forms of synaptic plasticity associated with learning and memory.
While these persistent changes in synaptic strength can be induced by a variety of manipulations
and their expression mechanisms are diverse, the long-term maintenance of most forms of LTP
and LTD requires the synthesis of new proteins (Gkogkas et al., 2010). Interestingly, it seems
that many of the signaling pathways that regulate cell division and growth in other cell types
have been adapted for the regulation of protein-synthesis dependent plasticity in neurons (see
section 1.3.3) (Kelleher et al., 2004). Alteration of synaptic strength is an energy intensive
process, and it has been suggested that competition for translation machinery may be a limiting
factor in the maintenance of long-term plasticity (Fonseca et al., 2004; Govindarajan et al.,
2011). The maintenance of long-term changes in synaptic strength is also associated with
alterations in the structure and/or number of synapses (Tada and Sheng, 2006). Thus, the proper
regulation of protein synthesis in neurons is essential for synaptic plasticity, and disruptions in
the signaling pathways that regulate translation will undoubtedly affect synaptic structure and
function.
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1.3.2 Local synaptic control ofprotein synthesis
Another aspect of neurons that makes the regulation of translation unique is their high
degree of compartmentalization. Most neurons have elaborate dendritic processes consisting of
thousands of synapses with well-defined patterning that are located distally from the cell soma.
One of the hallmarks of synaptic plasticity is input-specificity, whereby changes in synaptic
strength induced at a particular set of synapses do not spread to other synapses. This poses a
unique challenge for the cell-wide synthesis of new proteins to be properly transported only to
synapses undergoing plastic changes. Traditionally, transcription and translation were thought to
be tightly coupled processes that occur in the cell soma (Kelleher et al., 2004). Therefore,
translation was originally thought to play a permissive role in synaptic plasticity. Recently
however, it has been shown that many messenger (m)RNAs are trafficked to dendrites, where the
required translation machinery is also present (Steward and Levy, 1982), suggesting an
additional role for local synaptic control of protein synthesis (Steward and Schuman, 2001).
This compartmentalization of translation is intriguing as it provides a mechanism for maintaining
the input-specificity of long-lasting changes in synaptic efficacy that require new protein
synthesis.
While the roles of somatic transcription and translation in synaptic plasticity have been
well-characterized (Kandel, 2001 a), the importance of synaptically localized translation has only
recently been explored (Sutton and Schuman, 2006). Indeed, activity-dependent translation of
pre-existing dendritic mRNA at the synapse is necessary for the expression of multiple forms of
synaptic plasticity (Bradshaw et al., 2003; Cracco et al., 2005; Huber et al., 2000; Kang and
Schuman, 1996; Miller et al., 2002; Smith et al., 2005). This is evidenced by their dependence
on translation but not transcription, and the ability to maintain these modifications via new
translation in dendrites isolated from the parental soma (Huang et al., 2005; Huber et al., 2000;
Kang and Schuman, 1996; Vickers et al., 2005). Many proteins necessary for the maintenance of
synaptic plasticity and dendritic spine formation/remodeling have been shown to be locally
synthesized at the synapse (Lee et al., 2005; Tiruchinapalli et al., 2003) and activation of local
protein synthesis has been shown to affect spine morphology (Vanderklish and Edelman, 2002).
Thus, the local regulation of translation may be particularly important for the proper function of
synapses. Interestingly, the mRNA for many of the synaptic scaffolding molecules implicated in
autism are present at the synapse and undergo activity-dependent local translation (Bockers et
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al., 2004; Lee et al., 2005; Todd et al., 2003), thereby directly linking activity-dependent
synaptic translation and disrupted synaptic function in ASD.
1.3.3 Pathways regulating neuronal translation are disrupted in ASD
In order to fully understand the potential role of local protein synthesis in normal brain
function and disease pathophysiology, it is imperative to understand the molecular mechanisms
by which synaptic activity governs this process. While the involvement of neuronal protein
synthesis in the maintenance of synaptic plasticity and memory has been known for decades
(Flexner et al., 1963), only recently have we begun to elucidate the requisite upstream signaling
pathways. Two intracellular signaling cascades are prominently implicated in the regulation of
neuronal protein synthesis: (1) the mammalian target of rapamycin (mTOR) pathway; and (2) the
extracellular signal-regulated kinase (ERK) pathway (Figure 1.1). Recent work has established
that the ERK and mTOR signaling pathways couple synaptic activity to the translational
machinery during both protein synthesis-dependent LTP and LTD (reviewed in (Kelleher et al.,
2004)).
Initiation is typically considered the rate-limiting step for protein synthesis, and therefore
serves as a major target for translational control (Richter and Sonenberg, 2005). Both the mTOR
and ERK pathways can stimulate global translation by regulating components of initiation
(Figure 1.2A) (reviewed in (Costa-Mattioli et al., 2009)). Initiation factors (eIFs) recognize the
5' cap of an mRNA and promote the formation of a ribosomal complex that can scan for the
initiation codon to begin translation (Figure 1.2A). The mTOR and ERK pathways can regulate
this step by phosphorylation of eIF4E binding proteins (4E-BPs). Under basal conditions, 4E-
BPs bind and sequester eIF4E to inhibit translation. When phosphorylated, they release eIF4A
allowing for the initiation of translation (Figure 1.2A).
The mTOR pathway can also regulate initiation through activation of the p70 ribosomal
protein S6 kinases (S6Ks) leading to S6 and eIF4B phosphorylation, however the relevance of
S6K activation in stimulating translation remains unclear (Hay and Sonenberg, 2004). The ERK
pathway has also been shown to regulate translation by phosphorylation of several components
of the initiation complex, including the ribosomal protein S6 and eIF4B via ribosomal S6 kinases
(RSKs) as well as eIF4E via MAPK-interacting kinase (MNK) activation (Figure 1.1, 1.2A)
(reviewed in (Costa-Mattioli et al., 2009)). MNK-dependent phosphorylation of eIF4E decreases
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its affinity for the cap structure yet is still positively correlated with translation rates. It has been
hypothesized that eIF4E phosphorylation is associated with translation of a specific subset of
mRNAs as opposed to bulk translation (Costa-Mattioli et al., 2009), suggesting that the ERK
pathway can regulate translation in a gene-specific manner. Both pathways can also regulate
translation at the elongation step, where elongation factors (eEFs) promote the binding of an
amino acid bearing transfer (t)RNA to their corresponding mRNA codons and catalyze the
synthesis of polypeptide chains (Figure 1.2B). The major regulatory step for elongation is
phosphorylation of elongation factor 2 (eEF2) by its kinase (eEF2K), which suppresses
elongation (Mathews, 2000). RSK and S6K activation have been shown to inhibit the eEF2K,
thus relieving eEF2 of this suppression and promoting elongation (Figure 1.2B).
The relative contributions of the ERK and mTOR pathways to the regulation of protein
synthesis have been difficult to disentangle. Both pathways have been shown to converge on
many of the same targets, and it has been suggested that they can have a synergistic effect on
translation (Banko et al., 2006). Consistent with this idea, the activation of many receptors has
been shown to recruit both the ERK and mTOR pathways (Rozengurt, 2007; Sengupta et al.,
2010). However, in many cases, one pathway is activated preferentially over the other,
demonstrating that these pathways can also diverge and operate in parallel (Clerk et al., 2006;
Weng et al., 2001). Furthermore, there are many instances of cross-talk between the two
pathways, both inhibitory and promoting, suggesting a complex relationship between their
signaling (Mendoza et al., 2011). Thus ERK and mTOR represent parallel yet interconnected
pathways for regulating protein synthesis, involving many positive and negative feedback
mechanism that result in several points of convergence and divergence.
Intriguingly, a number of mutations associated with high rates of autism fall along the
pathways that regulate neuronal protein synthesis (Table 1.1, Figure 1.1) (Kelleher and Bear,
2008). Tuberous sclerosis (TSC) is a neurodevelopmental disorder with a high prevalence of
ASD (25-60%) caused by mutations in either the TSC1 or TSC2 gene (see Chapter 3) (Wiznitzer,
2004). TSC 1 and 2 form a complex that inhibits the rapamycin-sensitive mTOR-raptor complex
(mTORC 1) and deletion of TSC1 or 2 leads to enhanced mTORC 1 activity (Kwiatkowski and
Manning, 2005). An upstream regulator of mTORC 1, the phosphoinositide-3 kinase (P13K), has
also been linked to ASD. Loss-of-function mutations in the PTEN phosphatase, a negative
regulator of P13K (Georgescu, 2010), are responsible for a family hamartoma-tumor syndromes
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associated with ASD (up to 20%) (Butler et al., 2005). Neurofibromatosis 1 (NFl) is another
neurodevelopmental disorder with abnormally high rates of ASD caused by mutations in the NFl
gene (Boyd et al., 2009). The NFl gene product, neurofibromin, is an inhibitor of the small
GTPase Ras, which is a critical upstream regulator of the ERK pathway (Williams et al., 2009).
Several other components of the Ras-ERK pathway are also risk factors for both syndromic and
idiopathic ASD (Table 1.1, Figure 1.1), suggesting that the ERK pathway may also be central to
ASD pathophysiology (Betancur, 2011; Samuels et al., 2009).
The observation that many mutations in the ERK and mTOR pathways are
independently associated with ASD strongly implicates these pathways in the pathogenesis of
ASD. The role of these pathways in neuronal protein synthesis and synaptic plasticity suggests
that defects in translational regulation may represent a shared mechanism underlying synaptic
dysfunction, and consequently contribute to ASD pathophysiology. The role of neuronal
translation in autism pathology is further underscored by disorders that directly impact protein
synthesis rates or protein levels at the synapse (Table 1.1, Figure 1.1). Fragile X (FX), the
leading inherited cause of ASD, results from the loss of the fragile X mental retardation protein
(FMRP) (Pieretti et al., 1991; Verkerk et al., 1991). FMRP is an mRNA binding protein that
represses translation, and exaggerated synaptic protein synthesis in the absence of FMRP is
generally regarded as pathogenic in this disorder (see Chapter 2) (Garber et al., 2008).
Angelman syndrome is thought to result from the loss of UBE3A (Kishino et al., 1997; Matsuura
et al., 1997), an E3 ubiquitin ligase essential for the degradation of proteins in neurons and
therefore likely to modify synaptic protein levels (Greer et al., 2010). Rett syndrome is caused
by loss-of-function mutations in the methyl-CpG binding protein 2 (MeCP2), which can function
as both a transcriptional activator and repressor, thereby bidirectionally altering neuronal mRNA
and, subsequently, protein levels (Moretti and Zoghbi, 2006).
The disruptions observed in the above disorders suggest a convergence of diverse
molecular triggers on a common disease-causing pathway: synaptic protein synthesis. While
syndromic forms of ASD have pointed to disrupted synaptic protein synthesis in its
pathophysiology, it is interesting to speculate that this dysregulation may be involved in many
idiopathic forms of autism as well. The regulation of translation is exquisitely complex; thus,
there are many regulatory points along this pathway that when altered could disrupt proper
neuronal function. An intricate system like this may be vulnerable to an accumulation of multiple
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genetic perturbations that on their own have minimal effect, similar to the multifactorial genetic
etiology thought to underlie many forms of ASD.
The notion that many ASDs may result from alterations in synaptic protein synthesis is a
testable hypothesis and this thesis will determine if, and how, neuronal translation is altered in
two prominent mouse models of ASD, the Fmr1 KO and Tsc2+' mouse. Activity-dependent
gene expression is essential for proper synaptic function, neural circuit performance, and
cognitive and behavioral competency. If there is indeed a shared disruption of synaptic protein
synthesis in these mouse models of ASD, it suggests that this dysregulation may ultimately
contribute to the cognitive deficits associated with ASD, and that targeting this process may
serve a potential treatment not only for FX and TSC, but also for ASD of unknown etiology.
1.4 Dissecting the role of metabotropic glutamate receptors in ASD
If altered neuronal protein synthesis is indeed a shared deficit in ASD it suggests a host of
potential therapeutic targets. In fact, targeting the ERK and mTOR pathways has recently shown
promise in the treatment of several ASD-associated disorders (Ehninger et al., 2008a; Li et al.,
2005; Osterweil et al., 2013). However, many components of the pathways that regulate
neuronal protein synthesis are ubiquitously expressed in all cell types and are important for basic
processes such as cell cycling and growth (Cargnello and Roux, 2011; Tee and Blenis, 2005).
Thus, global manipulation of these pathways may cause potentially severe side effects. The ideal
target would be a neuronal receptor-based therapeutic that specifically modulates synaptic
signaling while maintaining the proper activity-dependent properties of the synapse.
The activity-dependent translation of pre-existing mRNAs at the synapse is mediated by
many signals, including growth factors and neuromodulators, acting on a variety of receptors
(Steward and Schuman, 200 1). As mentioned above, the two most prominent regulators of cell
signaling at excitatory synapses are the NMDAR and group 1 (Gp 1) mGluRs, and these receptors
have been strongly implicated in the regulation of synaptic protein synthesis as well (Gkogkas et
al., 2010). Due to their wide expression pattern and post-natal abundance, these glutamate
receptors are promising therapeutic targets for regulating synaptic protein synthesis. Gp 1
mGluRs, in particular the mGluR5 subtype, is a widespread and potent regulator of local
dendritic protein synthesis (Job and Eberwine, 2001; Weiler and Greenough, 1993), and mGluR-
dependent translation has been show to play a role in many forms of synaptic plasticity (Pfeiffer
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and Huber, 2006). There is also a well-developed class of pharmacological agents that modulate
mGluR function in receptor subtype-specific and activity-dependent manners (Conn et al., 2009)
(see Chapter 4). While there are many processes that can modulate synaptic protein synthesis,
we propose that targeting mGluRs, specifically mGluR5 (the predominant subtype in the
forebrain and hippocampus (Masu et al., 1991)), is a promising treatment strategy for ASD due
to their wide-expression, amenability to drug targeting, and prominent role in regulating
dendritic protein synthesis.
A particularly compelling example of a form of plasticity requiring local translation is
mGluR-dependent LTD (mGluR-LTD) in the CA1 region of the hippocampus. Activation of
Gp 1 mGluRs, either synaptically by paired-pulse low-frequency stimulation (PP-LFS) or
chemically with the selective agonist (S)-3,5-dihydroxyphenylglycine (DHPG), results in a
persistent decrease in synaptic strength that is mechanistically distinct from classical NMDAR-
dependent LTD (Oliet et al., 1997). NMDAR-LTD can be maintained for several hours solely
by post-translational modifications; in contrast, the maintenance of mGluR-LTD requires rapid
protein synthesis within minutes of its induction (Hou et al., 2006; Huber et al., 2000). This
protein synthesis is likely to be synaptic in nature, as mGluR-LTD can still be induced in the
apical dendrites of CA1 pyramidal neurons even if they are physically severed from the cell body
layer (Huber et al., 2000). mGluR-LTD is expressed, in part, by the removal of a-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors from synapses, which also
requires rapid de novo translation (Snyder et al., 2001). Furthermore, activation of group 1
mGluRs rapidly stimulates protein synthesis in hippocampal slices (Osterweil et al., 2010), and
specifically in dendrites and synaptoneurosomes (Job and Eberwine, 2001; Weiler and
Greenough, 1993). Thus, mGluRs are not only a promising target for the modulation of synaptic
protein synthesis, but mGluR-LTD is a sensitive functional read-out of dendritic translation as
well. In this sense, mGluR-LTD can be used as a tool for monitoring alterations in synaptic
protein synthesis levels resulting from mutations associated with ASD.
We have proposed that mGluR signaling is an avenue to both manipulate and monitor
dendritic translation rates. However, several lines of evidence suggest that alterations in mGluR-
dependent synaptic protein synthesis may specifically contribute to the pathophysiology of ASD.
First, many of the mutations associated with autism fall along the pathways required for mGluR-
mediated protein synthesis (Figure 1.1). Both the mTOR and ERK pathways have been shown
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to couple mGluRs to translation machinery and have been implicated in the expression of
mGluR-LTD (Gallagher et al., 2004; Hou and Klann, 2004). Second, a major function of the
structural proteins disrupted in ASD is to anchor glutamate receptors at the synapse (Figure 1.1)
(Sala et al., 2001), and deletion of these proteins has explicitly been shown to disrupt mGluR
function in several contexts (Bangash et al., 2011; Baudouin et al., 2012; Ronesi and Huber,
2008; Verpelli et al., 2011; Wan et al., 2011). Third, it is well-established that exaggerated
mGluR5 function is causally linked to the pathophysiology of FX (see Chapter 2) (Bear et al.,
2004). Findings from the FX field of study have been particularly influential in demonstrating
the importance of mGluR function in ASD and the potential of mGluR modulators for treatment
(Krueger and Bear, 2011). Finally, human genetic studies have found that the protein products
of many genes associated with ASD are either targets of FMRP or are embedded in the mGluR
signaling pathway (Figure 1.1) (Iossifov et al., 2012; Kelleher Iii et al., 2012). In fact, a recent
study has identified the gene encoding mGluR5 (GMR5) itself as a risk factor for ASD (Skafidas
et al., 2012). Thus, mGluR-mediated protein synthesis may be a common molecular pathway
disrupted in ASD, further supporting mGluR5 as a promising target for treatment.
The studies presented in this thesis are designed to dissect the nature and expanse of
disrupted mGluR function in the pathophysiology of ASD. In the next chapter, we demonstrate
that multiple consequences of mGluR-stimulated protein synthesis are altered in the mouse
model of FX, and thus may generally contribute to the pathogenesis of FX. In Chapter 3, we
show that disruptions in this pathway are not limited to FX, but that mGluR function is altered,
albeit in a surprising manner, in a mouse model of TSC, another prevalent disorder associated
with ASD. Results from this study suggest there is an optimal range of synaptic protein
synthesis and that deviations in either direction can adversely affect neuronal function.
Furthermore they suggest that opposing perturbations in synaptic function may manifest
similarly in cognitive impairment and autistic traits. In the final chapter, we address the
mechanisms by which mGluR activation is coupled to protein synthesis, which may elucidate
novel avenues for the next generation of mGluR-based therapies for the treatment of ASD.
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Translation repressor Pragile X Syndrome (Garber et al., 2008)
MECP2 Chromatin Rett Syndrome (Amir et al., 1999)
Remodeling
UBE3A Ubiquitination Angelman Syndrome (Glessner et al., 2009)
MEF2C Transcription factor ASD (Le Meur et al., 2010)
RFWD2 Ubiquitination ASD (Glessner et al., 2009)
Table 1.1 - Genes associated with high risk for ASD. Validated genes with highly penetrant
(although rare) mutations associated with ASD (Toro et al., 2010). This includes many
syndromic forms of ASD. Orange corresponds to genes involved in synaptic structure and
formation, blue corresponds to genes involved in synaptic signaling, and yellow corresponds to
genes involved with regulation of mRNA and protein abundance (see Figure 1.1).
FMR1
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Dendritic
spine
MECP
UBE3A -- Plasticity proteins
Figure 1.1 - Highly penetrant mutations associated with autism converge at the synapse.
Recent genetic evidence suggests that many genes associated with ASD are involved in the
regulation of synaptic function, and in particular, the regulation of local mRNA translation at the
synapse. While not exhaustive, the function of these genes can be classified into several groups:
synaptic structural and cell adhesion molecules (orange), synaptic signaling molecules (blue), or
molecules involved in regulating mRNA and protein abundance (yellow). Molecules outlined in
red have been shown to specifically affect mGluR function. See Table 1.1 for more details.
Abbreviations: 4E-BP, eIF4E binding protein; AMPAR, a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor; Ca , intracellular calcium; eIF4E, eukaryotic initiation factor 4E;
ERK1/2, extracellular signal-regulated kinase 1/2; FMRP, fragile X mental retardation protein; MeCP2,
methyl-CpG binding protein 2; MEK, Mitogen-activated protein kinase kinase; mGluR, metabotropic
glutamate receptor; MNK1/2, MAP kinase-interacting kinase 1/2; mTOR mammalian target of
rapamycin, NF 1, neurofibromatosis 1; NLGN neuroligin; NMDAR, N-methyl-D-aspartate receptor;
NRXN, neurexin; P13K, phosphatidylinositide 3-kinase, PIKE-L, P13K enhancer long isoform; PSD-95,
postsynaptic density protein 95; PKD1/2, phosphoinositide-dependent kinase 1/2; PTEN, phosphatase
and tensin homolog; RSK, ribosomal s6 kinase; SAPAP3, SAP90/PSD-95-associated protein; SHANK,
SH3 and multiple ankyrin repeat domains protein; SYNGAP, synaptic Ras GTPase-activating protein;
TSC, tuberous sclerosis complex; UBE3A, Ubiquitin-protein ligase E3A.
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Figure 1.2 - General and gene-specific mechanisms for translation initiation and
elongation. (A) Formation of the eIF4F initiation complex requires eIF4E binding to the 5' cap
of an mRNA, which then recruits the large 60S ribosomal subunit through an interaction with
eIF4G. 4E-BP sequesters eIF4E, preventing formation of the initiation complex. mTOR
phosphorylates 4E-BP, decreasing its affinity for eIF4E, and thereby promoting formation of the
initiation complex and translation. The ERK pathway can directly phosphorylate eIF4E via its
downstream effector MNK, which may decrease general translation rates but enhance translation
of specific mRNA (Costa-Mattioli et al., 2009). eIF2 associates with the small 40S ribosomal
subunit in its GTP-bound form and the initiator methionyl-tRNA (Met-tRNA), forming a ternary
complex that can recognize the AUG initiation codon and begin translation. Phosphorylation of
the a subunit of eIF2 inhibits this formation and causes a decrease in general translation
initiation, but once again may increase translation of some mRNA. While cap-dependent
initiation is considered the general way that translation is mediated, this gene-specific translation
may be mediated by initiation via upstream open reading frames (uORFs) on the 5' untranslated
region (UTR) or internal ribosome entry sequences (IRES) (see Chapter 3) (Costa-Mattioli et al.,
2009). (B) Once translation is initiated, polypeptide elongation is promoted by the elongation
factors eEF I and eEF2. eEFIa is required for peptide (orange circle) containing tRNA entry into
the ribosome. eEF2 catalyzes the translocation of the ribosome on the mRNA after peptide bond
formation. The major mechanism for regulating elongation is phosphorylation of eEF2 by its
kinase (eEF2K), which results in a decrease in general translation. Both the mTOR and ERK
pathways have been implicated in regulating elongation by inhibiting eEF2K, however the
relationship is complex (Mathews, 2000). Interestingly, mGluR activation has been shown to
activate eEF2K, potentially through its interaction with Homer, and suppress general elongation
while enhancing translation of a specific subset of mRNA (see Chapter 3) (Park et al., 2008).
Upon recognition of the UAG stop codon, termination factors promote release of the polypeptide
chain from the mRNA and ribosome. This entire process is typically performed on mass scale,
with multiple ribosomes rapidly and repeatedly translating an mRNA simultaneously in
polyribosomal complex.
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Chapter 2
Multiple facets of metabotropic glutamate receptor-mediated protein
synthesis are disrupted in the mouse model of Fragile X
Portions of this chapter were published with Dr. Mark F. Bear in Journal ofNeurophysioloy
(2010) Vol. 104, pp. 1047-1051.
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2.1 Abstract
Fragile X (FX), the most common inherited form of intellectual disability and ASD, is
caused by the loss of the fragile X mental retardation protein (FMRP). FMRP is a negative
regulator of local mRNA translation downstream of group 1 metabotropic glutamate receptor
(Gp 1 mGluR) activation. In the absence of FMRP there is excessive mGluR-dependent protein
synthesis, resulting in exaggerated long-term synaptic depression (LTD) in area CA1 of the
hippocampus. Understanding disease pathophysiology is critical for development of therapies
for FX, and the question arises of whether it is more appropriate to target excessive LTD or
excessive mGluR-dependent protein synthesis. Priming of long-term potentiation (LTP) is a
qualitatively different functional consequence of Gp 1 mGluR-stimulated protein synthesis at the
same population of CAl synapses where LTD can be induced. Therefore, we determined if LTP
priming, like LTD, is also disrupted in the Fmr1 KO mouse. We found that mGluR-dependent
priming of LTP is of comparable magnitude in WT and Fmr] KO mice. However, while LTP
priming requires acute stimulation of protein synthesis in WT mice, it is no longer protein
synthesis dependent in the Fmr1 KO. These experiments show that the dysregulation of mGluR-
mediated protein synthesis seen in Fmrl KO mice has multiple consequences on synaptic
plasticity, even within the same population of synapses. Furthermore, it suggests that there is a
bifurcation in the Gpl mGluR signaling pathway, with one arm triggering synaptic modifications
such as LTP priming and LTD, and the other stimulating protein synthesis that is permissive for
these modifications.
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2.2 Introduction
Fragile X (FX) is the most common inherited form of intellectual disability (ID) and the
leading known genetic cause of autism (Garber et al., 2008). A third of FX individuals are
diagnosed with autism, accounting for 2-5% of the autistic population (Garber et al., 2008). The
disease is typically caused by expansion of a CGG triplet repeat sequence upstream of the FMR1
gene that results in transcriptional silencing and consequent loss of the fragile X mental
retardation protein, FMRP (Garber et al., 2008; Pieretti et al., 1991). A key advance in our
understanding of FX was the isolation of the FMR1 gene and subsequent generation of the Fmr1
knockout (KO) mouse (1994). This mouse model has been cardinal to our understanding of the
molecular mechanisms of FX and the function of FMRP in the brain. Studies of the Fmr] KO
mouse have demonstrated the role of aberrant synaptic protein synthesis in the pathophysiology
of FX, and have specifically implicated disrupted mGluR-mediated plasticity and protein
synthesis. Furthermore, these studies have highlighted the potential for modulation of mGluR5
signaling in the treatment of FX and, potentially, other autism-related disorders.
2.2.1 Regulation ofprotein synthesis by FMRP
Several lines of evidence suggest a role for FMRP in the regulation of synaptic protein
synthesis. First, FMRP is an RNA-binding protein and a repressor of translation. FMRP
associates with mRNAs through one of three RNA-binding domains (Ashley et al., 1993; Siomi
et al., 1993), in some cases in conjunction with adaptor proteins (El Fatimy et al., 2012; Napoli et
al., 2008). There is evidence that FMRP can repress translation both by blocking initiation and
elongation (Bhakar et al., 2012; Santoro et al., 2012). Second, FMRP has been shown to
associate with polyribosomes throughout the neuron, including dendrites and spines (Antar et al.,
2004; Feng et al., 1997), and many mRNA targets of FMRP are dendritically localized and are
important for the regulation of synaptic plasticity and dendritic structure (Brown et al., 2001;
Feng et al., 1997; Khandjian et al., 2004; Laggerbauer et al., 2001; Lu et al., 2004; Todd et al.,
2003; Weiler et al., 2004; Zalfa et al., 2003). Third, basal protein synthesis rates are significantly
elevated in the brains of Fmr] KO mice (Dolen et al., 2007; Osterweil et al., 2010; Qin et al.,
2005). Moreover, synaptoneurosomes obtained from Fmr] KO brains have increased protein
levels of many FMRP targets, such as Map 1 b, CaMKIIa and Arc, as well as higher levels of
these mRNAs in polyribosomal fractions. This suggests that the excess protein synthesis is
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synaptic in nature (Zalfa et al., 2003). Finally, FMRP is required for the proper expression of
synaptic plasticity that requires local synaptic translation, specifically downstream of mGluR
activation.
Activation of group 1 (Gp 1) mGluRs has been shown to trigger dendritic mRNA
translation, including the synthesis of FMRP (Weiler and Greenough, 1993, 1999). In the
hippocampus, one functional consequence of activating Gp 1 mGluRs is induction of long-term
synaptic depression (LTD) at the Schaffer collateral-CAl synapse (Huber et al., 2001; Oliet et
al., 1997; Palmer et al., 1997), expressed in part by a loss of postsynaptic AMPA-type glutamate
receptors (Snyder et al., 2001; Waung et al., 2008) (see Chapter 1). In wild-type (WT) rats and
mice, mGluR-stimulated protein synthesis is obligatory for stable expression of LTD (Huber et
al., 2000; Huber et al., 2001). This led to the investigation of mGluR-LTD in Fmr1 KO mice,
under the assumption that FMRP was important for the expression of LTD. Surprisingly, LTD
magnitude is enhanced rather than deficient in the Fmr1 KO mouse, possibly due to exaggerated
protein synthesis (Huber et al., 2002). Consistent with this interpretation, mGluR-LTD in the
Fmr] KO mouse also no longer requires acute stimulation of protein synthesis, presumably due
to constitutive overexpression of "LTD proteins" (Hou et al., 2006; Nosyreva and Huber, 2006).
2.2.2 The mGluR theory offragile X
Understanding disease pathophysiology is critical for development of therapies for the
treatment of FX. The above studies suggest that mGluRs and FMRP normally act in functional
opposition to maintain an optimal level of synaptic protein synthesis - mGluR activation drives
protein synthesis and FMRP represses this protein synthesis (Figure 2. 1A) (Bear et al., 2004).
In the absence of FMRP, mGluR-dependent protein synthesis is left unchecked, resulting in
runaway protein synthesis and exaggerated LTD. One way to correct for this is to decrease
mGluR5 activity. Indeed, either pharmacologically or genetically reduction of mGluR can
reverse both the excessive mGluR-LTD (Figure 2.1 B) and protein synthesis in Fmr] KO mice.
As LTD mechanisms are believed to be important for sculpting synaptic connections during
postnatal development, a reasonable conjecture is that exaggerated LTD could be pathogenic in
FX (Huber et al., 2002). Moreover, increased LTD in hippocampal area CAl could contribute
specifically to the cognitive impairment that is characteristic of this disease. Thus, targeting
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impaired synaptic efficacy (e.g. by modulating AMPAR function) has been suggested as a
potential therapy for FX (Lynch et al., 2008).
While mGluR-LTD is one of the most-well characterized Gp 1 mGluR-mediated
processes in the hippocampus, their activation can have a myriad of cellular and synaptic effects.
These include changes in excitability, synaptic structure, and maintenance of plasticity
(Francesconi et al., 2004; Lee et al., 2002; Neyman and Manahan-Vaughan, 2008; Vanderklish
and Edelman, 2002). Importantly, many of these changes are dependent upon rapid, de novo
protein synthesis (Merlin, 1998; Raymond et al., 2000). It is also true that the FX phenotype is
multifaceted. Despite its simple genetic origin, the disorder consists of a remarkably diverse set
of behavioral and neurological symptoms, including delayed cognitive development, seizures,
anxiety, movement disorders, and altered dendritic structure (Reiss and Hall, 2007).
Therefore, it is possible that exaggeration of the multiple consequences of mGluR-
mediated protein synthesis may contribute to the many diverse characteristics of FX. It has now
been shown that decreasing mGluR5 activity not only reverses the excessive mGluR-LTD and
protein synthesis in Fmr1 KO mice, but also a constellation of phenotypes associated with FX,
suggesting these synaptic impairments are a causal factor in the pathophysiology of FX (Dolen et
al., 2007). Furthermore, the fact that many of the behavioral and synaptic dysfunctions can be
reversed acutely by pharmacological antagonism of mGluR5 has important clinical implications
(McBride et al., 2005; Michalon et al., 2012). In fact, preliminary human clinical trials using
drugs that inhibit mGluR5 have shown promise in the treatment of some of the symptoms
associated with FX (Hagerman et al., 2012). The question arises then of whether it is more
appropriate to target excessive LTD and impaired AMPA receptor function (Lynch et al., 2008),
or excessive mGluR-dependent protein synthesis (Bear, 2005; Bear et al., 2004).
2.2.3 mGluR-dependent priming of L TP
The phenomenon of LTP priming, first described by Abraham and colleagues in rats
(Cohen and Abraham, 1996; Cohen et al., 1998; Raymond et al., 2000), offers an interesting
opportunity to distinguish between the two above alternatives. Normally, weak high-frequency
stimulation (HFS) elicits modest long-term synaptic potentiation (LTP) at the Schaffer collateral-
CAl synapse. However, if Gpl mGluRs are first stimulated briefly with a low concentration of
the selective agonist R,S-dihydroxyphenylglycine (DHPG; 10 pM), then the LTP produced by
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subsequent HFS is augmented substantially. Like mGluR-LTD induced by higher DHPG
concentrations, LTP priming in WT rats is abolished by inhibitors of mRNA translation, but not
by inhibitors of transcription. Thus, LTD and LTP priming are qualitatively different functional
consequences of Gpl mGluR-stimulated protein synthesis at the Schaffer collateral-CA1
synapse. In the current study we ask if LTP priming, like LTD, is also disrupted in the Fmr1 KO
mouse.
We find, first, that priming of LTP results from weak activation of Gp 1 mGluRs with
DHPG in mouse CAl, as previously reported in rats. Second, although the effect of LTP
priming is quantitatively similar in Fmr1 KO and WT mice, it is blocked by a protein synthesis
inhibitor only in WT animals. These findings suggest that proteins overexpressed in FX are not
restricted to "LTD proteins", as they apparently include those required for LTP priming as well.
These findings also indicate that there is a post-translational component of mGluR-dependent
LTP priming. Instead of serving as a trigger for LTP priming (or LTD), dendritic protein
synthesis may rather serve as a gate for synaptic plasticity that normally opens only in response
to an mGluR-signaling event. In fragile X, it appears that this gate is perpetually open due to
excessive basal protein synthesis and overexpression of proteins that are normally rate-limiting
for these forms of synaptic modification.
2.3 Results
In order to confirm that there is facilitation of LTP by prior Gp 1 mGluR activation in
mice (as has been demonstrated in rats), we first established a tetanization protocol that produced
a sub-saturable level of LTP and has been shown to be amenable to priming (Cohen et al., 1998;
Mellentin et al., 2007). Brief HFS (1-s 100-Hz) produced a modest but reliable level of LTP one
hour post tetanus in slices from both WT and FmIrl KO mice (WT: 111.2 ± 2.1%, n = 9; KO:
113.8 ± 3.1%, n = 9; Figure 2.2). As has been reported previously, there was no significant
difference in the basal level of hippocampal LTP in Fmrl KO compared to WT mice (p = 0.51)
(Godfraind et al., 1996; Paradee et al., 1999).
We then replicated the previously reported mGluR-dependent priming of LTP in slices
obtained from WT mice (Cohen et al., 1998; Mellentin et al., 2007). The Gpl mGluR agonist
DHPG (10 ptM) was bath applied to slices for 10 minutes after a stable 20 minute baseline
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recording period. DHPG application produced a transient depression of synaptic responses that
recovered to baseline levels after a 30 minute washout. The same tetanus protocol as above (1-s,
100-Hz) now produced a significantly larger magnitude of LTP compared to unprimed slices
(unprimed: 111.2 ± 2.1%, n = 9; primed: 123.9 ± 3.8%, n = 10; p = 0.012; Figure 2.2A). These
findings in mice are consistent with those previously reported in rats (Cohen et al., 1998;
Mellentin et al., 2007).
We next characterized the effect of DHPG application on subsequent LTP in Fmrl KO
mice. As was the case in WT animals, the DHPG priming protocol also enhanced LTP in slices
from FmrI KO mice (unprimed: 113.8 ± 3.1%, n = 9; primed: 133.7 ± 6.7%, n = 11; p = 0.016;
Figure 2.2B). However, there was no significant difference in the magnitude of facilitation seen
in primed Fmrl KO slices as compared to primed WT slices (p = 0.22).
Finally, we examined the role of protein synthesis in DHPG induced priming in both WT
and FmrI KO mice. As expected (Raymond et al., 2000), a brief application of the protein
synthesis inhibitor cycloheximide (CHX; 60 pM, 30 minutes) completely abolished DHPG
induced priming in WT slices (unprimed: 117.5 ± 7.0%, n = 7; primed: 118.6 ± 6.0%, n = 9; p
0.94; Figure 2.3A). However, this same treatment had no effect on DHPG induced priming in
slices from FmrI KO mice (unprimed: 118.5 ± 7.0%, n = 7; primed: 149.6 ± 11.0%, n = 8; p =
0.035; Figure 2.3B). These results show that while the magnitude of LTP enhancement induced
by DHPG priming is not quantitatively different in FmrI KO mice, induction of priming is
qualitatively different in that it no longer requires the synthesis of new proteins (Figure 2.4).
2.4 Discussion
In this study we characterized mGluR-dependent priming of LTP in the FX background.
In WT mice we confirmed previous reports that brief application of the Gp 1 mGluR agonist
DHPG at a low dose enhances the magnitude of subsequent LTP, and that this priming of LTP is
protein synthesis dependent. In the Fmr1 KO we determined that although mGluR-dependent
priming of LTP is not significantly enhanced as compared to WT, it no longer requires acute
protein synthesis at the time of induction. These experiments provide valuable insight into the
nature of the underlying pathophysiology of FX, as well as provide details for the mechanisms of
LTP priming.
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The results of this study are threefold: (1) The proteins downstream of mGluR activation
that are regulated by FMRP are not limited to LTD proteins but rather are able to mediate
bidirectional changes in synaptic strength, as the removal of FMRP affects not only LTD but also
LTP; (2) mGluR-stimulated protein synthesis can be decoupled from mGluR-mediated plasticity
because mGluR activation is still necessary to trigger LTP priming in the Fmr1 KO even though
it no longer requires de novo protein synthesis; and (3) The dysregulation of mGluR-mediated
protein synthesis seen in Fmr1 KO mice has multiple consequences on synaptic plasticity, even
within the same population of CAl synapses, suggesting that alterations in many mGluR-
mediated processes may contribute to the FX phenotype, not just LTD.
2.4.1 mGluR-dependent translation regulates proteins required for both LTD and LTP
Although our goal was to determine if the impact of excessive protein synthesis in area
CAl of Fmr1 KO mice is exclusive to mGluR-LTD, the results also have implications for the
mechanisms of LTP priming. There have been several studies exploring the induction
mechanisms of mGluR induced priming (Cohen et al., 1999; Cohen et al., 1998; Mellentin et al.,
2007), yet little is known about how the facilitation is achieved. While priming depends on
availability of newly synthesized proteins, the exact identity of the proteins required has not been
explored. Fmr1 KO mice may prove to be a valuable tool in this regard.
The fact that bidirectional changes in synaptic plasticity are altered in Fmri KO mice
suggests two possibilities for the nature of FMRP targets. First, FMRP may control the synthesis
of many proteins, some of which are required for LTD and others that are necessary for LTP
maintenance. This is supported by the notion that FMRP regulates the synthesis of hundreds of
proteins, many of which are involved in synaptic plasticity (Darnell et al., 2011). It is interesting
to note that some proteins that are traditionally thought to be important in LTP but not LTD, such
as CaMKII, are targets of FMRP (but see (Mockett et al., 2011)). The fact that priming no
longer requires protein synthesis in the Fmrl KO mouse suggests that the proteins required for
the priming effect are already present. It may be possible to identify candidate proteins that are
necessary for priming by comparing their basal expression levels in Fmr1 KO mice with basal
and primed protein levels in WT controls.
Alternatively, there may be a common set of proteins that gate bidirectional changes in
synaptic strength mediated by mGluRs. Conceptually, these plasticity gatekeepers could be
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proteins involved in AMPAR cycling. It may be that these proteins are required to stabilize a
certain cycling pattern, and whether this is removal or insertion of AMPARs depends on the
activity or signals present at a particular synapse. Although speculative at this point, the protein
Arc is an interesting candidate gating molecule. It is normally expressed at low levels, but can
be rapidly synthesized in response to Gpl mGluR activation (Park et al., 2008; Waung et al.,
2008) and has been reported to be overexpressed in the Fmr1 KO (Zalfa et al., 2003). It is
known to interact with the molecular machinery responsible for AMPA receptor cycling through
the synaptic membrane (Chowdhury et al., 2006; Shepherd et al., 2006) and has been implicated
in both LTP and LTD (Park et al., 2008; Plath et al., 2006; Waung et al., 2008). Finally, the
absence of Arc renders synapses virtually immutable by experience or deprivation, at least in
visual cortex (McCurry et al.).
2.4.2 Loss of FMRP decouples mGluR-dependent priming of L TPfrom protein synthesis
The simplest model for priming is that Gpl mGluR signaling facilitates subsequent LTP
induction by directly stimulating protein synthesis. However, priming and protein synthesis are
decoupled in the Fmr] KO. Priming still results from mGluR activation in the KO (Figure 2.2),
but via a mechanism that operates without acute stimulation of protein synthesis above basal
levels (Figure 2.3). This finding suggests a model, illustrated in Figure 2.5, in which signaling
from Gp 1 mGluRs bifurcates, with one arm triggering priming and the other stimulating protein
synthesis that is permissive for synaptic modifications, including LTP priming and LTD. In WT
mice and rats, the protein synthesis "gate" is closed under basal conditions so no priming (or
LTD) is possible without concurrent mGluR stimulation of mRNA translation. In the KO,
however, increased basal protein synthesis leaves the gate open so that the varied consequences
of mGluR activation are determined solely by post-translational modifications. The fact that the
priming trigger can be dissociated from the protein synthesis gate in Fmrl KO mice could be
exploited in future studies to distinguish these bifurcating pathways, as only interventions that
disrupt the trigger pathway would be effective at blocking LTP priming in these mice. Thus, in
addition to serving as a valuable disease model, Fmrl KO mice are also useful for dissecting the
diverse mechanisms of Gp 1 mGluR signaling and for understanding the role of mGluRs in
normal brain function.
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It is interesting to note that while priming and LTD share the requirement for rapid
protein synthesis, it seems their induction mechanisms differ. mGluR-LTD may not require
canonical Gq-dependent signaling, as it is not sensitive to inhibitors of PLCP or PKC and does
not require intracellular Ca2+ increases (Gladding et al., 2009; Schnabel et al., 1999) (see Chapter
4). Conversely, mGluR-dependent priming of LTP both requires PLC activation and
intracellular Ca2+ release from ryanodine receptors (Cohen et al., 1998; Mellentin et al., 2007).
Thus, mechanistically distinct forms of mGluR-mediated plasticity can be evoked at the same
synapses, and the direction of plasticity may depend on the type of signal received. It has
previously been shown that there is a wide time-window (up to three hours) in which the priming
effect can be achieved (Raymond et al., 2000). mGluR-stimulated protein synthesis might
increase the general capacity of synapses to undergo bidirectional changes in synaptic strength.
It could be that strong mGluR activation preferentially evokes LTD and stimulates the local
synthesis of plasticity proteins, while weaker activation may preferentially induce mechanisms
required for LTP priming. The result would be a rearrangement in the inputs that a cell
preferentially responds to, which may contribute to some forms of learning (Clem and Huganir,
2010; Xu et al., 2009).
2.4.3 Implications for the pathophysiology offragile X
To develop appropriate therapies for FX it is important to understand the exact nature of
its pathophysiology. Specifically, the question arises of whether it is more appropriate to target
excessive LTD or excessive mGluR-dependent protein synthesis. Previous work from our lab
has shown that genetic or pharmacological reduction of mGluR5 expression corrects a wide
variety of phenotypes examined in these mice (Dolen et al., 2007; Michalon et al., 2012). In this
regard, it is remarkable that simply reducing the activity of one protein can have such a profound
effect on the constellation of symptoms associated with FX. However, Gp 1 mGluR activation
has been shown to have a myriad of cellular and synaptic effects, many which require de novo
protein synthesis, and there is an intriguing similarity between many of the symptoms observed
in FX and the processes regulated by mGluR dependent protein synthesis. Here we
demonstrated a novel phenotype in Fmr1 KO mice which suggests that the dysregulation of
mGluR-dependent protein synthesis is central to the pathogenesis of FX.
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Altered regulation of mGluR-dependent priming of LTP may contribute to the cognitive
impairment seen in FX, which is one of the defining characteristics of the syndrome. Recent
studies have shown that competition for translational machinery or newly synthesized proteins
may be a limiting factor for the number of synapses that can undergo long lasting-changes in
synaptic efficacy (Fonseca et al., 2004; Govindarajan et al., 2011). This competition may serve
as an important checkpoint, so that only a subset of synapses undergo stabilization. While the
ability to have long-lasting changes in synaptic efficacy is undoubtedly beneficial, it may be
possible to have too much of a good thing. FX could be a case in point, where extraneous
synapses are maintained, contributing to the cognitive deficits seen in the disorder.
The mGluR theory of fragile X posits that exaggerated responses to Gp 1 mGluR
activation are responsible for multiple aspects of the disease phenotype (Bear et al., 2004). A
key assumption is that FMRP negatively regulates varied responses triggered by mGluR-
stimulated protein synthesis. Findings that mGluR-dependent LTP priming in hippocampal area
CAl, epileptogenesis in CA3 (Chuang et al., 2005), and LTD in both CAl (Huber et al., 2002;
Nosyreva and Huber, 2006) and cerebellum (Koekkoek et al., 2005) are all dysregulated in the
Fmr1 KO mouse provide considerable support for this proposal.
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2.5 Methods
2.5.1 Animals
Fmri mutant mice (Jackson Labs) were bred on the C57Bl/6J clonal background. In an effort to
reduce variability due to rearing conditions, all experimental animals were bred from Fmrl
heterozygote mothers, group housed (animals weaned to solitary housing were excluded), and
maintained on a 12:12 hr. light:dark cycle. The Institutional Animal Care and Use Committee at
MIT approved all experimental techniques.
2.5.2 Hippocampal slice preparation
Transverse hippocampal slices (350 gm thick) were prepared from 6-10 week old mice in ice-
cold dissection buffer containing (in mM): NaCl 87, Sucrose 75, KCl 2.5, NaH2 PO 4 1.25,
NaHCO 3 25, CaCl 2 0.5, MgCl 2 7, Ascorbic acid 1.3, and D-glucose 10 (saturated with 95%
02/5% C02). Immediately following slicing the CA3 region was removed. Slices were
recovered in artificial cerebrospinal fluid (ACSF) containing (in mM): NaCl 124, KCl 3.5,
NaH 2PO4 1.23, NaHCO 3 26, CaCl2 2, MgCl 2 1, and D-glucose 10 (saturated with 95% 02/5%
C02) at room temperature for at least 3 h prior to recording.
2.5.3 Electrophysiology
Field recordings were performed in a submersion chamber, perfused with ACSF (2-3 ml/min) at
30 *C. Field excitatory postsynaptic potentials (fEPSPs) were recorded in CAl stratum radiatum
with extracellular recording electrodes filled with ACSF. Baseline responses were evoked by
stimulation of the Schaffer collaterals at 0.033 Hz with a 2-contact cluster electrode (FHC) using
a 0.2 ms stimulus yielding 40-60% of the maximal response. Priming was induced by applying
10 pM DHPG for 10 minutes (Mellentin et al., 2007). Pairs of primed and unprimed slices were
recorded simultaneously. LTP was induced with a 1-s 100-Hz tetanus. Protein synthesis was
inhibited by applying 60 gM cycloheximide (CHX) for 30 minutes as follows: 15 minutes of
pretreatment during baseline recording, 10 minutes during DHPG application, and 5 minutes post
DHPG application; or during the equivalent time of baseline recording in unprimed slices.
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fEPSP recordings were filtered at 0.1 Hz - 1 kHz, digitized at 10 kHz, and analyzed using
pClamp9 (Axon Instruments). The initial slope of the response was used to assess changes in
synaptic strength. Data were normalized to the baseline response and are presented as group
means ± SEM. LTP was measured by comparing the average response 55-60 minutes post
tetanus to the average of the last 5 minutes of baseline. ANOVA and unpaired t-tests were used
to determine statistically significant differences, unless otherwise specified. Experiments used
aged-matched and interleaved WT and Fmrl KO mice. For all experiments the experimenter
was blind to genotype.
2.5.4 Reagents
R,S-DHPG was purchased from Tocris Biosciences (Ellisville, MO). All other reagents were
purchased from Sigma (St. Louis, MO). Fresh bottles of DHPG were prepared as a 100x stock in
H20, aliquoted, and stored at -800C. Fresh stocks were made once a week. CHX was prepared at
1 00x stock in H20 daily. These stocks were diluted in ACSF to achieve final concentration.
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Figure 2.1 - The mGluR theory of fragile X. (A) FMRP and mGluR5 impose opposite
regulation on the local mRNA translation required for mGluR-LTD expression. In the absence
of FMRP, there is excessive protein synthesis and exaggerated LTD. One way this can be
ameliorated is by decreasing mGluR5 activity. (B) Significant effect of mGluR5 gene dosage on
LTD in Fmrl KO mice. 50 pM DHPG was applied for 5 min (arrow) to slices from Fmrl KO
(KO) and Grm5"~ x Fmrl KO (CR) animals (n = 14 and 11 slices from 6 and 5 mice for KO and
CR, respectively). Average field EPSP slopes 45-50 min after DHPG were significantly
different from 5 min averages immediately prior to DHPG in both genotypes (% baseline: KO =
78.1 ± 3.1 %, P = 0.000005; CR = 91.6 ± 1.4 %, P = 0.00007; paired t-test). However, reduction
of Grm5 gene dosage by 50% significantly decreases the magnitude of LTD in CR relative to
Fmrl KO mice (n = 5 and 6 animals, respectively, P = 0.0058, unpaired t-test). Representative
field potential traces (averages of 10 sweeps) were taken at times indicated by numerals. Parts of
this figure are previously published in (Dolen et al., 2007).
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Figure 2.2 - DHPG application facilitates subsequently induced LTP. fEPSPs were recorded
from the CA1 region of hippocampal slices from either (A) wild-type (WT) or (B) Fmr1 KO
mice. After 1 hour of baseline recording, unprimed slices were administered a 1-s 100-Hz
tetanus (indicated by arrow) which induced a modest level of LTP in both WT and KO slices
(WT: 111.2 ± 2.1%, n = 9 slices from 9 animals, open black circles; KO: 113.8 ± 3.1%, n = 9
slices from 8 animals, open red circles). In both genotypes, a 10 minute priming application of
the Gp 1 mGluR agonist DHPG (10 gM, black bar) significantly enhanced the magnitude of
subsequent LTP induced using this same 100-Hz tetanus (WT: 123.9 ± 3.8%, n = 11 slices from
11 animals, closed black circles, p < 0.02; KO: 133.7 ± 6.7%, n = 11 slices from 10 animals,
closed red circles, p < 0.02). Representative field potential traces (average of 10 sweeps) were
taken at times indicated by numerals. Scale bars equal 0.5 mV, 5 ms. Error bars represent SEM.
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Figure 2.3 - DHPG-induced priming of LTP does not require protein synthesis in FMr1
KO mice. Delivery of the protein synthesis inhibitor cycloheximide (60 pM, 30 min; CHX, gray
bar) before and during DHPG priming prevented facilitation of LTP in slices from wildtype mice
(A; unprimed: 117.5 ± 7.0%, n = 7 slices from 6 animals, open black circles; primed: 118.6 ±
6.0%, n = 8 slices from 6 animals, closed black circles; p = 0.94), however, this treatment had no
effect on DHPG induced priming in slices from Fmrl KO mice (B; unprimed: 118.5 ± 6.1%, n =
7 slices from 6 animals, open red circles; primed: 149.6 ± 11.0%, n = 8 slices from 7 animals,
closed red circles; p < 0.05). Representative field potential traces (average of 10 sweeps) were
taken at times indicated by numerals. Scale bars equal 0.5 mV, 5 ms. Error bars represent SEM.
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Figure 2.4 - Summary of DHPG-induced priming of LTP and its protein synthesis
dependency in wild-type and FMr1 KO mice. Bar graphs represent the average percent LTP
observed 55-60 minutes post tetanus. Wild-type (WT) unprimed: open black, wild-type primed:
closed black, Fmri KO (KO) unprimed: open red, Fmr1 KO primed: closed red. Asterisks
denote significant differences (unpaired student's t-test, p < 0.05).
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Figure 2.5 - Model for role of FMRP in mGluR-dependent priming of LTP. The finding
that LTP priming by mGluR activation occurs in the Fmr1 KO without a need for acute protein
synthesis suggests a bifurcation in the signaling pathway. The priming step (1) occurs in
response to mGluR activation via a mechanism involving posttranslational modification of
synaptic proteins (possibly the AMPA receptor itself). In WT animals, priming is not possible
without (2) concurrent mGluR activation of mRNA translation and synthesis of protein(s) that
gate plasticity. In the absence of the translational repressor FMRP, the gating proteins are
constitutively overexpressed, rendering priming no longer sensitive to protein synthesis
inhibitors. The identity of the hypothetical gating proteins remains to be determined.
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Chapter 3
Mutations causing syndromic autism define an axis of synaptic
pathophysiology
Portions of this chapter were published together with Dr. Emily K. Osterweil, and Dr. Mark F.
Bear in Nature (2011) Vol. 480, pp. 63-8.
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3.1 Abstract
Tuberous sclerosis complex and fragile X are genetic diseases characterized by
intellectual disability and autism. Because both syndromes are caused by mutations in genes that
regulate protein synthesis in neurons, it has been hypothesized that excessive protein synthesis is
one core pathophysiological mechanism of intellectual disability and autism. Using
electrophysiological and biochemical assays of neuronal protein synthesis in the hippocampus of
Tsc21- and Fmr1 KO mice, we show that synaptic dysfunction caused by these mutations
actually falls at opposite ends of a physiological spectrum. Synaptic, biochemical and cognitive
defects in these mutants are corrected by treatments that modulate metabotropic glutamate
receptor 5 in opposite directions, and deficits in the mutants disappear when the mice are bred to
carry both mutations. Thus, normal synaptic plasticity and cognition occur within an optimal
range of metabotropic glutamate receptor-mediated protein synthesis, and deviations in either
direction can lead to shared behavioural impairments.
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3.2 Introduction
Greater than 1% of the human population has an autism spectrum disorder (ASD), and it
has been estimated that up to 70% of those with ASD also have intellectual disability (ID)
(Newschaffer et al., 2007). In the large majority of cases, the cause is unknown. However,
genetically defined syndromes with increased prevalence of autism and ID offer an opportunity
to understand the brain pathophysiology that manifests as ASD and ID, and this knowledge can
suggest potential therapies. A case in point is fragile X syndrome (FX), caused by silencing of
the FMR1 gene and loss of the protein product, FMRP. Studies of the Fmr1 knockout (KO)
mouse revealed that in the absence of FMRP, protein synthesis is increased downstream of
metabotropic glutamate receptor 5 (mGluR5). Multiple consequences of mGluR-mediated
protein synthesis are altered in Fmr1 KO mice (Chapter 2). Likewise, diverse mutant
phenotypes in FX animal models have been corrected by genetic or pharmacological inhibition
of mGluR5, and preliminary human clinical trials using drugs that inhibit mGluR5 have shown
promise (Krueger and Bear, 2011). Because several other syndromic forms of ASD and ID are
associated with mutations of genes that regulate mRNA translation at synapses, it has been
hypothesized that altered synaptic protein synthesis might contribute generally to the autistic
phenotype (Chapter 1) (Kelleher and Bear, 2008). The aim of the current study was to test the
hypothesis that a mutation responsible for another genetic syndrome associated with ASD and
ID-tuberous sclerosis complex (TSC)-produces abnormalities in synaptic protein synthesis
and plasticity similar to FX. If this were the case, treatments developed for one disorder might
be beneficial for the other, and possibly for autism and ID more broadly.
3.2.1 Tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is a neurodevelopmental disorder characterized by
central nervous system dysfunction (Prather and de Vries, 2004). The choice of TSC was guided
by several considerations: Like FX, (1) TSC is a single-gene disorder with core symptoms of
ASD and ID; (2) the affected gene(s) lie in a signaling pathway that couples cell surface
receptors to mRNA translation; (3) there are well validated mouse models of the disease, and (4)
some mutant phenotypes in these mouse models have responded to pharmacological treatments
that affect protein synthesis (Ehninger et al., 2008a; Meikle et al., 2008; Onda et al., 2002).
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The disease is caused by heterozygous mutations in the genes encoding TSC 1 (also
known as hamartin) or TSC2 (also known as tuberin) proteins that together form the TSC1/2
complex. TSC1/2 acts to inhibit Rheb, a Ras family GTPase with high specificity for mTOR
within a protein complex called mTORC1 (Figure 1.1) (Kwiatkowski and Manning, 2005).
Rheb activation of mTORC 1 can stimulate mRNA translation and cell growth, and excessive
mTORCl activation is believed to be pathogenic in TSC (Ehninger et al., 2009). TSC is
characterized by the growth of hamartomas that are thought to result from inactivation of the
functional allele within the tumor cells (loss of heterozygosity) (Carbonara et al., 1994; Green et
al., 1994). Although some neurological manifestations of TSC are thought to be related to tumor
growth in the cerebral cortex, others, including cognitive impairment and autism, have been
proposed to result from abnormal signaling at synapses (de Vries and Howe, 2007). Consistent
with this idea, mice engineered to carry heterozygous loss-of-function mutations in Tscl or Tsc2
have been shown to have hippocampus-dependent learning and memory deficits without having
tumors in the brain or seizures (Ehninger et al., 2008a; Goorden et al., 2007). Here we chose the
Tsc2*1 mouse model because TSC2 mutations are more common and produce a more severe
phenotype in humans (Cheadle et al., 2000), and this animal model is in widespread use
(Ehninger et al., 2008a; Nie et al., 2010; Onda et al., 1999; Young et al., 2010). Of particular
significance, postnatal treatment of Tsc2*7 mice with the mTORC 1 inhibitor rapamycin was
previously shown to ameliorate hippocampal memory impairments suggesting the exciting
possibility that some aspects of TSC, like FX, might be amenable to drug therapy (Ehninger et
al., 2008a).
While dysregulated mTOR activity is generally regarded as pathogenic in TSC, it is
unclear how this relates to the cognitive impairments associated with the disorder. A prominent
hypothesis is that synaptic dysfunction in TSC relates to increased protein synthesis in response
to elevated mTORC 1 activity (Hoeffer and Klann, 2010). Signaling via mTORC 1 has been
suggested to contribute to the coupling of mGluR5 to protein synthesis and, although still
controversial, it has been proposed that elevated mTOR activity might also be a cause of elevated
protein synthesis in the Fmr1 KO mouse (Sharma et al., 2010). A sensitive electrophysiological
read-out of local mRNA translation in response to mGluR5 activation is long-term synaptic
depression (LTD) in area CAI of the hippocampus (Huber et al., 2000; Huber et al., 200 1).
Indeed, it was exaggerated LTD in the Fmr1 KO mouse that led to the mGluR theory of FX
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(Chapter 1) (Bear et al., 2004; Huber et al., 2002). Therefore, to test the hypothesis of a shared
pathophysiology between TSC and FX, we first examined mGluR-LTD in the hippocampus of
male Tsc2 1 mice.
3.3 Results
3.3.1 Excessive mTOR signaling suppresses the protein synthesis required for mGluR-LTD
LTD was induced by activation of group 1 (Gp 1) mGluRs (mGluR 1 and 5) with the
selective agonist DHPG ((R,S)-3,5-dihydroxyphenylglycine) in hippocampal slices (Huber et al.,
2001). Unexpectedly, we discovered that DHPG-induced LTD was deficient rather than
enhanced in the hippocampus of Tsc2*/- mice, as compared to WT controls (Figure 3.1 A). A
similar deficit was observed when mGluR-LTD was induced by patterned electrical stimulation
of Schaffer collateral synapses (Figure 3.1 B). In agreement with a previous report (Ehninger et
al., 2008a), basal synaptic transmission in CAl appeared normal in the Tsc2* mice, indicating
that the impairment in mGluR-LTD is not due to general disruption of synaptic function (Figure
3.1 D,E). Moreover, there was no difference in the magnitude of the NMDA receptor-dependent
form of LTD between WT and Tsc2*' mice (Figure 3.1 C) demonstrating that the deficit is
specific to mGluR-LTD, as these same synapses are able to undergo activity-induced depression
via a different mechanism. To test the possibility of a general disruption in Gp 1 mGluR
function, we examined DHPG-induced phosphorylation of extracellular signal-regulated kinase
(ERK), a common measure of Gp 1 mGluR signaling and a critical step for mGluR-mediated
protein synthesis and LTD (Gallagher et al., 2004; Osterweil et al., 2010). Basal ERK
phosphorylation and DHPG-induced increases in ERK phosphorylation are unaltered in Tsc2*/-
mice (Figure 3.1 F). These results suggest that the deficit in mGluR-LTD seen in the Tsc2*/-
hippocampus is not due to a global dysregulation of synaptic function or Gp 1 mGluR signaling.
mGluR-LTD in area CAl of the hippocampus is expressed via two independent
mechanisms: reduced probability of presynaptic glutamate release (Fitzjohn et al., 2001; Mockett
et al., 2011; Nosyreva and Huber, 2005) and reduced expression of postsynaptic AMPA
receptors (Luscher and Huber, 2010; Nosyreva and Huber, 2005). In WT animals, the
postsynaptic modification is known to require immediate translation of mRNAs available in the
dendrites of hippocampal pyramidal neurons (Huber et al., 2000; Snyder et al., 2001).
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Accordingly, we found that LTD in WT mice at the age range examined (postnatal day (P) 25-
30) is reliably reduced by the protein synthesis inhibitor cycloheximide (60 pM; Figure 3.2A).
The presynaptic component of LTD was monitored by measuring paired-pulse facilitation (PPF),
which showed a persistent increase following DHPG that reflects reduced probability of
glutamate released at the presynaptic terminal (Figure 3.3) (Fitzjohn et al., 2001; Mockett et al.,
2011; Nosyreva and Huber, 2005). Changes in PPF were not inhibited by cycloheximide (Figure
3.2C; Figure 3.3), suggesting that residual LTD in the presence of the drug is expressed
presynaptically. While LTD was reduced in Tsc2*/- mice, the persistent PPF change after DHPG
was no different than in WT, suggesting a deficient postsynaptic modification (Figure 3.2C;
Figure 3.3). Indeed, unlike WT, cycloheximide treatment had no effect on LTD in the Tsc2**
animals (Figure 3.2B). These data suggest a selective loss of the protein synthesis-dependent
component of LTD in the mutant mice.
These electrophysiological results in the Tsc2*'- hippocampus stand in stark contrast to
the Fmr1 KO mouse in which mGluR-LTD is exaggerated (Huber et al., 2002). In the FX mouse
model, increased LTD correlates with an increased rate of basal mRNA translation downstream
of mGluR5. Therefore we were compelled to examine protein synthesis in hippocampal slices
from the Tsc2*1 mouse as previously described for the Fmr1 KO mouse (Osterweil et al., 2010).
Consistent with the mGluR-LTD findings, we found a small but significant decrease in 35S-
methionine/cysteine incorporation into protein under basal conditions in the hippocampus of
Tsc2*/- mice (Figure 3.2D). This finding suggested the possibility that protein(s) required for
mGluR-LTD are deficiently translated in the hippocampus of Tsc2*/- mice. To test this idea we
examined levels of Arc, a plasticity related protein that is rapidly synthesized in response to Gp 1
mGluR activation and is required for mGluR-LTD (Park et al., 2008; Waung et al., 2008).
Interestingly, we found that Arc expression is decreased in Tsc2*/- hippocampal slices (Figure
3.2E). To determine whether this decrease was due to diminished translation, we measured the
amount of newly-synthesized Arc in Tsc2*/~ slices by performing immunoprecipitation
experiments on metabolically-labeled slices (see Methods) (Osterweil et al., 2010). Examination
of the 3S-incorporated fraction revealed a significant reduction in Arc translation in the
hippocampus of Tsc2*/- mice (Figure 3.2F). These results suggest that mGluR-LTD is deficient
in the Tsc2*/- hippocampus due to a decrease in the translation of the proteins required to
stabilize LTD, including Arc.
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As in the human disease, the germ line mutation in Tsc2 can have myriad secondary
consequences on neural development that could contribute to the observed LTD and protein
synthesis phenotypes. To test the hypothesis that the deficient mGluR-LTD seen in Tsc2+' mice
is a specific consequence of unregulated mTOR activity, we examined the effects of the
mTORC 1 inhibitor rapamycin. We found that acute rapamycin treatment (20 nM) restored
mGluR-LTD in the Tsc2*/- mice to WT levels (Figure 3.4A), while this same treatment had no
effect on mGluR-LTD or its protein synthesis dependency in slices from WT mice (Figure
3.4D,E). This rescue is due specifically to the recovery of the protein synthesis-dependent
component of LTD, as the effect of rapamycin in Tsc2*/- mice was eliminated in the presence of
cycloheximide (Figure 3.4B). The same rapamycin treatment also restored basal protein
synthesis rates in Tsc2/- hippocampal slices back to WT levels (Figure 3.4C). The simple model
that best fits the data is that unregulated mTOR activity caused by the Tsc2/- mutation
suppresses the protein synthesis that is required for mGluR-LTD (Figure 3.5A).
3.3.2 Augmentation of mGluR5 rescues synaptic and behavioral impairments in Tsc2*'~ mice
In the Fmr1 KO model of FX, excessive mGluR-LTD and hippocampal protein synthesis
can be corrected by reducing signaling via mGluR5 (Figure 2.1) (Dolen et al., 2007; Michalon et
al., 2012; Osterweil et al., 2010). We therefore wondered if the opposite approach of
potentiating mGluR5 signaling with a positive allosteric modulator (PAM) could be beneficial in
this model of TSC (Figure 3.5A). PAMs are compounds that do not activate mGluR5 directly
but act on an allosteric site to potentiate physiological activation of the receptor (Conn et al.,
2009). Indeed, we found that pretreatment of hippocampal slices with the mGluR5 PAM 3-
Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB (Kinney et al., 2005)) restored the
magnitude of mGluR-LTD in Tsc2*/ mice to WT levels (Figure 3.5B). The rescue of LTD
appears to be due specifically to recovery of the protein synthesis-dependent component because
the effect of CDPPB was completely eliminated by cycloheximide (Figure 3.5C). Consistent
with this conclusion, CDPPB treatment also restored basal protein synthesis levels (Figure 3.5D)
and rescued the deficit in Arc synthesis in the Tsc2*/- mice (Figure 3.5E). Thus, allosteric
augmentation of mGluR5 signaling can overcome the inhibitory effect of unregulated mTOR
activity on the synaptic protein synthesis that supports LTD.
In an important recent study, cognitive impairments in the Tsc2*/- mice were shown to be
significantly improved by treating the animals with the mTORC 1 inhibitor rapamycin (Ehninger
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et al., 2008a). In light of our electrophysiological and biochemical findings, we wondered if a
similar amelioration would be observed with the mGluR5 PAM. A robust phenotype was
reported to be an impairment in the ability of the Tsc2*/- mice to distinguish between familiar
and novel contexts in a fear conditioning paradigm. Advantages of this paradigm are the
learning occurs in one trial making it amenable to acute drug treatment, and the memory is
hippocampus-dependent (Frankland et al., 1998). Although a requirement for CA1 LTD per se
has not been established, contextual fear discrimination does depend on both mGluR5 (Lu et al.,
1997) and new protein synthesis at the time of training (Stiedl et al., 1999). In this assay, mice
are first exposed to a distinctive context in which they receive an aversive foot shock. The next
day, context discrimination is tested by dividing the animals into two groups; one is placed in the
familiar context associated with the shock, and the other is placed in a novel context (Figure
3.5F). Context discrimination is assessed by measuring the time the animals express fear by
freezing in each context. Although the WT mice clearly discriminate between contexts, the
Tsc2*/- mice do not (Ehninger et al., 2008a) (Figure 3.5G). To test the effect of augmenting
mGluR5 signaling, mice from both genotypes were injected i.p. with CDPPB (10 mg/kg) 30
minutes prior to training. Although this treatment had no effect in the WT mice, it was sufficient
to correct the deficit in context discrimination observed in the Tsc2*/- mice. These results show
that augmentation of mGluR5 signaling is beneficial at the behavioral level in Tsc2+/- mice and
that disrupted mGluR5 function may be relevant to cognitive impairments associated with TSC.
3.3.3 Mutations in Fmr1 and Tsc2 cancel one another on a functional axis
Contrary to our initial hypothesis we found that mutations causing FX and TSC, two
disorders associated with autism and ID, show mirror symmetrical alterations in protein
synthesis-dependent LTD and have beneficial responses to treatments that modulate mGluR5 in
opposite directions (Figure 3.6A). These findings raised the intriguing possibility that these two
mutations could cancel one another on this functional axis. To test this hypothesis, we
introduced an Fmr1 deletion into the Tsc21- background by crossing Tsc2*/- males with Fmr1'/
females (Figure 3.6B). This approach also enabled us to compare directly with WT the effects of
the Tsc2*/ and Fmr] l mutations in littermates reared under identical conditions. As expected,
mGluR-LTD was diminished in Tsc2'- mice and excessive in the Fmr1 KO mice, as compared to
WT (Figure 3.6C,D). However, mice harboring both mutations showed mGluR-LTD that was
indistinguishable from WT (Figure 3.6C,D).
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While Tsc2*/- and Fmr1- mutations cause opposite alterations in mGluR-LTD and
protein synthesis, the human disorders they are associated with have similar neurological and
cognitive phenotypes. Might opposite deviations in synaptic function lead to shared cognitive
impairments? To examine this question, we compared context discrimination in the Tsc2*/- and
Fmr1 KO mice and discovered that indeed they do share a deficit in this measure of memory
(Figure 3.6E). Remarkably, instead of being exacerbated, this memory deficit was erased in the
double mutants (Figure 3.6E). These results suggest that the opposing synaptic deviations seen
in Tsc2*/- and Fmr1 KO mice may manifest similarly at the behavioral level, as introducing both
mutations not only reverses the disruptions of synaptic plasticity but rescues this memory
impairment as well.
3.4 Discussion
LTD and protein synthesis downstream of mGluR5 have attracted attention in the context
of several diseases, most notably FX (Luscher and Huber, 2010). In the Fmr1 KO mouse model,
basal protein synthesis is elevated and LTD is exaggerated downstream of an mGluR5 signaling
pathway involving ERK (Osterweil et al., 2010). In Chapter 2 we demonstrated multiple
consequences of mGluR-mediated protein synthesis are affected in Fmr1 KO mice, suggesting
that this disruption could contribute to the constellation of phenotypes associated with FX.
Indeed, partial inhibition of mGluR5 or ERK corrects multiple aspects of fragile X in animal
models (Dolen et al., 2010; Krueger and Bear, 2011; Michalon et al., 2012; Osterweil et al.,
2013). Recent data suggest that the mTOR signaling pathway is also constitutively overactive in
the Fmr] KO mouse (Sharma et al., 2010), but the relevance to exaggerated protein synthesis
and altered synaptic function has been controversial.
mGluR activation has been shown to recruit both the ERK and mTOR pathways, and
disentangling the contributions of each to mGluR-dependent LTD and protein synthesis has been
difficult. The current findings show that inhibition of mTOR with rapamycin does not disrupt
mGluR-LTD in WT mice or its protein synthesis dependency. However, this same treatment
rescues LTD and protein synthesis rates in the Tsc2*/- mice, suggesting that increased synaptic
mTOR activity suppresses the protein synthesis required for LTD in these animals (Figure 3.5A).
These results are supported by two other recent studies demonstrating disrupted mGluR-LTD in
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different but complimentary mouse models of TSC (Bateup et al., 2011; Chevere-Torres et al.,
2012). The results from Bateup et al. are particular enlightening, as they showed that sparse in
vivo knockdown of Tscl results in deficient LTD, demonstrating that this disruption is not only
acute but cell autonomous as well. The idea that reduced protein synthesis is a causative factor
in the observed deficit in synaptic plasticity is supported by the finding that pharmacological
rescue with both rapamycin and CDPPB is abolished by cycloheximide, and the observation that
Arc is deficiently translated in the Tsc2+' mice. There is good evidence that Arc is one protein
that normally must be synthesized to support mGluR5-dependent forms of long-term plasticity
(Park et al., 2008; Waung et al., 2008).
3.4.1 Mechanisms of m TOR-dependent suppression of translation
Precisely how excess mTOR activity suppresses synthesis of plasticity proteins
downstream of mGluR activation remains to be determined. An intriguing hypothesis is that the
effect of elevated mTOR on protein synthesis may be mediated through FMRP (Figure 3.7A). It
has been shown that post-translational modifications of FMRP can regulate translational
repression (Bhakar et al., 2012). Phosphorylation has been suggested to stall ribosomal
translocation while maintaining the association of FMRP with mRNA, thus inhibiting translation
of FMRP targets (Ceman et al., 2003; Muddashetty et al., 2011). Recent work has attempted to
determine the phosphatases and kinases that may regulate FMRP downstream of mGluR
activation. One model proposes that mGluR5 stimulation initially results in activation of the
protein phosphatase 2A (PP2A), which dephosphorylates FMRP, resulting in de-repression of
protein synthesis (Narayanan et al., 2007) (Figure 3.7A). However, FMRP is rapidly re-
phosphorylated in an mTOR-dependent manner via S6 kinase (S6K), suppressing translation
once again (Narayanan et al., 2008; Santoro et al., 2012). Thus, if mTOR is chronically over-
activated, as is the case when TSC1/2 function is disrupted, this could lead to
hyperphosphorylation of FMRP, resulting in the translational suppression of FMRP targets
required for LTD (Figure 3.7A). This model is supported by a recent study demonstrating that
local translation of the potassium channel Kv4.2 is suppressed via mTOR-dependent
phosphorylation of FMRP (Lee et al., 2011). The fact that deleting FMRP in the Tsc2"'
background rescues both protein synthesis rates and LTD levels also lends some support to this
model. However, if increased phosphorylation of FMRP was solely responsible for the
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diminished protein synthesis and LTD in Tsc2"~ mice, then the double mutants should
phenocopy Fmr1 KO mice rather than resemble WT animals. Therefore, additional mechanisms
are likely involved in mTOR-mediated suppression of protein synthesis.
The above scenario demonstrates that translation is a tightly regulated process that
requires precise timing of all its components. mTOR is known to promote initiation of
translation and numerous studies have demonstrated increased phosphorylation of mTOR targets
(e.g. 4E-BP 1 and S6K) in Tsc2 deficient cells (Kwiatkowski and Manning, 2005). There is also
good evidence to suggest that phosphorylation of FMRP can stall elongation (Bhakar et al.,
2012). The mTOR-dependent phosphorylation of FMRP may normally serve as a checkpoint to
limit runaway protein synthesis (Figure 3.7A). However, when mTOR is constitutively active,
the timing of this feedback loop is disrupted, resulting in stalled elongation even when initiation
is being promoted. In this way, chronically overactive mTOR signaling may counter-intuitively
result in decreased protein synthesis rates. A prediction of this model is that there will be a
higher percentage of stalled ribosomes in Tsc2 deficient neurons, particularly those that are also
associated with FMRP.
An alternative, although not mutually exclusive, model is that mTOR stimulates
translation of an unrelated pool of mRNAs not regulated by mGluRs (Figure 3.7B) (Bear et al.,
2004; Ehninger et al., 2009; Park et al., 2008). The fact that mGluR-LTD is altered in opposite
directions in Tsc21- and Fmr] KO mice (3.6A), and that both deviations are corrected in the
double mutants, suggests that the pool comprising LTD proteins is differentially regulated by
FMRP and TSC1/2 (Figure 3.7B). A potential mechanism for this "push-pull" regulation of
translation is cap- verses non-cap-dependent protein synthesis. mTOR activation is known to
recruit the components required for 5'cap-dependent translation, which is sometimes regarded as
global or general translation (Hay and Sonenberg, 2004) (Figure 1.2A). However, there are
alternative mechanisms for translation initiation that does not require ribosomal binding to the
5'cap and can result in gene-specific translation. Some mRNAs have an internal ribosomal entry
site (IRES) in the 5' UTR that allows the ribosome to directly scan for the initiation codon and
initiate translation (Mathews, 2000). Interestingly, many mRNA that are FMRP targets and are
translated downstream of mGluR activation have this IRE sequence, such as Arc, Map Ib,
CaMKIIa (Pinkstaff et al., 2001). Thus, mRNA translation can be regulated in a global or gene-
specific manner. It has been suggested that the regulation of gene-specific translation is
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particularly important for synaptic plasticity and memory consolidation in the hippocampus
(Jiang et al., 2010). The differentiation between TSC-mTOR-dependent translation and mGluR-
ERK-FMRP-dependent translation may be defined by the mechanism of initiation.
3.4.2 Regulation of gene-specific translation
Regulation of the initiation factor eIF2a is a well-characterized mechanism for
modulating both global and gene-specific translation (Costa-Mattioli et al., 2009). eIF2a
facilitates binding of the initiator methionyl-tRNA to the 40S ribosomal subunit (Figure 1.2A).
Phosphorylation of eIF2a disrupts formation of this complex, inhibiting general translation while
paradoxically resulting in the upregulation of a specific subset of mRNA containing upstream
open reading frames (uORFs) (Costa-Mattioli et al., 2009). Increasing (Jiang et al., 2010) or
decreasing (Costa-Mattioli et al., 2005) eIF2a phosphorylation in the hippocampus has been
shown to bidirectionally modify synaptic plasticity and memory consolidation, suggesting this
mechanism could be important for proper neuronal function. Interestingly, these changes are not
thought to be the result of altered global translation but rather due changes in the translation of
the uORF-containing mRNA for the transcription factor ATF4, a negative regulator (Karpinski et
al., 1992) of CRE-dependent transcription critical for memory consolidation (Silva et al., 1998).
eIF2a is not directly regulated by the mTOR pathway, but rather is regulated by a set of
kinases that respond to various cellular stressors (Mathews, 2000). However, it has been
suggested that dysregulated protein synthesis and disturbances in nutrient signaling caused by
uncontrolled mTOR signaling might lead to endoplasmic reticulum (ER) stress in TSC 1/2-
deficient cells (Ozcan et al., 2008). Indeed, Tsc2 deficient neurons have been shown to have an
increased ER stress response (Di Nardo et al., 2009) and deletion of Tsc2 results in increased
phosphorylation of eIF2a by its kinase PERK (Ozcan et al., 2008). Thus, loss of Tsc2 may result
in a negative feed back loop that results in the suppression of general translation by eIF2a but an
increase in translation of uORF containing mRNA. However, while it has been shown that
complete absence of TSC 1/2 function results in increased ER stress and eIF2a phosphorylation,
this has not been demonstrated in the Tsc2*/- animals used in this study. In fact, direct
comparison of Tsc2 lacking tumor cells (resulting from loss of heterozygosity) and neighboring
Tsc2*/- cells revealed increased ER stress specifically in the tumor cells (Ozcan et al., 2008),
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suggesting that heterozygous deletion may not be sufficient to activate the stress response
pathway.
Another potential mechanism for differential translation involves the regulation of the
elongation factor eEF2. Inhibition of eEF2 results in a general blockage of translation elongation
(Figure 1.2B). However, it has been suggested that by doing so, poorly initiated transcripts
benefit from the increased concentration of free translation initiation factors, including several
FMRP targets known to be regulated by mGluR activation (Park et al., 2008). Phosphorylation
of eEF2 in response to mGluR5 activation has shown to promote translation of LTD proteins,
such as Arc and MAP lb (Park et al., 2008). Conversely, activation of the mTOR pathway
inhibits eEF2 kinase activity, thereby decreasing eEF2 phosphorylation, which may suppress the
LTD pool and favor translation of targets downstream of mTOR (Costa-Mattioli et al., 2009;
Mathews, 2000). Thus, recruiting the mTOR pathway can stimulate synthesis of a subset of
proteins that mutually inhibits the translation of another through either the regulation of initiation
(eIF2a) or elongation (eEF2). Determining how the components of the eIF2a and eEF2
pathways are altered in Tsc2-' mice, and if the protein targets downstream of these pathways are
increased or decreased, will lend insight into how translation is disrupted in the Tsc21- animals.
Even given that mTOR and ERK modulate different pools of proteins, it still seems
counter-intuitive that excessive mTOR signaling would lead to decreased total levels of protein
synthesis if it regulates global translation. However, it is important to remember that because
neurons are non-dividing cell, their protein make-up is different than most cell types. mTOR
signaling is thought to selectively regulate the expression of mRNA containing 5' terminal
oligoprymidine (TOPs) motifs (Thoreen et al., 2012). TOP-containing mRNA includes many
components required for cell differentiation, growth, and proliferation, including components of
the translational machinery itself (Hay and Sonenberg, 2004). In this way, stimulation of TOP-
containing mRNA can subsequently increase the overall capacity for translation, and it is through
this mechanism that mTOR is thought to most effectively exert its control over translation rates.
Thus, while mTOR is regarded as a stimulator of global protein synthesis, its regulation of
translation is actually quite complex, and probably restricted to expression of a specific subset of
genes. An important distinction of TOP-dependent translation is that it is significantly
suppressed in non-dividing cells (Mathews, 2000). Therefore, in neurons, translation of this pool
of mRNA may represent a smaller percentage of overall protein synthesis. In this way,
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promotion of the mTOR regulated pool, as seen in Tsc2 deficient neurons, may actually lead to
decreased overall protein synthesis rates.
3.4.3 Functional significance ofgene-specific translation
If there are indeed two pools of mRNA that are differentially translated by the TSC-
mTOR and the mGluR5-ERK-FMRP pathways, it suggests there is likely a difference in the
functional consequences of their synthesis. In addition to deficient mGluR-LTD, a recent report
has demonstrated the Tsc2*/- mice have a reduced threshold for the induction of protein
synthesis-dependent LTP. It was shown that a weak LTP-inducing stimulation that normally
produces a protein synthesis-independent, transient early-phase potentiation (E-LTP) is
converted into persistent late-phase LTP (L-LTP) without the requirement of new protein
synthesis. L-LTP normally requires the synthesis of new proteins, suggesting that the proteins
required for the maintenance of LTP are already present in Tsc2*' mice.
Interestingly, the eEF2 kinase KO mouse displays a strikingly similar phenotype-
deficient mGluR-LTD and enhanced L-LTP (Park et al., 2008)- suggesting mTOR-dependent
regulation of eEF2 is indeed a potential mechanism for switching between mGluR- and mTOR-
regulated mRNA pools. Reconstituting the inhibition of elongation normally imposed by eEF2
kinase with a low concentration of CHX was shown to rescue mGluR-LTD in the eEF2 kinase
KO. This treatment may be similarly effective in Tsc2*' mice if the suppression of mGluR-LTD
is indeed due to mTOR-dependent activation of eEF2. In contrast, increasing eIF2a
phosphorylation results in deficient L-LTP (Jiang et al., 2010), suggesting this may not the
manner by which mTOR regulates protein synthesis in the Tsc2*/ mice.
The above studies suggest a simple hypothesis: TSCl/2, mTOR, and eEF2 kinase
regulate a pool of mRNA required for synaptic strengthening (LTP) while mGluR5, ERK and
FMRP control the synthesis of proteins required for synaptic weakening (LTD) (Figure 3.7B).
There is some evidence that LTP is deficient in the hippocampus of Fmr1 KO mice (Hu et al.,
2008; Lauterborn et al., 2007; Lee et al., 2011; Meredith et al., 2011; Shang et al., 2009),
however others have found no difference in the threshold for LTP (Godfraind et al., 1996; Zhang
et al., 2009). Moreover, in Chapter 2 we demonstrated that FMRP-regulated protein synthesis
does play a role in some forms of LTP maintenance. Thus, the differential translation of mRNA
at the synapse is likely to be more complicated than simply LTP vs. LTD. However this model
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provides a framework for testable hypotheses that may lend more insight into how protein
synthesis is regulated at the synapse and what functions it serves. Determining which proteins
are under control of TSC 1/2 and FMRP will be instrumental to our understanding of the different
functions these two pools may serve. Proteomic comparison of the Tsc2*/ x Fmr1 KO cross
mice provide an excellent means to this end, as they allow for examination of the protein make-
up of the same synapses in littermate mice carrying the Fmr] mutation, the Tsc2 mutation, or
both, under identical experimental conditions.
3.4.4 Role of mGluR dysfunction in TSC and ASD
The current findings also suggest a new treatment for behavioral deficits associated with
TSC. Previous studies in the Tsc2*/- mouse raised the exciting possibility that cognitive aspects
of the disorder might be ameliorated with rapamycin, even when treatment is begun in adulthood
(Ehninger et al., 2008a). Our data show that an mGluR5 PAM may be similarly effective.
While rapamycin has been used clinically, it is problematic for chronic treatment because of its
strong immunosuppressive properties and potential for harmful side-effects (Tsai et al., 2013).
Furthermore, studies have shown that some beneficial effects of rapamycin are short-lived and
symptoms return as soon as treatment is terminated (Bissler et al., 2008). Thus, positive
modulation of mGluR5 may be a useful compliment or alternative to rapamycin treatment in
TSC. The benefits of mGluR5 PAMs are that they have higher receptor specificity, enhance
activity in a physiologically relevant manner, and most importantly, they specifically target the
synaptic mechanisms that are likely responsible for the cognitive and behavioral impairments in
TSC. Future studies are needed to determine the efficacy of mGluR5 treatment on other aspects
of the disorder, such as tumor growth and seizures.
TSC and FX represent two leading genetic risk factors for ASD and ID (Fombonne,
2003). Although great strides have been made in identifying genetic variations that correlate
with non-syndromic autism, there is little known about ASD pathophysiology-knowledge that
is essential for developing effective therapies. Our test of the hypothesis that the Fmr1 KO and
Tsc2 - mouse models of FX and TSC have a shared synaptic pathophysiology revealed instead
that they are at opposite ends of a spectrum: the Fmr] mutation causes exaggerated synaptic
protein synthesis and LTD that are corrected by inhibition of mGluR5 (Dolen et al., 2007;
Michalon et al., 2012), whereas the Tsc2 mutation causes diminished synaptic protein synthesis
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and LTD that are corrected by augmentation of mGluR5 (Figure 3.6A). Moreover, the opposing
effects of these mutations balance one another at synaptic and behavioral levels in the double
mutant. This finding is interesting in light of recent discoveries that gain- and loss-of-function
mutations in individual genes, such as MECP2, can often yield syndromes with overlapping
features, such as epilepsy, cognitive impairment, and ASD (Ramocki and Zoghbi, 2008). Our
findings reveal that even genetically heterogeneous causes of ASD and ID may produce similar
deficits by bidirectional deviations from normal on a common functional axis.
The results presented here not only provide further insight into ASD etiology, but also to
the treatment of ASD. The present results suggest that altered mGluR activity may indeed be a
common autism pathology, further supporting the notion for mGluR5-based therapies. However,
the relationship between this molecular perturbation and the clinical manifestation of ASD is
complex, as we found that opposing alterations in mGluR-mediated protein synthesis may
manifest as similar cognitive impairments. The important implication is that therapies designed
to correct one cause of ASD are not likely to be effective for all other causes, and might well be
deleterious. It will be critical to understand where a patient lies on the spectrum of synaptic
function to choose an appropriate therapy for ASD and other psychiatric disorders.
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3.5 Methods
3.5.1 Animals
Tsc2*/- male and female mutant mice on the C57Bl/6J clonal background were bred with
C57Bl/6J WT partners to produce the WT and Tsc2*1 offspring used in this study. For genetic
rescue experiments, heterozygous Tsc2 male mice (Tsc2 1) were bred with heterozygous Fmr1
females (Fmr1 x*/x ), both on the C57B1/6J clonal background, to obtain Fl male offspring of
four genotypes: wild type (Tsc2+'*, Fmr1'l), Fmr] KO (Tsc2+'*, Fmr1- ), Tsc2 Het (Tsc2 ',
Fmr +/Y), and Cross (Tsc2+-, Fmrl- ) (Figure 3.6.B). All experimental animals were age-
matched male littermates, and were studied with the experimenter blind to genotype and
treatment condition. Animals were group housed and maintained on a 12:12 hr. light:dark cycle.
The Institutional Animal Care and Use Committee at MIT approved all experimental techniques.
3.5.2 Electrophysiology
Acute hippocampal slices were prepared from P25-35 animals in ice-cold dissection buffer
containing (in mM): NaCl 87, Sucrose 75, KCl 2.5, NaH2 PO 4 1.25, NaHCO 3 25, CaCl 2 0.5,
MgSO 4 7, Ascorbic acid 1.3, and D-glucose 10 (saturated with 95% 02 / 5% C0 2). Immediately
following slicing the CA3 region was removed. Slices were recovered in artificial cerebrospinal
fluid (ACSF) containing (in mM): NaCl 124, KCl 5, NaH2 PO 4 1.23, NaHCO 3 26, CaCl 2 2,
MgCl 2 1 and D-glucose 10 (saturated with 95% 02/5% C0 2 ) at 32.5 C for >3 hours prior to
recording.
Field recordings were performed in a submersion chamber, perfused with ACSF (2-3 ml/
min) at 30 "C. Field EPSPs (fEPSPs) were recorded in CA1 stratum radiatum with extracellular
electrodes filled with ACSF. Baseline responses were evoked by stimulation of the Schaffer
collaterals at 0.033 Hz with a 2-contact cluster electrode (FHC) using a 0.2 ms stimulus yielding
40-60% of the maximal response. fEPSP recordings were filtered at 0.1 Hz - 1 kHz, digitized at
10 kHz, and analyzed using pClamp9 (Axon Instruments). The initial slope of the response was
used to assess changes in synaptic strength. Data were normalized to the baseline response and
are presented as group means ± SEM. LTD was measured by comparing the average response
55-60 minutes post DHPG application to the average of the last 5 minutes of baseline.
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The input output function was examined by stimulating slices with incrementally
increasing current and recording the fEPSP response. Paired pulse facilitation was induced by
applying two pulses at different interstimulus intervals. Facilitation was measured by the ratio of
the fEPSP slope of stimulus 2 to stimulus 1. NMDAR-dependent LTD was induced by
delivering 900 test pulses at 1 Hz. mGluR-LTD was induced by applying R, S-
Dihydroxyphenylglycine (R,S-DHPG, 50 pM) or S-Dihydroxyphenylglycine (S-DHPG, 25 gM)
for 5 minutes, or by delivering 1200 pairs of pulses (with a 50 ms interstimulus interval) at 1 Hz.
In some experiments slices were incubated with the protein synthesis inhibitor cycloheximide
(60 pM) for 30 minutes as follows: 20 minutes during baseline recording, 5 minutes during
DHPG application and 5 minutes post DHPG application. For mGluR PAM experiments, slices
were pretreated with CDPPB (10 ptM) or DMSO control for 30 minutes in same manner as
above, either in the presence of cycloheximide or control ACSF. For rapamycin experiments,
slices were pretreated with rapamycin (20 nM) or DMSO control, with or without
cycloheximide, for at least 30 minutes prior to recording and throughout the entire experiment.
Significance was determined by two-way ANOVA and post-hoc Student's t-tests. Statistics were
performed using each animal as an "n", with each animal represented by the mean of 1-4 slices.
All experiments were performed blind to genotype and include interleaved controls for genotype
and treatment.
3.5.3 Metabolic labeling of new protein synthesis
Performed as described by Osterweil et al (Osterweil et al., 2010). Briefly, 500 pm slices were
recovered for 4 h in 32.50C ACSF (in mM: 124 NaCl, 3 KCl, 1.25 NaH2PO 4, 26 NaHCO 3, 10
dextrose, 1 MgCl 2 , 2 CaCl2, saturated with 95% 02 and 5% C0 2), incubated for 30 min with 25
ptM ActD ± rapamycin (20 nM) or CDPPB (10 pM), and transferred to fresh ACSF ± drug with
10 pCi/ml 3 5S-Met/Cys (Perkin Elmer) for another 30 min. After labeling, slices were
homogenized, and labeled proteins isolated by TCA precipitation. Samples were read with a
scintillation counter and also subjected to a protein concentration assay (Bio-Rad). Final data
were expressed as counts per minute (CPM) per jig protein, normalized to the 3 5S-Met/Cys
ACSF used for incubation, and the average incorporation of all samples analyzed in that
experiment. For autoradiography, homogenized slices were processed for SDS PAGE,
transferred to nitrocellulose, stained for total protein using the Memcode staining kit (Pierce),
and 3 5S-incorporated proteins visualized with the aid of a phosphorimager (Fujifilm).
Chapter 3 - Opposing deviations in mGluR5 function in Fmri KO and Tsc2+/ mice 87
3.5.4 Immunoblotting
Immunoblotting was performed according to established methods using primary antibodies to
Arc (Synaptic Systems), p-ERKl/2 (Thr202/Tyr2O4) (Cell Signaling Technology) or ERKl/2
(Cell Signaling Technology). ERK1/2 phosphorylation was measured by densitometry (Quantity
One), and quantified as the densitometric signal of p-ERK1/2 divided by the ERKl/2 signal in
the same lane. To quantify Arc expression, the densitometric signal of Arc was divided by the
total protein signal (determined by Memcode staining) in the same lane.
3.5.5 Immunoprecipitation
Hippocampal slices (5-8 per animal) were metabolically labeled with 50 pCi/ml 35S-Met/Cys for
3 h, and immunoprecipitation (IP) performed on yoked WT and Tsc2+/- slices essentially as
described previously(Osterweil et al., 2010). Briefly, slices were homogenized in IP lysis buffer
(Pierce) plus protease inhibitors (EMD Biosciences), spun at 16,000 x g, and supernatants pre-
cleared with protein A/G sepharose. To avoid contamination of the Arc signal with IgG heavy
chain, immunoprecipitation was performed using columns of monoclonal Arc antibody (a
generous gift from P. Worley) crosslinked to protein A/G sepharose (Pierce Crosslink IP Kit).
Immunoprecipitated Arc was resolved on SDS PAGE gels, transferred to nitrocellulose, and
exposed to a phosphorimager screen for 2-3 weeks. The same membranes were then
immunoblotted for Arc. For each sample, the ratio of 3 5S-incorporated : total was calculated by
dividing the density of the band seen by autoradiography to the density of band seen by
immunoblot (in the same lane). To ensure the specificity of Arc IPs, lysates from metabolically
labeled hippocampal slices were incubated with either mouse monoclonal anti-Arc or non-
immune mouse IgG, and IP experiments performed as described above. Immunoblot analysis
reveals that Arc is significantly enriched in anti-Arc IPs versus IgG IPs from the same lysates (t-
test IgG vs. Arc *p = 0.002; n = 5 animals). Additionally, autoradiographs confirm the absence
of 3 5S-incorporated protein in the IgG IP.
3.5.6 Contextual fear conditioning
6-12 week old WT, Tsc2*/, Fmr1-l, and Cross (Tsc2*/- x Fmrl) mice were fear conditioned to
the training context with one 0.8 mA shocks (2 sec) as described by Ehninger et al {Ehninger,
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2008, 18568033}. The mice were allowed 3 minutes to explore context before conditioning and
were removed 15 sec after the shock was given and returned to home cage. Conditioned fear
response was assessed 24 hours later by a trained observer blind to condition, measuring the
percentage of time spent freezing during the test period (3 min session). To determine context
specificity of the conditioned response, mice trained at the same time were separated into two
groups: one group was tested in the same training context and the other tested in a novel context.
This novel context was created by varying: distal cues, odor (2% acetic acid vs. 70% ethanol),
floor material (plastic vs. metal bars), and lighting (red vs. white) of the testing apparatus. For
rescue experiments, animals received a single injection of CDPPB (10 mg/kg, i.p.) 30 minutes
prior to training session.
3.5.7 Reagents
(R,S)-3,5-dihydroxyphenylglycine (R,S-DHPG) was purchased from Tocris Biosciences
(Ellisville, MO) and (S)-3,5-dihydroxyphenylglycine (S-DHPG) was purchased from Sigma (St.
Louis, MO). Fresh bottles of DHPG were prepared as a 1 00x stock in H20, divided into
aliquots, and stored at -80'C. Fresh stocks were made once a week. Rapamycin (EMD
Biosciences, San Diego, CA) was prepared at 10 mM stock in DMSO and stored at -80'C. Final
concentration of rapamycin was 20 nM in < 0.01% DMSO. Cycloheximide (Sigma) was
prepared daily at 100x stock in H20. For slice experiments, 3-Cyano-N-(1,3-diphenyl-1H-
pyrazol-5-yl)benzamide (CDPPB, EMD Biosciences) was prepared daily at 75 mM stock in
DMSO with 0.5% bovine serum albumin (BSA) and diluted in ACSF to achieve final
concentration of 10 gM in < 0.1% DMSO. For in vivo experiments, CDDPB was suspended in a
vehicle consisting of 20% (2-Hydroxypropyl)-(R)-cyclodextrin in sterile saline. All other
reagents were purchased from Sigma.
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Figure 3.1 - Tsc2 '~ mice have a specific deficit in mGluR-LTD
(A) DHPG induces significantly less LTD in slices from Tsc2*/ mice as compared to slices from
littermate WT mice (74.3 ± 1.4%, n = 5 animals, 10 slices; Tsc2*/~: 86.3 ± 3.1%, n = 6 animals,
12 slices; *p = 0.004). (B) Synaptically-induced mGluR-LTD, elicited by delivering pairs of
pulses (50 ms interstimulus interval) at 1 Hz for 20 minutes (PP-LFS, 1200 pulses) in the
presence of the NMDA receptor antagonist D-(-)-2-Amino-5-phosphonopentanoic acid (D-AP5,
50 gM), is also deficient in slices from Tsc2+'~ mice (WT: 65.1 ± 2.1%, n = 3 animals, 9 slices;
Tsc2*/': 85.0 ± 2.5%, n = 4 animals, 11 slices; *p = 0.003). (C) The magnitude of NMDA
receptor-dependent LTD evoked by low frequency stimulation (LFS, 900 pulses at 1 Hz) does
not differ between genotypes (WT: 79.8 ± 1.6%, n = 4 animals, 6 slices; Tsc2*/~: 79.4 ± 1.9%, n
= 6 animals, 6 slices; p = 0.610). (C) Basal synaptic transmission (plotted as fEPSP amplitude
against presynaptic fiber volley amplitude) does not differ between genotypes. Scales bars equal
0.5 mV, 5 ins. Error bars represent SEM. (D) Paired pulse facilitation is normal across several
inter-stimulus intervals (20, 30, 50, 100, 200, 300, 500 ms) in Tsc2*/- mice. Scale bars equal 0.5
mV, 20 ms for representative field potential traces. Error bars represent SEM. (E) Hippocampal
slices were stimulated with 50 pM DHPG for 5 min, and ERK1/2 activation (phosphorylation)
assessed via immunoblot (WT: 100.0 ± 6.1%, WT DHPG: 119.6 5.5%, Tsc2*'~: 97.5 ± 5.6%,
Tsc2+' DHPG: 116.2± 3.9%; ANOVA: genotype p = 0.623, treatment *p = 0.0008, genotype x
treatment p = 0.923; n = 9 animals). Results reveal that DHPG significantly increases ERK1/2
activation in both WT (*p = 0.040) and Tsc2*/~ (*p = 0.003). Error bars represent SEM.
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Figure 3.2 - The protein synthesis-dependent component of mGluR-LTD is absent in
Tsc2*'~ mice. (A) LTD is significantly attenuated by pretreatment with the protein synthesis
inhibitor cycloheximide (CHX, 60 pM, gray bar) in slices from WT animals (control: 74.3 ±
1.4%, n = 5 animals, 10 slices; CHX: 85.2 ± 2.8%, n = 4 animals, 7 slices; *p = 0.014). (B)
CHX treatment has no effect on DHPG-LTD in slices from Tsc2*'~ mice (control: 86.3 + 3.1%, n
= 6 animals, 12 slices; CHX: 85.3 3.2%, n = 4 animals, 7 slices, p = 0.796). ANOVA:
genotype *p = 0.041, treatment p = 0.089, genotype x treatment *p = 0.045. (C) Presynaptic
LTD is not affected by genotype or CHX (see also Figure 3.3). DHPG significantly increased
PPF in slices from both WT and Tsc2*/- mice (PPF with a 50 ms inter-stimulus interval: WT
baseline: 1.37 ± 0.02, WT DHPG: 1.59 ± 0.06, n = 5 animals, 9 slices, *p = 0.003; Tsc2*/-
baseline: 1.39 ± 0.02, Tsc2*1~ DHPG: 1.64 ± 0.03, n = 5 animals, 9 slices, *p = 0.001) and this
effect was not blocked by CHX (WT DHPG + CHX: 1.58 ± 0.06, n = 7 animals, 11 slices, p
0.89; Tsc2*/~ DHPG + CHX: 1.64 ± 0.04, n = 6 animals, 7 slices, p = 0.94). (D) Metabolic
labeling of hippocampal slices reveals a significant reduction of basal protein synthesis in Tsc2*/-
mice (WT: 100.0 ± 3.1%, Tsc2*'~: 88.2 ± 3.3%, n = 13 animals; *p = 0.043). Differences in
protein synthesis are exemplified by representative autoradiograph and total protein stain of the
same membrane. (E) Immunoblotting experiments show that Arc expression is significantly
reduced in Tsc2*/- hippocampal slices (WT: 100.0 ± 4.7%, Tsc2*/~: 76.6 ± 6.4%, n = 12 animals;
*p = 0.005). (F) Arc translation was measured by metabolic labeling of hippocampal slices,
followed by immunoprecipitation of Arc. Comparison of the ratios of 3 5S-incorporated : total
Arc reveals a significant reduction in Arc translation in the Tsc2*/~ hippocampus (WT: 100.0
11.5%, Tsc2*1-: 74.7 ± 6.8%, n = 19 animals; *p = 0.0498 ).
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Figure 3.3 - Presynaptic component of DHPG-induced LTD. Pairs of stimulation at several
different inter-stimulus intervals were delivered during the baseline period and 60 minutes post
DHPG application in slices either pretreated with CHX or control ACSF. (A,B) DHPG
significantly increased paired pulse facilitation (PPF) in slices from both wild-type (A) and
Tsc2±/~ mice (B) across many inter-stimulus intervals (WT, n = 5 animals totaling 9 slices; Tsc2+'
, n = 5 animals totaling 9 slices; *p < 0.01, +p < 0.05). (C,D) The enhancement of PPF by
DHPG is not affected by the protein synthesis inhibitor cycloheximide (WT, n = 7 animals
totaling 11 slices; Tsc2*/-, n = 6 animals totaling 7 slices; *p < 0.01, +p < 0.05). There was no
difference in paired pulse ratio between wild-type and Tsc2*/~ mice at baseline, post DHPG, or
post DHPG + CHX. Error bars represent SEM.
93
A
a-1.8-
1.6-
C 1.4-
C,-
a-1.2-
'- 1.0-
0
0~.
C
(L
CM,
ClJa-
0
Cu
cr 500
0.8V-
94 Chapter 3 - Opposing deviations in mGluR5 function in Fmr1 KO and Tsc2"~ mice
Chapter 3 - Opposing deviations in mGluR5 function in Fmr1 KO and Tsc2+ mice
A B C
e DMS0 oRapamycin eDMSO oRAP in CHX -
1 2 1 2 1 2 1 2
- ~(V V- - A/-- t100--
120 DHPG 120 DHPG 75-
100o - - 2-- --- --  - -- - - -- - -
6R 80- A* 80- ~ 50-
60- 60 -- 25
0 40- RAP 0 40- RAP + CHX
S20 20 1
2L -20-10 0 10 20 30 40 50 6070 -20-10 0 10 20 30 40 50 60 70 . APO
Time (min) Time (min) Control Rap
D E F
e*DMSO oRapamycin * DMSO 0 RAP in CHX p-p70S6K
1 2 1 2 1 2 1 2
p7056K
120 DHPG 120 PG 150-
100 - - - - - - - - - - 100 - - - -1 0 I
80 - 80100..-.-.-.-0-
0. .60-
0 0 50
-m 40 RAP Vi 40 RAP + CHX
20 T- Vi20
-20-10 0 10 20 30 40 50 60 70 -20 -10 0 10 20 30 40 50 670 0
Time (min) Time (min) Rapamycin - +
Figure 3.4 - Excessive mTOR activity suppresses the protein synthesis required for
mGluR-LTD. (A) Pretreatment of slices with the mTORC 1 inhibitor rapamycin (RAP, 20 nM,
gray bar) significantly enhances DHPG-induced LTD in slices from Tsc2*/~ mice (DMSO: 85.7
2.1%, n = 8 animals, 17 slices; RAP: 72.9 ± 1.8%, n = 7 animals, 18 slices; *p = 0.002). (B) The
rescue by rapamycin of DHPG-induced LTD in Tsc2+1~ mice is prevented by the protein synthesis
inhibitor cycloheximide (DMSO: 87.1 ± 4.7%, n = 6 animals, 10 slices; RAP: 88.1 ± 2.4%, n = 7
animals, 9 slices; p = 0.796). ANOVA: rapamycin treatment *p = 0.043, cycloheximide
treatment *p = 0.004, rapamycin x cycloheximide *p = 0.018. (C) Metabolic labeling
experiments show that rapamycin (20 nM) normalizes protein synthesis in the Tsc2*/-
hippocampus to WT levels (WT DMSO: 100.0 ± 2.5%, WT RAP: 106.5 ± 3.6%, Tsc2*/- DMSO:
88.8 ± 2.6%, Tsc2*/~ RAP: 100.4 ± 3.9%; ANOVA: genotype *p = 0.008, treatment *p = 0.006,
genotype x treatment p = 0.430; t-test: WT vs. Tsc2*/- DMSO *p = 0.003; WT vs. Tsc2*/- RAP p
= 0.344; Tsc2*'~ DMSO vs. RAP *p = 0.037; n = 22 animals). Error bars represent SEM. (D)
Pretreatment of slices from WT mice with rapamycin (RAP, 20 nM, gray bar) has no effect on
DHPG-induced LTD in hippocampal slices from WT animals (DMSO: 73.2 ± 3.3%, n = 7
animals totaling 12 slices; RAP: 71.9 ± 4.1%, n = 7 animals totaling 12 slices; p = 0.807).
Representative field potential traces (average of 10 sweeps) were taken at times indicated by
numerals. Scale bars equal 0.5 mV, 5 ms. Error bars represent SEM. (E) Co-application of
cycloheximide and rapamycin in WT slices still attenuates LTD (DMSO+CHX: 88.2% ± 11.8%,
n = 3 animals totaling 5 slices; RAP+CHX: 87.4% ± 12.6%, n = 2 animals totaling 4 slices) (F)
Rapamycin treatment robustly downregulates mTORC 1 activity. Recovered hippocampal slices
were incubated ± 20 nM rapamycin for 1 hour, then homogenized and processed for SDS PAGE.
mTORC1 activity was assessed by measuring the phosphorylation of p70S6K (at Thr3 89), the
direct substrate of mTORC 1. Western blotting confirms that rapamycin robustly reduces
p70S6K activation (control 100 ± 9%, rapamycin 15 ± 4%, *p = 0.0001; n = 13 animals). Error
bars represent SEM.
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Figure 3.5 - Positive modulation of mGluR5 reverses synaptic and behavioral deficits in
Tsc2*/~ mice. (A) Model to account for effects of Tsc2* - and Fmr-Y mutations on mGluR5- and
protein synthesis-dependent LTD. This model predicts that this impairment can be overcome
either by inhibiting mTOR with rapamycin or by augmenting mGluR5 signaling with CDPPB, an
mGluR5 PAM. (B) Pretreatment of slices from Tsc2*/~ mice with CDPPB (10 gM, gray bar)
significantly enhances DHPG-induced LTD (DMSO: 86.4 ± 2.5%, n = 8 animals, 13 slices;
CDPPB: 71.7 ± 3.9%, n = 7 animals, 12 slices; *p < 0.001). (C) CDPPB treatment fails to
enhance DHPG-induced LTD in Tsc2*~ mice when co-applied with the protein synthesis
inhibitor cycloheximide (DMSO: 89.0 ± 4.4% n = 8 animals, 10 slices; CDPPB: 83.9 ± 2.1%, n
7 animals, 9 slices; p = 0.64). ANOVA: CDPPB treatment *p = 0.008, CHX treatment p =
0.087, CDPPB x CHX *p = 0.034. (D) CDPPB (10 gM) restores protein synthesis in the Tsc2*/
hippocampus to WT levels (WT DMSO: 100.0 ± 3.2%, WT CDPPB: 97.2 1.9%, Tsc2*'~
DMSO: 86.1 ± 2.7%, Tsc2*'~ CDPPB: 94.9 ± 3.0%; ANOVA: enotype *p = 0.006, treatment p
= 0.275, genotype x treatment *p = 0.041; t-test: WT vs. Tsc2 DMSO *p = 0.012; WT vs.
Tsc2*/~ CDPPB p = 0.538; Tsc2*/- DMSO vs. CDPPB *p = 0.049; n = 17 animals). (E) CDPPB
exposure significantly increases Arc translation in the Tsc2*/~ hippocampus (WT DMSO 100.0 ±
28.2%, WT CDPPB 121.0 ± 21.2%, Tsc2*'~ DMSO 59.2 ± 7.0%, Tsc2*/- CDPPB 129.4 ± 20.3%;
ANOVA genotype p = 0.554, treatment *p = 0.0094, genotype x treatment p = 0.114; t-test:
Tsc2*/~ DMSO vs. CDPPB *p = 0.026; n = 6 animals). Error bars represent SEM. (F)
Experimental design of context discrimination task. (G) WT mice display intact memory by
freezing more in the familiar context than the novel context (Black bars; Familiar: 50 ± 7.7%, n
= 12; Novel: 34.1 ± 3.2%, n = 14; *p = 0.003). A single injection of CDPPB (10 mg/kg, i.p.) 30
minutes prior to training has no effect on WT context discrimination (Familiar: 42.3 ± 3.7%, n =
12; Novel: 26.4 ± 3.6%, n = 12; *p = 0.005). Control Tsc2*' mice display a significant
impairment in context discrimination (Blue bars; Familiar: 40.9 ± 5.3%, n = 11; Novel: 39.3 ±
5.2%, n = 14; p 0.501), but this deficit is corrected by a single injection of CDPPB (Familiar:
44.5 ± 4.3%, n = 11; Novel: 31.6 ± 3%, n = 12; *p = 0.034). Error bars represent SEM.
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Figure 3.6 - Genetic cross of Tsc2+'- and Fmr1 KO mice rescues synaptic and behavioral
impairments present in both single mutants. (A) The data suggest that mutations in TSC and
FXS cause opposing deviations in synaptic function which impairs neuronal performance and
respond to opposite alterations in mGluR5 signaling(Bear et al., 2008; Kelleher and Bear, 2008).
These results raise the possibility that introducing both mutations to a mouse may normalize
aspects of neural function. (B) Genetic rescue strategy. Heterozygous Tsc2 male mice (Tsc2+~)
were bred with heterozygous Fmr1 females (Fmr1 x*/x-) to obtain male offspring of four
genotypes: wild type (Tsc2*'*, Fmr ±Y), Fmr1 KO (Tsc2*'*, Fmr Y), Tsc2 Het (Tsc2*/-, Fmr1*),
and Cross (Tsc2, Fmr1~l). (C) DHPG-induced LTD is significantly decreased in slices from
Tsc2*1~ mice (*p = 0.002) and significantly increased in slices from Fmr] T mice (*p = 0.017), as
compared to WT slices. DHPG-LTD in slices from Tsc2*/~ x Fmr-l mice is comparable in
magnitude to WT slices (p = 0.558). (WT: 78.9 + 2.1%, n = 7 animals, 17 slices; Fmr : 71.2
2.7%, n = 7 animals, 21 slices; Tsc2: 89.5 ± 2.6%, n = 7 animals, 15 slices; Cross: 77.4 ± 1.8%, n
= 9 animals, 19). (D) Summary of LTD data. Bar graphs represent percent decrease from
baseline in fEPSP (average of last 5 minutes of recording ± SEM); *p < 0.05, **p < 0.01. (E)
Both mutations cause a deficit in context discrimination that is rescued in the double mutant.
WT mice (Familiar: 42.9 + 4.6%, n = 11; Novel: 27.8 3.4%, n = 12; *p = 0.024) , Fmr1~l mice
(Familiar: 49.0 ± 5.6%, n = 11; Novel: 43.5 6.7%, n = 12; p = 0.483), Tsc2*/- (Familiar: 42.1 ±
6.8%, n = 12; Novel: 35.6 6.0%, n = 12; p = 0.395) and Tsc2*' x FmrT'l mice (Familiar: 50.5
± 5.2%, n = 11; Novel: 29.8 ± 5.2%, n = 11; *p = 0.011). Error bars represent SEM.
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Figure 3.7 - Models to account for opposing alterations in mGluR responses in Tsc2*~- and
Fmr1 KO mice. (A) Hyperphosphorylation of FMRP model. Phosphorylation of FMRP is
thought to enhance its translation repressing abilities. mTOR is known to regulate FMRP
phosphorylation via is downstream effector S6K. In Tsc2*/- mice, the tonic inhibition of mTOR
normally imposed by TSC1/2 is absent, resulting in chronic over-activation of mTOR. This
excessive mTOR activation may lead to hyperphosphorylation of FMRP and suppress the
synthesis of FMRP targets, subsequently leading to deficient mGluR-LTD and decreased protein
synthesis rate. Some predictions of this model would be increased phoso-FMRP levels in Tsc2*'
mice and restoration of LTD and protein synthesis levels in these mice by expression of a
phospho-resistance FMRP. Activation of mGluR5 has been demonstrated to de-phosphorylate
FMRP, suggesting that mGluR5 PAM treatment may restore LTD and protein synthesis rates by
enhancing the activity of PP2A. (B) Two pools model. Two pools of mRNA exist at the
synapse whose translation is mutually exclusive. mGluR-mediated ERK activation results in
synthesis of proteins required for LTD and regulated by FMRP (Pool 1). mTOR regulates
synthesis of a separate, competing pool of proteins required for expression of L-LTP that is
regulated by TSC 1/2 (Pool 2). Consistent with this idea, de-repression of Pool 1 (by deletion of
Fmr1) results in exaggerated LTD while de-repression of Pool 2 (by reduction in Tsc2) results in
enhanced LTP. Potential mechanisms for mutual inhibition may involve differential regulation
of initiation and/or elongation by the ERK and mTOR pathway or competition for translation
machinery.
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4.1 Abstract
Evidence from genetic and molecular studies has demonstrated that altered synaptic
protein synthesis downstream of metabotropic glutamate receptor 5 (mGluR5) may be a common
disruption in autism spectrum disorders (ASD). This work has suggested a variety of targets,
one of the most promising being direct manipulation of mGluR5 activity. However, there is a
concern that global manipulation of mGluR5 will also affect processes that are unrelated to
autism pathophysiology, resulting in side effects that will sharply limit the utility of this
approach. Ideally, pharmacological treatments should specifically interfere with the signaling
pathways that regulate protein synthesis leaving other arms of signaling unaffected. In this
study, we determined if P-arrestin signaling is a critical link between mGluR5 activation and
mGluR-mediated protein synthesis and synaptic plasticity. P-arrestins are adaptor proteins that
are important for the regulation of G-protein coupled receptors (GPCRs), such as mGluR5, and
recently have been shown to be directly involved in a novel form of GPCR signaling that is
independent of G-protein activation. Specifically, f-arrestins have been shown to recruit the
extracellular regulated kinase (ERK) pathway required for mGluR-dependent protein synthesis
and synaptic plasticity. We found that mGluR-mediated ERK activation was severely disrupted
in P-arrestin 2 heterozygous and homozygous KO mice. The consequences of this disruption
were functionally relevant, as the protein synthesis-dependent component of mGluR-LTD was
also absent in these mice. Thus, targeting P-arrestin-mediated signaling may be a way to
specifically modulate dysregulated protein synthesis associated with ASD, potentially leading to
the next generation of selective drugs for the treatment of ASD.
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4.2 Introduction
In Chapter 2 we demonstrated that many processes that rely on mGluR-mediated protein
synthesis are exaggerated in the Fmr1 KO mouse, including mGluR-LTD, and it has been
suggested that this exaggeration may account for the diverse phenotypes associated with fragile
X (FX) (Bear et al., 2004). While the role of aberrant neuronal protein synthesis and mGluR5
activity in the pathophysiology of FX is well characterized, we demonstrated in Chapter 3 that
disruptions in the mGluR pathway do not appear to be limited to this disorder. In a mouse model
of tuberous sclerosis complex (TSC), the Tsc2+' mouse, there is diminished synaptic protein
synthesis and mGluR-LTD, suggesting that genetically heterogeneous causes of autism spectrum
disorders (ASD) and intellectual disability (ID) may produce similar deficits through
bidirectional deviations in mGluR-mediated protein synthesis (Figure 3.6). Recent studies have
now demonstrated disrupted mGluR function in numerous animal models of syndromic and non-
syndromic ASD (Bangash et al., 2011; Baudouin et al., 2012; Chen et al., 2011; Huber et al.,
2002; Phelan and McDermid, 2012), and human genetic studies have found that the protein
products of many genes embedded in the mGluR signaling pathway, including mGluR5 itself,
are associated with ASD (Iossifov et al., 2012; Kelleher Iii et al., 2012) (Skafidas et al., 2012).
Thus, there is an abundance of evidence to suggest that mGluR-mediated protein synthesis is a
common molecular pathway disrupted in ASD, making mGluR5 an attractive target for the
treatment of ASD.
Positive and negative allosteric modulators (PAMs and NAMs) of mGluR5 represent a
promising class of drugs for the treatment of ASD. Allosteric modulators are drugs that do not
directly activate or inhibit a receptor, but rather modulate the receptors' response to endogenous
activation, thereby modulating activity in a physiologically relevant way (Conn et al., 2009).
Furthermore, because these molecules do not bind to the orthosteric ligand binding site, which is
highly conserved between receptor subtypes, allosteric modulators with high subtype specificity
can be developed (Conn et al., 2009). Studies in the mouse models of FX and TSC have already
demonstrated the potential of using allosteric modulators of mGluR5 as a treatment for ASD.
For example, chronic treatment of Fmr1 mice with the mGluR5 NAM CTEP was shown to
correct not only mGluR-LTD and protein synthesis, but also a host of behavioral phenotypes
(Michalon et al., 2012). In line with this view, preliminary human clinical trials using mGluR5
NAMs have shown promise in the treatment of some symptoms associated with FX (Hagerman
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et al., 2012). In the previous chapter, we demonstrated that augmentation of mGluR5 with the
PAM CDDPB rescues biochemical, electrophysiological and behavioral impairments in Tsc2+1-
mice. Thus, positive modulators of mGluR5 may prove to be similarly beneficial in patients
with TSC.
Stimulating protein synthesis, however, is only one of the many functions of mGluR5
signaling. mGluR5 activation has a diverse array of cellular effects, including 2 "d messenger
recruitment, mobilization of intracellular calcium (Ca2+) stores, modulation of ion channels, and
the synthesis of endocannabinoids (Hermans and Challiss, 2001). Therefore, global
manipulation of mGluR5 activity, such as with the PAMs and NAMs described above, is likely
to affect some or all of these processes. Since evidence suggests that a primary pathogenic
culprit in ASD is altered protein synthesis, not mGluR signaling per se, therapies for ASD
should, ideally, specifically target mGluR-mediated protein synthesis while leaving these other
cellular processes unaffected. Indeed, there are reports that mGluR5 antagonism can result in
unwanted side effects (Olive, 2009) and these could jeopardize the success of clinical trials.
Therefore, it is of utmost importance to understand the mechanisms which couple mGluR5
activation to protein synthesis in order to develop more selective therapeutic interventions in
ASD.
4.2.1 Signaling pathways that couple mGluRs to protein synthesis
Although mGluR5 is a well-established activator of protein synthesis (Job and Eberwine,
2001; Osterweil et al., 2010; Weiler and Greenough, 1993), it remains uncertain how activation
of the receptor regulates this process. Canonically, mGluR5 signaling occurs through the Gq-
dependent activation of phospholipase Cp (PLC), which hydrolyzes phosphoinositides (PI)
leading to increases in diacyl glycerol (DAG), which subsequently activates protein kinase C
(PKC) and D (PKD), and inositol triphosphate (IP3), whose receptor activation leads to
intracellular Ca 2 release (Figure 4.1A)(Abe et al., 1992). However, the role of this canonical
pathway in mGluR-mediated protein synthesis and LTD is unclear. While mGluR-LTD is
deficient in Gq knock out (KO) mice (Kleppisch et al., 2001), acute inhibition of PLCP or PKC
does not affect mGluR-LTD or protein synthesis (Mockett et al., 2011; Schnabel et al., 1999).
Furthermore, mGluR-LTD is not Ca2+-dependent as it can be evoked in the presence of Ca 2
chelators, with depletion of intracellular Ca2 stores, and even in a Ca 2 free medium (Fitzjohn et
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al., 2001; Gladding et al., 2009). Thus, mGluR-mediated protein synthesis may be mediated in a
G-protein independent manner.
On the other hand, mGluR activation has been shown to couple the ERK and mTOR
pathways (Figure 1.1), whose activation has proven to be crucial for mGluR-dependent protein
synthesis and LTD (Gallagher et al., 2004; Hou and Klann, 2004; Osterweil et al., 2010).
Targeting the ERK and mTOR pathways has been investigated as a potential avenue for
treatment in several ASD-associated disorders, and general inhibitors of mTOR or ERK have
indeed shown promise in some animal models (Ehninger et al., 2008a; Li et al., 2005; Osterweil
et al., 2013). However, the mTOR and ERK pathways are ubiquitously activated in all cell types
and are important for basic processes such as cell cycling and growth (Cargnello and Roux,
2011). Therefore, as with mGluR5-targeted therapies, manipulating this pathway may cause
potentially severe side effects (Tsai et al., 2013). The ideal pharmacological treatment would be
a neuronal receptor (e.g. mGluR5) based therapeutic agent that specifically interferes with the
signaling pathways that regulate protein synthesis while leaving the other arms of signaling
unaffected. Thus, it is imperative to understand the mechanisms that couple mGluR5 activation
to mTOR and ERK signaling in order to identify novel therapeutic targets in ASD.
Recent evidence has suggested that mGluR5 activation is coupled to the mTOR pathway
through interactions with the post-synaptic scaffolding protein Homer (Ronesi and Huber, 2008).
Homer can recruit the small GTPase phosphoinositide-3 kinase enhancer (PIKE) to directly
activate PI3K, leading to subsequent activation of the mTOR pathways (Figure 1.1). Disrupting
mGluR-Homer interactions specifically inhibits DHPG-induced P13K and mTOR activation
without affecting ERK signaling, suggesting that manipulation of this interaction may be a
specific way to regulate mGluR-dependent mTOR activation. However, studies in the Tsc2"
mouse (presented in Chapter 3) suggest that mTOR activation may actually suppress the
synthesis of LTD proteins (Figure3.5a). Therefore, disrupting this interaction may actually lead
to excess protein synthesis downstream of mGluR activation.
Consistent with this idea, mGluR5 is less associated with Homer in Fmr1 KO mice and
there is deficient mGluR-mediated mTOR activation (Ronesi et al., 2012). Increasing mGluR-
Homer interactions rescues some aspects of exaggerated protein synthesis in these mice, once
again suggesting that increasing mTOR activation may negatively regulate the protein synthesis
exaggerated in Fmr1 KO mice. However, restoring mGluR-Homer interactions in Fmr1 KO
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mice does not rescue exaggerated LTD or excess levels of specific LTD proteins, such as Arc
and Map lb (Ronesi et al., 2012). Therefore, alterations in mGluR-mTOR signaling are likely to
be a secondary consequence of disrupted protein synthesis in the Fmr1 KO mice. Thus, while
increasing mGluR-mediated mTOR activation via Homer interactions may be a beneficial
avenue for therapy in an indirect manner, it does not directly target the dysregulated protein
synthesis that is likely to be pathogenic.
The ERK pathway is a well-established mediator of mGluR-dependent protein synthesis
and LTD (Gallagher et al., 2004; Osterweil et al., 2010), and manipulation of several
components of this pathway has proved to be therapeutic in the mouse model of FX. Previous
work has shown that there is a hypersensitivity to ERK signaling in Fmr1 KO mice, and
inhibition of this pathway ameliorates excessive protein synthesis in these animals (Osterweil et
al., 2010). Furthermore, mild inhibition of Ras, an upstream regulator of ERK (Figure 1.1),
ameliorates several FX phenotypes in Fmr1 KO mice at the molecular, cellular, and behavioral
level (Osterweil et al., 2013).
Despite the strong support for the role of the ERK activation in mGluR-mediated protein
synthesis, how mGluR5 may couple to the ERK signaling cascade is poorly understood. While it
is known that Gq-protein activation can result in ERK phosphorylation via PKC signaling (Ueda
et al., 1996), mGluR activation in the hippocampus has been shown to recruit the ERK pathway
even in the presence of PLC inhibitors (Ronesi et al., 2012). Moreover, the fact that inhibition of
PKC or PLC3 does not disrupt mGluR-mediated protein synthesis (Mockett et al., 2011) or LTD
(Gallagher et al., 2004; Schnabel et al., 1999) suggests this G-protein dependent pathway is not
required for mGluR-mediated, ERK-dependent protein synthesis. Therefore, it is likely that
mGluR5-mediated ERK activation is achieved via a G-protein independent mechanism. The aim
of this study is to determine if 0-arrestins are the critical link between mGluR5 signaling and
subsequent activation of the ERK pathway, and thus a way to specifically target mGluR-
mediated protein synthesis and synaptic plasticity.
4.2.2 Q-arrestin-mediated signaling
p-arrestins are adaptor proteins that are important regulators of GPCR signaling and
cycling. Recently they have been shown to be directly involved in a novel form of GPCR
signaling that is independent of G-protein activation and which has distinct biochemical and
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functional consequences (Shenoy and Lefkowitz, 2011). The binding of -arrestins to GPCRs is
a requisite step for agonist-induced desensitization and internalization, resulting in the
termination of G-protein signaling (Figure 4.1 B) (Shenoy and Lefkowitz, 2011). However, by
acting as a scaffold, p-arrestins can also recruit signaling molecules to the receptor, leading to
the G-protein independent activation of these signaling pathways (Figure 4.1 C) (Pierce and
Lefkowitz, 2001). In this way, p-arrestins can dissociate GPCR signaling from its G-protein
counterpart, inhibiting canonical G-protein pathways while concurrently activating distinct G-
protein-independent signaling cascades (Figure 4.1 C). Interestingly, one of the most prominent
pathways recruited by this -arrestin-mediated signaling is the ERK pathway (Daaka et al., 1998;
Luttrell et al., 2001).
f-arrestins can provide a scaffold for Raf, MEK, ERK, and MNK (DeWire et al., 2008;
Luttrell et al., 2001), suggesting their binding to GPCRs may regulate mRNA translation via the
ERK pathway (Figure 4.1 C). In fact, j-arrestins have been shown to directly mediate protein
synthesis in an ERK-dependent manner (DeWire et al., 2008). This suggests the intriguing
possibility that protein synthesis downstream of mGluR5 is mediated by P-arrestin-dependent
ERK activation, and therefore dissociable from other G-protein-dependent mGluR processes
(Figure 4.1 C). If there is indeed this bifurcation in mGluR5 signaling, targeting the f-arrestin
pathway may be a way to specifically modulate the dysregulated protein synthesis and
accompanying synaptic and behavioral deficits observed in ASD without affecting other mGluR-
mediated processes. Importantly, there is a well-developed class of pharmacological agents that
preferentially target P-arrestin signaling over concurrent G-protein signaling, or vice versa-the
so called 'biased ligands' (Violin and Lefkowitz, 2007). Therefore, if f-arrestins are critically
involved in mGluR-mediated protein synthesis, it may be possible to develop more targeted
therapeutic agents for the treatment of ASDs without the side effects of current receptor-based
therapies or broad-spectrum signaling inhibitors.
There are two known neuronal isoforms of p-arrestin, P-arrestinl and 2. As of yet, there
is no systematic way to identify which -arrestins bind to which GPCRs as both isoforms
associate with a variety of classes of GPCRs (DeWire et al., 2007). Currently, it is unknown
which of the isoforms, or both, associate with mGluR5 (De Blasi et al., 2001). However, there
were several reasons we chose to explore the role of P-arrestin2 in mGluR-mediated protein
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synthesis and plasticity over f-arrestinl. First, P-arrestin2 is more promiscuous, binding to a
larger number of GPCRs (Kohout et al., 2001). Additionally, while both isoforms have been
shown to mediate cell signaling independent of G-protein activation, there is stronger evidence to
support the role of P-arrestin2 in modulating ERK activation and in directly stimulating protein
synthesis, particularly downstream of Gq-coupled receptors like mGluR5 (DeWire et al., 2007;
DeWire et al., 2008). Thirdly, f-arrestin2 is the more highly expressed isoform in the
hippocampus (Attramadal et al., 1992)(http://mouse.brain-map.org). Therefore, in the
experiments described in this chapter, we characterized the effect of genetically reducing I-
arrestin2 on mGluR function in the hippocampus. However, this does not preclude the
involvement of -arrestinI in regulating mGluR function, particularly in other brain areas
(Dhami and Ferguson, 2006). We found that mGluR-mediated ERK activation was severely
disrupted in P-arrestin2 heterozygous (Arrb2*/-) and homozygous (Arrb2-/-) KO mice. The
consequences of this disruption were functionally relevant, as the protein synthesis-dependent
component of mGluR-LTD was also absent in these mice. The results presented here
demonstrate that ERK activation downstream of mGluR5 is dependent upon P-arrestin-mediated
signaling, and thus may be a fundamental link between mGluRs and the dysregulated protein
synthesis in ASD.
4.3 Results
We first tested the hypothesis that P-arrestin2 is required for mGluR-induced ERK
activation in the hippocampus (Figure 4.2). Hippocampal slices from wild-type (WT), Arrb2*/~,
and Arrb2-'- mice were stimulated with the selective mGluR1/5 agonist (S)-
dihydroxyphenylglycine (DHPG, 25 uM) for 5 minutes, and levels of ERK phosphorylation were
assessed immediately, 15 minutes, and 30 minutes following DHPG treatment (Figure 4.2A).
We found no difference in basal ERK phosphorylation (pERK) or total protein levels between
slices obtained from WT and Arrb2 mutant mice (Figure 4.2B,C). DHPG treatment induced a
rapid and robust increase in pERK within 5 minutes in WT slices that was sustained for at least
15 minutes post-DHPG stimulation (Figure 4.2A). In contrast, DHPG-induced ERK activity was
markedly attenuated in slices from both Arrb2*' and Arrb2'- mice as compared to WT, with
pERK levels returning to baseline levels within 15 minutes for both mutants (Figure 4.2A). The
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residual ERK activation seen in the Arrb2 mutants is likely due to G-protein mediated signaling
(Wei et al., 2003).
P-arrestins have been shown to mediate several signaling cascades in addition to ERK,
including the AKT-mTOR pathway that has been implicated in the regulation of protein
synthesis and mGluR-LTD (DeWire et al., 2007; Gladding et al., 2009). There was no difference
in phosphorylation of Akt, mTOR, or its downstream target p70 S6 kinase between the WT and
the Arrb2 mutants (Figure 4.3). Furthermore, mGluR activation did not recruit the mTOR
pathway and reduction of Arrb2 did not affect stimulated activity of this pathway (Figure 4.3).
This is consistent with our previous results demonstrating mTOR signaling is not required for the
expression of mGluR-LTD (Figure 3.4).
ERK activation is required for mGluR-dependent protein synthesis and mGluR-LTD.
As expected, the same DHPG stimulation that increased pERK levels in WT slices also resulted
in significant LTD (Figure 4.4 A,D). This WT mGluR-LTD was significantly reduced when
DHPG was applied in the presence of the protein synthesis inhibitor cycloheximide (CHX,
60pM; Figure 4.4 A,D), demonstrating its protein synthesis dependency. In slices from Arrb2-'
and Arrb2'- mice, however, mGluR-LTD was significantly decreased as compared to WT levels
and the magnitude of mGluR-LTD was unaffected by CHX treatment (Figure 4 B,C). As with
our previous studies, the residual LTD remaining in Arrb2 deficient or CHX treated slices is
likely due to changes in presynaptic function (Figure 3.3). The data presented here demonstrate
that the protein synthesis-dependent component of mGluR-LTD is absent in Arrb2' mice.
Moreover, they suggest that f-arrestin 2 plays a prominent role not only in mediating mGluR-
dependent ERK activation but LTD as well.
There have been few studies to date examining the effect of P-arrestin deletion on
synaptic function. Determining whether synaptic function is affected by B-arrestin 2 deletion is
critical for interpreting the phenotypes observed in mGluR-mediated plasticity. We found there
was no difference in basal synaptic transmission, as measured by input-output relationship, or
presynaptic function, as measured by paired-pulse ratio (Figure 4.5 A,B). This suggests that
there are no gross alterations in synaptic function that may account for the deficiency in mGluR-
mediated plasticity observed in the Arrb2 mutants. Furthermore, we found no difference in the
magnitude of NMDAR-dependent LTD (Figure 4.5C), which is a mechanistically distinct form
of LTD that does not require ERK activation or protein synthesis for its initial maintenance.
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This demonstrates that the disruption of mGluR-LTD is not due to a global disruption in the
ability of Arrb2 deficient synapses to undergo activity-dependent depression.
4.4 Discussion
In this study, we examined the role of P-arrestin 2 in mGluR signaling in the
hippocampus. We found that mGluR-dependent ERK activation is deficient in Arrb2*/- and
Arrb2- mice. No differences were found in the recruitment of other signaling pathways, namely
the mTOR pathway, suggesting that P-arrestin 2 specifically couples mGluR activation to the
ERK cascade. The disruption in ERK activation appears to have functional consequences as
well, as Arrb2 deficiency was accompanied by diminished mGluR-LTD, likely due to the loss of
the protein synthesis-dependent component of this form of plasticity. As ERK activation is a
robust upstream indicator and LTD is a sensitive downstream consequence of mGluR-mediated
protein synthesis, these results suggest that p-arrestin 2 may couple mGluR activation to mRNA
translation. However, more work must be done to fully characterize P-arrestin signaling
downstream of mGluR function before these implications can be fully realized.
While P-arrestins have been shown to mediate GPCR-dependent cell signaling that is
independent of G-protein activation, they also act as important regulators of agonist-induced
GPCR desensitization and internalization (Figure 4.1). Therefore genetic deletion of Arrh2 is
likely to affect G-protein-dependent signaling downstream of mGluR5 activation in addition to
disrupting -arrestin-mediated processes. Determining whether canonical mGluR signaling is
affected by A rrb2 deletion is critical for proper interpretation of the cellular phenotypes observed
in this study. It will therefore be essential to examine G-protein-dependent mGluR-mediated
processes, such as PI turnover, Ca2+ mobilization or PKD phosphorylation in the Arrb2 mutants.
PKD phosphorylation is a particularly promising assay, as it is PLC- and PKC-dependent but
also specific to mGluR5 activation (Krueger et al., 2010).
-arrestin 2 regulates the function of many GPCRs (Pierce and Lefkowitz, 2001) and
therefore germ line deletion of A rrb2 likely affects many processes. The fact that mGluR-
mediated ERK activation and LTD were specifically disrupted in Arrb2 mutants, without the
alteration of basal ERK signaling or synaptic function, suggests that -arrestin 2 directly
mediates mGluR function. However, more work is required to explicitly demonstrate 0-
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arrestin2-mGluR5 interaction. Acute manipulation of this coupling may lend greater insight to
the role of -arrestin 2 in mGluR signaling. It will be important in future studies to specifically
delineate between G-protein- and -arrestin-dependent signaling in mGluR function. Ideally this
could be achieved by pharmacological agents with biased signaling (see below), however it is
also possible to engineer Gq-coupled receptors that have biased activation towards either G-
protein (Lan et al., 2009) or 1-arrestin signaling (Wei et al., 2003). These mutant receptors
would be able to distinguish the relative contributions of G-protein and p-arrestin signaling to
mGluR function in the hippocampus and would help define the mechanisms of mGluR-mediated
protein synthesis and LTD.
4.4.1 Implications for mGluR signaling and LTD
Activation of several neuronal GCPRs has been shown to recruit $-arrestin-dependent
signaling (Del'guidice et al., 2011; Zheng et al., 2008), including several mGluR subtypes
(Emery et al., 2012; Gu et al., 2012). However, to our knowledge, this is the first demonstration
that f-arrestin 2 is involved in mGluR5-dependent signaling in the hippocampus. An intriguing
implication of this result is that receptor internalization is required for mGluR-mediated ERK
activation and LTD (Figure 4.1 C). This may impose some distinctive qualities onto mGluR-
mediated ERK signaling, providing novel insights into mGluR function and the mechanisms of
mGluR-LTD.
p-arrestin-mediated signaling has several distinct temporal and spatial aspects compared
to traditional G-protein-dependent signaling, and this may influence the nature of mGluR5
coupling to the ERK cascade and protein synthesis machinery. In most cases, G-protein-
dependent ERK activation is rapid and succinct. Peak levels of ERK activity occur within 2
minutes of receptor activation and return to baseline levels by 10 minutes (Ahn et al., 2004).
Conversely, P-arrestin-dependent signaling typically has a slower onset, as it is recruited to
terminate G-protein signaling, and results in more sustained ERK activation (Ahn et al., 2004).
mGluR-LTD is thought to rely on rapid translation of mRNA at the synapse, and it has been
estimated that new protein synthesis is required within minutes of receptor activation (Huber et
al., 2000). The results presented here reveal a deficiency in DHPG-induced ERK activity in as
soon as 5 minutes following mGluR activation, suggesting P-arrestin-dependent ERK activation
is sufficiently rapid to mediate the protein synthesis requirements of mGluR-LTD.
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@-arrestin-dependent ERK signaling is also spatially distinct from its G-protein-
dependent counterpart. ERK activated by G-proteins generally accumulates in the nucleus,
regulating transcription factors such as Elk-I (Tohgo et al., 2002). In contrast, ERK signaling
mediated by f-arrestins is generally excluded from the nucleus and instead confined to the
cytoplasmic compartment (Ahn et al., 2004). This difference in localization likely results in
distinct physiological consequences for ERK activation mediated by f-arrestins compared to G-
proteins. Indeed, overexpression of -arrestins inhibits Gq-dependent Elk-I activation in the
nucleus, while simultaneously enhancing cytosolic ERK signaling (Luttrell et al., 2001). The
restriction of P-arrestin-activated ERK to the cytosol indicates that it is particularly well-placed
to mediate dendritic mRNA translation downstream of mGluR activation. In fact, P-arrestin-
mediated signaling is known to regulate protein synthesis in an ERK-dependent manner (DeWire
et al., 2008). Further experiments will be required to determine if hippocampal mGluR-mediated
S-arrestin signaling follows this same spatially localized pattern. If it does, modulation of f-
arrestin-dependent mGluR signaling may be a way to specifically manipulate the synaptic
protein synthesis required for LTD and implicated in the pathophysiology of ASD.
f-arrestins have been shown to scaffold a wide variety of proteins (Shenoy and
Lefkowitz, 2011). Aside from moderating signal cascades, P-arrestin-mGluR interactions may
regulate additional processes, which may provide some novel insight into the mechanisms of
LTD. As we have demonstrated, there are two independent mechanisms for the expression of
mGluR-LTD: reduced probability of presynaptic glutamate release (Fitzjohn et al., 2001;
Mockett et al., 2011; Nosyreva and Huber, 2005) and reduced expression of postsynaptic AMPA
receptors (Luscher and Huber, 2010; Nosyreva and Huber, 2005). Even within this postsynaptic
LTD there is a further segregation in mechanism. While rapid protein synthesis is required to
stabilize AMPAR internalization, there is an initial endocytosis that is not protein synthesis-
dependent (Snyder et al., 2001). Recent evidence suggests that LTD results in lateral diffusion
of AMPARs that are then internalized from a perisynaptic location (Lu et al., 2007; Petrini et al.,
2009), which is also where mGluRs are most highly expressed (Lujan et al., 1996). It is possible
then that -arrestins may scaffold mGluRs with local AMPARs, thus concurrently internalizing
AMPARs with mGluRs, and thereby regulating both the initial protein synthesis-independent
AMPAR endocytosis as well the subsequent protein synthesis-dependent component via ERK
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activation. Analysis of the mGluR--arrestin complex and associated proteins may help uncover
mechanisms of mGluR-dependent AMPAR internalization yet to be elucidated.
4.4.2 Implications for ASD treatment
Alterations in hippocampal protein synthesis and mGluR-LTD have previously been
utilized to gain insight into the pathophysiology of several mouse models of autism (Auerbach et
al., 2011; Huber et al., 2002; Michalon et al., 2012). In particular, increases in protein synthesis
and LTD downstream of mGluR5 are thought to be pathogenic in Fmr1 KO mice (Chapters 2).
In Chapter 3 we demonstrated there were decreases in these processes in the Tsc2*' mice and,
remarkably, introducing both Fmr] and Tsc2*' mutations restored proper LTD levels (Chapter
3). The LTD phenotype in the Arrb2 mutants is strikingly similar to that previously described in
Tsc2+' mice (Chapter 3), suggesting genetic reduction of Arrb2 levels may be similarly effective
in normalizing mGluR-mediated protein synthesis in Fmr1 KO mice. If this is the case, it is a
strong indicator that P-arrestin 2 signaling may be causally linked to the cellular processes
disrupted in ASD and that manipulation of P-arrestin 2 may be effective at treating the core
disturbances in FX, and possibly other forms of ASD.
GPCRs respond to wide variety of signals and initiate a large number of distinct cellular
signaling pathways. This versatility has made GPCRs an attractive target for pharmacological
therapies, and over 50% of the current drugs used clinically target these receptors (Insel et al.,
2007). The finding that P-arrestin- and G protein-dependent cellular signaling are
pharmacologically separable has important implications for our understanding of GPCR
signaling and the use of GPCR modulators for the treatment of disease. For some disorders, only
one of these two signaling pathways may translate into beneficial physiological effects, while the
other could mediate undesirable outcomes (Shukla et al., 2011). The use of mGluR5 modulators
for the treatment of ASD may be a case in point. Thus, development of functionally selective
(i.e. biased) ligands or allosteric modulators that preferentially target one signaling arm over the
other may result in more refined therapeutic interventions for this disorder.
Evidence from genetic and molecular studies suggests that altered regulation of synaptic
protein synthesis may be a common dysfunction in ASD. One of the most promising
approaches to address this dysfunction in a viable therapeutic manner is the manipulation of
117
118 Chapter 4 -/-arrestin2 signaling mediates mGluR-dependent ERK activation and LTD
mGluR5 signaling (Chapters 2,3). However, there is still a concern that global manipulation of
mGluR5 will affect processes that are unrelated to autism pathophysiology, yielding side effects
that will sharply limit the utility of this approach. The results presented here indicate that
mGluR activation may be coupled to the pathways required for translation in a f-arrestin-
dependent manner. This presents the intriguing possibility that f-arrestin-biased modulation of
mGluR5 may be a way to specifically manipulate the signaling pathways that regulate protein
synthesis without affecting other mGluR-mediated processes that are unrelated to ASD
pathophysiology. There is evidence that mGluR5 allosteric modulators with biased signaling
may already exist (Sheffler et al., 2011), and development could eventually be optimized for
biased modulation, leading to the next generation of selective drugs for the treatment of ASD.
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4.5 Methods
4.5.1 Animals
The Arrb2 mice were a generous gift from the lab of Dr. Lefkowitz. Arrb2- male and female
mutant mice on the C57B1/6J clonal background were bred together to produce the WT, Arrb2*/,
and Arrb2-'~ offspring used in this study. All experimental animals were age-matched male
littermates, and were studied with the experimenter blind to genotype and treatment condition.
Animals were group housed and maintained on a 12:12 hr. light:dark cycle. The Institutional
Animal Care and Use Committee at MIT approved all experimental techniques.
4.5.2 Electrophysiology
Slices were prepared as described previously (Chapter 3). Acute hippocampal slices were
prepared from P28-35 animals in ice-cold dissection buffer containing (in mM): NaCl 87,
Sucrose 75, KCl 2.5, NaH2PO4 1.25, NaHCO3 25, CaCl2 0.5, MgSO4 7, Ascorbic acid 1.3, and
D-glucose 10 (saturated with 95% 02 / 5% C02). Immediately following slicing the CA3 region
was removed. Slices were recovered in artificial cerebrospinal fluid (ACSF) containing (in
mM): NaCl 124, KCl 5, NaH2PO4 1.23, NaHCO3 26, CaCl2 2, MgCl2 1, and D-glucose 10
(saturated with 95% 02/5% C02) at 32.5'C for 3 hours prior to recording.
Field recordings were performed in a submersion chamber, perfused with ACSF (2-3 ml/
min) at 30 *C. Field EPSPs (fEPSPs) were recorded in CAl stratum radiatum with extracellular
electrodes filled with ACSF. Baseline responses were evoked by stimulation of the Schaffer
collaterals at 0.033 Hz with a 2-contact cluster electrode (FHC) using a 0.2 ms stimulus yielding
40-60% of the maximal response. fEPSP recordings were filtered at 0.1 Hz - 1 kHz, digitized at
10 kHz, and analyzed using pClamp9 (Axon Instruments). The initial slope of the response was
used to assess changes in synaptic strength. Data were normalized to the baseline response and
are presented as group means ± SEM. LTD was measured by comparing the average response
55-60 minutes post DHPG application to the average of the last 5 minutes of baseline.
The input output function was examined by stimulating slices with incrementally
increasing current and recording the fEPSP response. Paired pulse facilitation was induced by
applying two pulses at different interstimulus intervals. Facilitation was measured by the ratio of
the fEPSP slope of stimulus 2 to stimulus 1. NMDAR-dependent LTD was induced by
delivering 900 test pulses at 1 Hz. mGluR-LTD was induced by S-Dihydroxyphenylglycine (S-
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DHPG, 25 pM) for 5 minutes, or by delivering 900 pairs of pulses (with a 50 ms interstimulus
interval) at 1 Hz. In order to determine the protein synthesis dependency of mGluR-LTD, slices
were incubated with the protein synthesis inhibitor cycloheximide (60 pM) for at least 10
minutes prior to recording and throughout the entire experiment. The magnitude of LTD was
measured by comparing the average response 55-60 minutes post DHPG/PP-LFS/LFS
application to the average of the last 5 minutes of baseline. Statistical significance for input-
output function, paired-pulse facilitation, and mGluR- or NMDAR-dependent plasticity was
determined by two-way ANOVA and post-hoc Student's t-tests. Statistics were performed using
each animal as one "n", with each animal represented by the mean of 1-4 slices. All experiments
were performed blind to genotype and include interleaved controls for genotype and treatment.
4.5.3 Immunoblotting
Hippocampal slices were prepared and recovered as described above. Sets of slices were
stimulated with DHPG (25 pM) for 5 minutes and then processed either immediately, 15
minutes, or 30 minutes after stimulation. Yoked unstimulated slices were also processed to
assess basal signaling levels. Immunoblotting was performed according to established methods
using primary antibodies to p-ERKl/2 (Thr202/Tyr2O4) (Cell Signaling Technology), ERK1/2
(Cell Signaling Technology), p-Akt (Ser473) (Cell Signaling Technology), Akt (Cell Signaling
Technology), p-mTOR (Ser2448) (Cell Signaling Technology), mTOR (Cell Signaling
Technology), p-p70 s6 kinase (Ser371) (Cell Signaling Technology), and p70 s6 kinase (Cell
Signaling Technology). Protein levels were measured by densitometry (Quantity One), and
quantified as the densitometric signal of phospho-protein divided by the total protein signal in
the same lane. To quantify basal ERK expression, the densitometric signal of ERK was divided
by the total protein signal (determined by Memcode staining) in the same lane. Significance was
determined by a repeated measures two-way ANOVA between time post-DHPG (-5,0,15,30
min) and genotype. All experiments were performed by an experimenter blind to genotype.
4.5.4 Reagents
(S)-3,5-dihydroxyphenylglycine (S-DHPG) was purchased from Sigma (St. Louis, MO).
Fresh bottles of DHPG were prepared as a 1 00x stock in H20, divided into aliquots, and stored at
-80'C. Fresh stocks were made once a week. Cycloheximide (Sigma) was prepared daily at
1 00x stock in H20. All other reagents were purchased from Sigma.
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Figure 4.1 - Activation of mGluR5 leads to divergent signaling cascades. (A) Canonically
mGluR5 is coupled to the pertussis toxin-insensitive G-protein a subunit q/1 1 effector (Gq). Gq
activates the enzyme PLC, leading to cleavage of PIP2 and increases in PKC activity and
intracellular calcium (Ca 2) release, resulting in various cellular processes (see text). (B)
Classical role for $-arrestins. G-protein signaling is terminated by phosphorylation of mGluR5
and the binding of p-arrestins, which promotes interaction with clatherin and subsequent
internalization of receptor. (C) New evidence suggests P-arrestins can also act as scaffold for
signaling molecules and promote activation of distinct signaling cascades independent of G-
protein activation, in particular the ERK pathway. mGluR5-mediated mRNA translation and
long term synaptic depression (LTD) is independent from the Gq-protein pathway and may rely
on $-arrestin-dependent ERK activation. Abbreviations: AMPAR, a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor; DAG, diacylglycerol; ERK, extracellular signal-regulated kinase;
FMRP, fragile X mental retardation protein; GRK, G-protein receptor kinase; GDP, guanosine
diphosphate; GTP, guanine triphosphate; IP3, inositol-1,4,5-triphoshpate; MEK; mitogen activated
protein kinase (MAPK) kinase; mGluR5, metabotropic glutamate receptor; MNK, MAP kinase-
interacting kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C, PLC$,
phospholipase Cp;
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Figure 4.2 - mGluR-mediated ERK phosphorylation is attenuated in Arrb2 mutants.
(A) Hippocampal slices were stimulated with 25 pM DHPG for 5 min, and ERK activation
(pERK/ERK) assessed via immunoblot before stimulation (time 0; WT: 0.90 + 0.08, Arrb2*'~:
0.76 ± 0.06, Arrb2-'~: 0.74 ± 0.07), immediately after DHPG (WT: 1.57 ± 0.14, Arrb2* -: 1.28
0.21, Arrb2~'~: 1.05 ± 0.10), 15 minutes after DHPG (WT: 1.16 ± 0.08, Arrb2*': 0.92 ± 0.09,
Arrb2-1-: 0.82 ± 0.05) and 30 minutes after DHPG (WT: 1.20 ± 0.21, Arrb2: 0.95 ± 0.05, Arrb2~
-: 0.76 ± 0.05; n = 11 for all groups). Two-way repeated measures ANOVA demonstrated there
was a significant effect of genotype (p = 0.031) and time (p < 0.001) but no interaction (p =
0.981). There was a significant difference in pERK between WT and Arrb2~'~ (p = 0.031), WT
and Arrb2*/- (p = 0.05), but not Arrb2*/ and Arrb2~'~ (p = 0.48). A significant increase in pERK
was seen in WT mice at 5 minute (p = 0.002), 15 minutes (p = 0.049) but not 30 minutes (p =
0.164). A significant increase in pERK was seen at 5 minutes in Arrb2/- mice (p = 0.013) but not
atl 5 (p = 0.292) or 30 (0.181) minutes. There was no significant increase in pERK at 5 (p =
0.053), 15 (p = 0.503) or 30 (p = 0.612) minutes in Arrb2-'~ mice. Basal levels of (B) total ERK
(WT: 0.96 ± 0.06, Arrb2*/~: 1.14 ± 0.08, Arrb2~1~: 1.08 ± 0.05) and (C) phospho-ERK (WT: 0.87
± 0.06, Arrb2*/-: 0.85 ± 0.09, Arrb2-/-: 0.90 ± 0.09) were not significantly different. Error bars
represent SEM.
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Figure 4.3 - The Akt-mTOR pathway is not recruited by mGluR activation and is
unaltered in Arrb2 mutants. (A) Hippocampal slices were stimulated with 25 pM DHPG for 5
min, and AKT activation (pAKT/total AKT) assessed via immunoblot before stimulation (time
0; WT: 1.07 ± 0.07, Arrb2*~: 0.89 ± 0.08, Arrb2 ~: 0.88 ± 0.08), immediately after DHPG (WT:
1.23 ± 0.10, Arrb2*~: 0.97 ± 0.08, Arrb2~~: 0.85 ± 0.09), 15 minutes after DHPG (WT: 1.17 ±
0.07, Arrb2'~: 0.85 ± 0.05, Arrb2-1-: 0.93 ± 0.08) and 30 minutes after DHPG (WT: 0.99 ± 0.07,
Arrb2/- : 0.85 ± 0.08, Arrb2-1-: 1.10 ± 0.12; n = 11 for all groups). Two-way repeated measures
ANOVA demonstrated there was no significant effect of genotype (p = 0.137) or time (p =
0.737) and no interaction (p = 0.233). (B) Hippocampal slices were stimulated with 25 gM
DHPG for 5 min, and mTOR activation (p-mTOR/total mTOR) assessed via immunoblot before
stimulation (time 0; WT: 0.90 ± 0.07, Arrb2 ': 0.99 ± 0.05, Arrb2~': 0.86 ± 0.06), immediately
after DHPG (WT: 1.07 ±0.09, Arrb2+1-: 1.03 ± 0.06, Arrb2-i-: 0.85 ± 0.06), 15 minutes after
DHPG (WT: 1.15 ± 0.06, Arrb2*/~: 1.16 ± 0.06, Arrb2-'-: 0.96 ± 0.04) and 30 minutes after
DHPG (WT: 1.02 ± 0.10, Arrb2*/-: 1.10 ± 0.10, Arrb2~'~: 0.91 ± 0.10; n = 11 for all groups). A
two-way repeated measures ANOVA demonstrated there was a significant effect of genotype (p
= 0.024) but not time (p = 0.054) and no interaction (p = 0.835). While there was a significant
difference between Arrb2*'- and Arrb2-' mice (p =0.034), there was no difference in WT and Arrb2-
/_ (p = 0.063) or Arrb2*/- (p = 0.508). (C) Hippocampal slices were stimulated with 25 gM DHPG
for 5 min, and p70 activation (phosphor-p70/ total p70) assessed via immunoblot before
stimulation (time 0; WT: 0.88 ± 0.12, Arrb2*/~: 1.02 ± 0.11, Arrb2-/-: 1.08 ± 0.13), immediately
after DHPG (WT: 0.90 ± 0.08, Arrb2+/: 0.98 ± 0.04, Arrb2'~: 1.13 + 0.11), 15 minutes after
DHPG (WT: 1.02 ± 0.10, Arrb2*/~: 0.94 ± 0.10, Arrb2~'~: 1.07± 0.15) and 30 minutes after
DHPG (WT: 0.95 ± 0.14, Arrb2*/~: 1.00 ± 0.104, Arrb2~'~: 0.87 ± 0.12; n = 7 for all groups).
Two-way repeated measures ANOVA demonstrated there was no significant effect of genotype
(p = 0.712) or time (p = 0.604) and no interaction (p = 0.705). Error bars represent SEM.
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Figure 4.4 - Loss of the protein synthesis-dependent component of mGluR-LTD in Arrb2
mutants. (A) LTD is significantly attenuated by pretreatment with the protein synthesis
inhibitor cycloheximide (CHX, 60 pM) in slices from WT animals (control: 63.0 + 1.9%, n = 13
animals; CHX: 84.1 ± 3.0%, n = 7 animals; *p < 0.001). (B) CHX treatment has no effect on
DHPG-LTD in slices from Arrb2+' mice (control: 74.1 ± 3.1%, n = 12 animals; CHX: 76.0 ±
3.7%, n = 11 animals; p = 0.719). (C) CHX treatment has no effect on DHPG-LTD in slices
from Arrb2-/- mice (control: 80.8 ± 7.3%, n = 10 animals; CHX: 84.6 ± 3.6%, n = 7 animals; p =
0.1.03). (D) DHPG-induced LTD is significantly decreased in Arrb2 mutants (ANOVA:
genotype *p = 0.02, treatment p = 0.002, genotype x treatment p = 0.06; WT vs. Arrb2*/- p =
0.075, WT vs. Arrb2-/- p = 0.008). Bar graphs represent the average percent LTD observed 55-60
minutes post DHPG. Representative field potential traces (average of 10 sweeps) were taken at
times indicated by numerals. Scale bars equal 0.5 mV, 5 ms. Error bars represent SEM.
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Figure 4.5 - Normal basal synaptic function and NMDAR-dependent LTD in Arrb2
mutants. (A) Basal synaptic transmission (plotted as fEPSP amplitude against presynaptic fiber
volley amplitude) does not differ between genotypes. Scale bars equal 0.5 mV, 20 ms for
representative field potential traces. (B) Paired pulse facilitation is normal across several inter-
stimulus intervals (20, 30, 50, 100, 200, 300, 500 ms) in Arrb2 mutants. Scale bars equal 0.5
mV, 20 ms. (C) The magnitude of NMDA receptor-dependent LTD evoked by low frequency
stimulation (LFS, 900 pulses at 1 Hz) does not differ between genotypes (WT: 83.9 ± 3.5%, n =
6 animals; Arrb2/-: 87.9 ± 0.4%, n = 8 animals; A rrb2*/~: 87.2 ± 0.5%, n = 8 animals p = 0.610).
Representative field potential traces (average of 10 sweeps) were taken at times indicated by
numerals. Scales bars equal 0.5 mV, 5 ms. Error bars represent SEM.
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5.1 Introduction
Our understanding of the etiology of autism has greatly evolved since the disorder was
first described by Kanner in the 1940s (Kanner and Eisenberg, 1957). While researchers
originally believed that autism resulted from emotional deprivation in infancy, it is now
appreciated that autism is a biological disorder rooted in genetic perturbations. Despite this
advance, the clinical heterogeneity and complex genetics of autism spectrum disorder (ASD) has
made it difficult to untangle its underlying pathophysiology. Many questions remain about the
nature of ASD, and there is still disagreement as to whether autism should be considered a large
set of related disorders with diverse mechanisms (Geschwind and Levitt, 2007) or a single
disorder with a common dysfunction at the cellular or systems level that is variably expressed
(Kelleher and Bear, 2008). However, recent evidence from human genetic studies and animal
models has converged on synaptic dysfunction as the core of ASD pathology (Gilman et al.,
2011; Spooren et al., 2012; Zoghbi, 2003; Zoghbi and Bear, 2012).
While there are undoubtedly many ways for this dysfunction to arise, as evidenced by the
hundreds of gene implicated in ASD (Betancur, 2011), it has been proposed here that
dysregulation of synaptic protein synthesis may be a common cellular mechanism underlying
ASD (Kelleher and Bear, 2008). The studies in this thesis were designed to examine the
contribution of synaptic protein synthesis to the pathogenesis of ASD by examining the mouse
models of fragile X (FX) and tuberous sclerosis complex (TSC), the two most common inherited
causes as ASD. Surprisingly, we found the synaptic pathophysiology of TSC and FX to be
mirror images of one another (Figure 3.6A). These results suggest that bidirectional deviations
in neuronal protein synthesis may be associated with ASD. This not only supports the general
notion that proper synaptic function requires a fine balance of local protein synthesis, but it
demonstrates that disruptions in either direction can lead to overlapping behavioral phenotypes.
The direction of the dysfunction may matter less, with respect to symptomatology, than the fact
that this process has been pushed outside its optimal range. While bidirectional changes in gene
dosage have previously been associated with autism (Christian et al., 2008; Okamoto et al., 2007;
Vandewalle et al., 2009), this is the first demonstration, to our knowledge, of genetically
heterogeneous causes of ASD resulting from opposing alterations at the molecular level. Major
questions remain as to how these changes in protein synthesis arise, and where these opposing
alterations may converge to result in the complex phenotypes associated with ASD.
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5.2 Contribution of mGluRs to the synaptic pathophysiology of autism
While there are many signals that can mediate mRNA translation, we have examined
protein synthesis through the lens of group 1 (Gp 1) mGluRs, particularly mGluR5, the
predominant subtype in the forebrain and hippocampus (Masu et al., 1991). We view the role of
mGluRs in the synaptic pathophysiology of ASD as threefold: (1) mGluR-LTD is a sensitive
assay for interrogating the status of synaptic protein synthesis in animal models of ASD; (2) the
mGluR5 receptor is a potent modulator of synaptic protein synthesis and therefore well situated
to be a target for the treatment of ASD; and (3) the downstream proteins regulated by mGluRs
may specifically be central to ASD pathology.
Two assays have greatly aided our examination of the role of neuronal protein synthesis
in animal models of ASD: metabolic labeling and mGluR-LTD. Biochemical measurement of
metabolically labeled amino acid incorporation into acutely-prepared brains slices provides a
direct measure of protein synthesis rates. However, the assay does not distinguish somatic verses
dendritic translation and lacks information on the functional consequences of these changes.
Electrophysiological measurements of mGluR-mediated LTD, on the other hand, is by no means
a direct measure of protein synthesis, but it is known to require rapid local translation of pre-
existing mRNA at the synapse (Huber et al., 2000). Thus, mGluR-LTD could be considered a
sensitive tool for monitoring changes specifically in local dendritic translation.
The studies in this thesis indicate that examination of mGluR-LTD is indeed a reliable
indicator of altered protein synthesis. We have shown that Fmr1 KO and Tsc2+' mice have
opposing alterations in basal hippocampal protein synthesis rates, and this is reflected in their
levels of mGluR-LTD (Chapter 3). Furthermore, treatments that modify LTD in these animals
also restore proper protein synthesis levels, suggesting that the two are causally linked. These
complimentary assays are simple but reliable tools for examining alterations in synaptic protein
synthesis. Their use can be extended in future studies to other mouse models of ASD, thereby
allowing us to determine the prevalence of dysregulated synaptic protein synthesis in the
disorder.
Not only are mGluRs a sensitive tool for monitoring synaptic protein synthesis but they
are also a potential way to manipulate translation. mGluR5 is a robust activator of local protein
synthesis (Job and Eberwine, 2001; Weiler and Greenough, 1993) that is widely expressed
throughout the brain (Masu et al., 1991). Moreover, the mGlu5 receptor is particularly amenable
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to pharmacological manipulation with a well-developed class of allosteric modulators that
regulate its activity in a subtype specific and activity-dependent manner (Sheffler et al., 2011).
Studies in the mouse models of FX and TSC have already demonstrated the potential for
allosteric modulators of mGluR5 in the treatment of ASD. For example, a diverse array of
mutant phenotypes in FX animal models have now been corrected by pharmacological inhibition
of mGluR5 (Michalon et al., 2012). Similarly, in Chapter 3 we demonstrated that augmenting
mGluR5 in Tsc2+' mice rescues deficits at the biochemical, electrophysiological and behavioral
levels. In Chapter 4, we illustrated the potential to specifically modulate synaptic protein
synthesis downstream of mGluR5 activation, via P-arrestins, without affecting other mGluR5-
mediated processes. Thus it may be possible to develop mGluR5-based therapies that are not
only physiologically responsive, but also specific to the processes thought to underlie many
forms of synaptic pathophysiology in ASD.
The above evidence demonstrates that controlling mGluR activity is a method for both
monitoring and manipulating synaptic protein synthesis. However, mGluR-mediated protein
synthesis may be specifically disrupted in several forms of ASD. There is considerable support
for the notion that dysregulation of mGluR-dependent protein synthesis is central to the
pathogenesis of FX (Bhakar et al., 2012). In many ways, it is remarkable that simply reducing
the activity of mGluR5 can have such a profound effect on the constellation of symptoms
associated with FX. However, mGluR-mediated plasticity is prominent in many brains areas
associated with ASD, and in many cases this plasticity requires rapid protein synthesis for its
maintenance (Luscher and Huber, 2010). In Chapter 2, we demonstrated that multiple
consequences of mGluR-dependent protein synthesis are altered in Fmr1 KO mice, even within
the same population of synapses. Therefore, disruption of mGluR-mediated protein synthesis
will likely have diverse consequences across many brain regions. Indeed, modulation of
mGluR5 function has been shown to reverse phenotypes in many brain regions in FX, and has
even proved beneficial in processes where mGluR activity had previously not been implicated
(Dolen et al., 2007; Hays et al., 2011).
Disruption in mGluR function is not limited to FX, however. We have shown that
mGluR-LTD and protein synthesis are disrupted in both Fmr1 KO mice and in a mouse model of
TSC, suggesting that genetically heterogeneous causes of ASD may lead to disrupted mGluR
function (Chapter 3). Indeed, mGluR dysfunction has now been demonstrated in numerous
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other animal models of ASD as well (Bangash et al., 2011; Baudouin et al., 2012; Chen et al.,
2011; Phelan and McDermid, 2012). Interestingly, the genes disrupted in many of these animal
models are involved with scaffolding mGluRs at the synapse, suggesting that both upstream
regulation of mGluRs and the downstream signaling pathways mediated by mGluRs are
associated with ASD. Consistent with these animal studies, human genetic data has shown many
genes involved in the regulation of mGluR-mediated protein synthesis are associated with ASD,
including the gene for mGluR5 itself (Iossifov et al., 2012; Kelleher Iii et al., 2012). Thus,
multiple lines of evidence suggest that mGluR-mediated protein synthesis is a common
molecular pathway disrupted in ASD.
As was described above, mGluR-LTD is sensitive to alterations in synaptic protein
synthesis. Therefore, it is also possible that altered mGluR function in some animal models of
ASD is a consequence of dysregulated synaptic protein synthesis by other mechanisms, rather
than a cause of dysregulation. Many animal models of ASD associated with disrupted mGluR
function exhibit alterations in AMPAR and NMDAR function as well (Bangash et al., 2011;
Bozdagi et al., 2010; Ehninger et al., 2008a; Lee et al., 2011; Lee et al., 2008; Won et al., 2012),
which may also contribute to deviations in synaptic protein synthesis. Even in FX, where
evidence for the pathogenic nature of mGluR5 is most abundant, mGluR activation is unlikely to
be the only avenue by which synaptic protein synthesis is disrupted. For example, removal of
FMRP occludes TrkB-mediated increases in protein synthesis (Osterweil et al., 2010) and alters
other forms of G-protein-coupled receptor (GPCR)-mediated protein synthesis-dependent
plasticity (Connor et al., 2011; Volk et al., 2007). Therefore it is likely that multiple signaling
pathways can converge to regulate synaptic protein synthesis.
However, as discussed below, neuronal translation is not a uniform entity. There may be
specific subsets of mRNA whose translation is relevant to the synaptic pathophysiology of ASD.
While mGluRs are not the only way to regulate mRNA translation, the set of proteins controlled
by mGluR activation may be particularly important to the pathophysiology of ASD,
demonstrated by the fact that they are regulated by both FMRP and TSC 1/2. While the breadth
of proteins involved in ASD remains to be characterized, examination of mGluR-dependent
processes is clearly a useful approach to understanding its synaptic pathophysiology.
Furthermore, regulation of mGluR5 may be a way to specifically regulate the pool of proteins
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implicated in ASD, and therefore is a promising therapeutic avenue for the treatment of this
disorder.
5.3 Regulating protein synthesis at the synapse
It has long been known that the synthesis of new proteins is essential for both neuronal
function and memory formation (Kandel, 2001 a). However, the idea that mRNA translation
could be compartmentalized in neurons was not realized until the observation of polyribosomes
in spines by Steward and Levy in 1982 (Steward and Levy, 1982). mRNA localization is an
elegant mechanism for spatially restricting gene expression within the neuron, facilitating rapid
responses at stimulated synapses while confining biochemical changes to a specific
compartment. This compartmentalization therefore allows for multiple layers of control.
However, with this increased control comes increased complexity. While it is now widely
accepted that many mRNAs localize to dendrites, and that local translation of this dendritic
mRNA contributes to many forms of plasticity, major questions remain. For example, it is
unclear how synaptic activity regulates dendritic translation and how this local translation is
delineated from somatic transcription and translation. Moreover, the identities of the mRNA
preferentially translated at the synapse and the functions they may serve have yet to be fully
defined. The studies in this thesis begin to elucidate the potential mechanisms for the differential
regulation of translation in neurons and define the purposes they may serve.
5.3.1 Somatic verses synaptic translation
The ERK and mTOR pathways are implicated in both translational and transcriptional
regulation (Kandel, 2001b; Richter and Klann, 2009; Sweatt, 2004), and it has been difficult to
determine how activation of these pathways can differentially regulate synaptic and somatic
processes (Kelleher et al., 2004). A recent study demonstrated that BDNF-dependent ERK
activation may regulate translation in a compartment-specific manner, as it was shown to
specifically activate eIF4E in synaptic fractions while only phosphorylating eEF2 in the cell
body (Kanhema et al., 2006). The mTOR pathway has also been shown to undergo compartment
specific activation (Belelovsky et al., 2005). Thus, activity-dependent regulation of the
translational machinery may be spatially restricted by sequestering signaling cascades into
particular subcellular compartments. P-arrestin-mediated signaling is an attractive mechanism
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for mediating spatially segregated ERK activation downstream of mGluR5. In Chapter 4, we
demonstrated that mGluR-mediated ERK activation requires f-arrestin2. A defining
characteristic of P-arrestin-dependent signaling is that it is restricted to the cytosol and does not
translocate to the nucleus (Luttrell et al., 200 1). Thus, mGluR-dependent ERK signaling may be
restrained to the dendritic compartment, thereby specifically regulating local protein synthesis at
the synapse.
Another way to selectively isolate translation to a specific compartment is by localizing
mRNA-specific translational repressors, such as FMRP. Evidence suggests that FMRP may be
required for the regulation of dendritic but not somatic translation; multiple forms of plasticity
dependent upon local translation are altered in Fmr1 KO mice (Huber et al., 2002) (Chapter 2),
while transcription-dependent forms are not (Godfraind et al., 1996; Paradee et al., 1999).
Consistent with this idea, a recent study found that while removal of FMRP resulted in increased
levels of Arc protein in hippocampal dendrites, there was actually a slight decrease in Arc levels
in the soma (Niere et al., 2012). This suggests that FMRP's role in the nucleus may be different
than its role at the synapse. While mTOR signaling has been shown to specifically regulate
dendritic translation, it also has important functions in the nucleus (Hay and Sonenberg, 2004).
Thus, while removal of FMRP may specifically alter dendritic protein synthesis, removal of Tsc2
is likely to affect somatic and synaptic function.
5.3.2 Multiple pools of mRNA are differentially translated in neurons
The results presented here indicate there is a dichotomy in the signaling pathways that
regulate neuronal protein synthesis. While the ERK and mTOR pathways are generally thought
to stimulate protein synthesis in parallel, or even synergistically (Banko et al., 2006), we found
that activation of these pathways can have contrasting effects on hippocampal protein synthesis
and plasticity. Specifically, removal of Fmr1 results in excessive protein synthesis and LTD
downstream of mGluR5-ERK signaling, while enhancing mTOR signaling by decreasing Tsc2
levels results in diminished protein synthesis and LTD (Figure 3.6A). How can activation of the
pathways that mediate global translation have such disparate effects on neuronal protein
synthesis and protein synthesis-dependent plasticity? In Chapter 3 we proposed that the
regulation of translation requires temporal precision and disruption of this activity-dependent
timing may lead to unexpected consequences (Figure 3.7A). As discussed above,
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compartmentalization of these signaling cascades to distinct cellular domains may result in
differential regulation of cellular and synaptic processes. Most interestingly, we have discussed
the possibility that the ERK and mTOR pathways may regulate the translation of different pools
of proteins whose expression is mutually exclusive (Figure 3.7B).
While both the ERK and mTOR pathways are known to regulate global translation rates,
there is also ample evidence demonstrating their involvement in gene-specific translation
(Gkogkas et al., 2010). Emerging evidence suggests that gene-specific regulation of translation
may be particularly important for proper neuronal function, potentially as a mechanism for
delineating between synaptic and somatic processes (Pfeiffer and Huber, 2006). As discussed in
Chapter 3, there are multiple mechanisms by which this differential translation can be achieved.
However, the most straightforward explanation for the mutually inhibitory effects of mTOR and
ERK on translation may simply be competition for a finite resource.
Although difficult to quantify, electron microscopic studies indicate that the number of
ribosomes at individual synapses is quite limited (Ostroff et al., 2002). As activated
polyribosomes typically translate a single mRNA, at most one or two mRNAs are being
translated at the synapse at any given time (Schuman et al., 2006). Indeed, recent functional data
has suggested that competition for translation machinery may be the rate-limiting step for protein
synthesis-dependent plasticity (Fonseca et al., 2004). In fact, experiments in which late-phase
LTP (L-LTP) is induced at a single spine have shown there is competition between two adjacent
stimulated spines within a dendritic branch (Govindarajan et al., 2011). Thus, the limiting factor
for dendritic translation may be the availability of translational machinery. Under these
conditions, increasing initiation probability via the ERK or mTOR pathway will likely not
increase overall translational capacity. However, it may be possible to qualitatively alter the
nature of the synthesis by modifying aspects of the translational machinery, such as eIF2a or
eEF2 (see Chapter 3). Thus, the differential effects on protein synthesis and plasticity exerted by
the ERK and mTOR pathways may be explained by their altering the preference of limited
translational resources from one pool to another.
More work is required to dissect the distinct contributions of the ERK and mTOR
pathways to synaptic function, and how alterations in these pathways may contribute to the
pathogenesis of ASD. One thing is certain, however: the regulation of protein synthesis is
complicated. Due to this complexity, there are important caveats to the study of protein
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synthesis regulation. It is critical to realize that manipulating different aspects of the
translational pathway may yield varying results depending on the cellular and experimental
context in which they are performed. This is particularly relevant when attempting to translate
observations made in mitotic cells to neurons, where the function of protein synthesis is
markedly different. The Fmr1 KO x Tsc2 cross line may provide a unique opportunity to
study the subtleties associated with protein synthesis regulation in the brain, as they allow for
examination of mutations that result in opposite changes in neuronal protein synthesis in
littermate mice under identical experimental conditions.
5.3.3 Identifying the two pools
The results presented in this thesis suggest that dysregulation of a specific set of proteins,
rather than global translation, is critical to the synaptic pathophysiology of ASD. A major
obstacle to our understanding of the role of synaptic protein synthesis in ASD pathophysiology is
identification of the proteins that are dysregulated. Specifically, determining which proteins are
under control of the TSC 1/2-mTOR and ERK-FMRP pathways will be instrumental to our
understanding of the different functions these two pathways may serve. We have suggested that
the protein Arc may be a prototypical member of the FMRP pool (Chapter 2). Arc mRNA is
present in dendrites where it is rapidly translated on demand (Shepherd and Bear, 2011). It has
been shown to be a target of FMRP (Zalfa et al., 2003) and dendritic expression of this protein is
increased in Fmr1 KO mice (Niere et al., 2012). Furthermore, Arc is required for the expression
of mGluR-LTD, and decreasing Arc levels in the Fmr1 KO mouse reverses their LTD phenotype
(Park et al., 2008; Waung et al., 2008). In Chapter 3, we demonstrated that there is diminished
Arc synthesis in the Tsc2+' mouse, suggesting that this protein is bidirectionally regulated by
FMRP and TSC1/2. The divergence in ERK- and mTOR-dependent regulation of Arc is further
demonstrated by a study examining the mechanism for LTP consolidation in the dentate gyrus
(Panja et al., 2009), where it was shown that the maintenance of L-LTP requires ERK-dependent
synthesis of Arc. Interestingly, while LTP stimulation also recruited the mTOR pathway, it was
completely dispensable for the maintenance of L-LTP (Panja et al., 2009), supporting a dominant
role for ERK signaling in the regulation of Arc.
Emerging evidence suggests that the neuroligin family of proteins may be potential
targets of the mTOR pool. A recent study examined the consequences of excessive eIF4E
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activity by overexpressing eIF4E or knocking out 4E-BP2, a specific inhibitor of eIF4E (Figure
1.2A). Inhibition of 4E-BP2 is a major function of the mTOR pathway (Figure 1.2A), thus
excessive eIF4E activity is likely to have similar functional consequence to chronic activation of
the mTOR pathway as seen in Tsc2* -mice. Consistent with our findings (Chapter 3), excessive
eIF4E activity does not result in an overall increase in protein synthesis rates ((Gkogkas et al.,
2013) but see (Santini et al., 2013)). However, examination of candidate proteins revealed that
there was a specific increase in the synthesis of neuroligins. Mice with excessive eIF4E activity
also displayed autistic phenotypes similar to those found in Tsc2*/- mice (Young et al., 2010),
which could be rescued by decreasing neuroligin 1 levels (Gkogkas et al., 2013). Furthermore,
the authors found that a reporter gene fused to the 5' UTR of Nlgni was better translated in cells
with excessive mTOR signaling (Pten~' or Tsc2 KO cells) similar to those with increased eIF4E
activity. Thus, while mTOR suppresses the synthesis of proteins downstream of mGluR5
activation, e.g. Arc, it stimulates translation of other proteins associated with autism, namely the
neuroligins.
Two other recent studies have demonstrated that neuroligins may act to suppress the
mGluR-ERK pool. First, it was shown that deletion of Nlgn3 results in excessive mGluR-LTD
in the cerebellum, suggesting that decreases in neuroligin may promote mGluR function and the
expression of LTD. Consistent with this notion, a second study found that neuroligin 1 levels
are reduced in the hippocampus and cerebellum of Fmr1 KO mice, and overexpression of Nlgn1
specifically rescues social deficits in the Fmr1 KO mouse (Dahlhaus and El-Husseini, 2010).
Thus, neuroligins may be differentially regulated by mGluR5 and mTOR in the opposite manner
than Arc. This suggests these proteins exist in separate pools and once again demonstrates the
bidirectional modification of proteins associated with ASD.
The idea that mTOR signaling can regulate the synthesis of neuroligins may clarify the
plasticity phenotypes seen in Tsc2*' mice. The Neuroligin-Shank complex is important for the
anchoring of NMDAR and mGluRs at the synapse (Figure 1.1). Despite this mutual interaction,
it seems that disruption of this complex affects NMDAR- and mGluR-mediated plasticity in
opposite directions. Deletion of neuroligins in mice results in decreased NMDAR responses and
plasticity (Budreck et al., 2013; Sudhof, 2008) but excessive mGluR function (Baudouin et al.,
2012). Likewise, a Shank3 mutation associated with ASD that results in a 90% decrease in
Shank3 levels in hippocampus leads to deficient NMDAR-LTP and LTD but enhanced mGluR-
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LTD (Bangash et al., 2011). Furthermore, deletion of SAPAP3, which mediates the interaction
between neuroligins and Shanks, also results in excessive mGluR5 signaling (Wan et al., 2011).
Why does disrupting this synaptic scaffolding complex result in opposing regulation of mGluRs
and NMDARs? Results from our p-arrestin study suggest that receptor internalization may be
required for mGluR-mediated signaling and LTD (Chapter 4). Thus, decreasing mGluR
association with the synaptic membrane may actually increase mGluR-mediated plasticity by
making it more readily internalized by P-arrestin. It is interesting to speculate that there may be
increased neuroligin expression in Tsc2*/- mice, leading to enhanced retention of NMDA and
mGlu receptors at the synapse, which results in exaggerated NMDAR-LTP but deficient mGluR-
LTD.
The above examples demonstrate how identification of the proteins dysregulated in
models of ASD may lead to a better understanding of how synaptic function is disrupted in the
disorder. However, it is unlikely that there are only one or two global "plasticity proteins" -
multiple proteins likely regulate different processes in parallel. Ideally, unbiased screens to
examine the protein make-up of synapses in mouse models of ASD will illuminate the processes
essential for proper synaptic function and those that may be disrupted in autism. To date, these
efforts have been hindered by variability and replicability of experimental results. Comparison
of the Fmr1 KO x Tsc2+' cross mice may add another layer of validity to these studies, as
proteins that are increased in one mutant, decreased in the other, but normalized in the double
mutants are likely to be central to the synaptic processes associated with ASD.
5.3.4 Functional distinction between ERK and m TOR regulated protein synthesis
Proper neuronal function requires synaptic strength to be maintained within an optimal
functional range (Figure 3.6A) and this necessitates mechanisms to prevent runaway LTP/LTD.
It has been proposed that synapses can modulate the threshold for the induction of plasticity
based upon their previous history of activity (Abraham and Bear, 1996). This metaplasticity is a
potential way to maintain an optimal range of synaptic strength. There are many examples of
reciprocal interactions between the proteins associated with ASD, and it is intriguing to speculate
that these proteins may represent a network required for synaptic metaplasticity. For example,
we suggested above that neuroligin expression may differentially regulate LTP and LTD. It has
also been shown that surface levels of neuroligin 1 are bidirectionally altered by the induction of
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LTD or LTP (Schapitz et al., 2010). Indeed, many of the structural proteins involved in
regulating glutamate receptor function are also themselves regulated by activation of these
receptors (Ehlers, 2003). Many targets of FMRP have been shown to be parts of the translation
machinery or involved in the signaling pathways that mediate protein synthesis as well (Darnell
et al., 2011).
These structural and signaling proteins may form a self-regulating complex that is
constantly assessing synaptic function and directing local translation in order to appropriately
constrain synaptic strength within its functional range, potentially by regulating the threshold for
LTP and LTD (Bienenstock et al., 1982). Specifically, we have proposed that there are two
pools of proteins that regulate synaptic function in an opposite manner: an mGluR-ERK pool
required for synaptic weakening (e.g. Arc) and a TSC1/2-mTOR pool required for synaptic
strengthening (e.g. Neuroligins). It is easy to imagine that if either of these opposing constraints
is lost, the result is an imbalance in synaptic strength and disruption of neuronal function.
While we have proposed that the mTOR and ERK pathways are differentially activated
and have divergent functions in neurons, it has been shown that mGluR activation can recruit
both of these pathways, begging the question as to how this divergence is achieved. It is possible
that different types of mGluR stimulation can activate different pathways. We discussed in
Chapter 2 that while mGluR-LTD and LTP priming share a requirement for local translation, the
upstream mechanisms are distinct. We suggested that the qualitative nature of mGluR
stimulation received may determine LTP vs. LTD. Likewise, different stimulation paradigms
may determine if the ERK or mTOR pathway is preferentially activated. The fact that mGluR-
mediated ERK activation and LTD may require f-arrestin-dependent internalization of the mGlu
receptor suggests that strong activation is required for mGluR-LTD. Prolonged weak activation
may preferentially recruit the mTOR pathway via Homer interactions, leading to the synthesis of
LTP proteins. Support for this hypothesis comes from the fact that inhibition of mTOR with
rapamycin prevents mGluR-dependent enhancement of LTP with a priming-like stimulus
(Cammalleri et al., 2003), while it does not disrupt mGluR-LTD, at least in our hands (Figure
3.4). Thus, the strength and duration of mGluR stimulation may preferentially evoke different
signaling pathways resulting in opposite changes in synaptic strength. Differences in overall
activity levels may also alter which pathway is preferentially activated. These experimental
differences may contribute to the conflicting results in the literature.
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5.4 Synaptic pathophysiology beyond post-synaptic protein synthesis
Several lines of evidence point to synaptic dysfunction in the pathophysiology of ASD.
The results presented here demonstrate that altered dendritic protein synthesis may be a major
contributor to this dysfunction, however it is unlikely the only player. While proper post-
synaptic regulation of translation is clearly important, there are many other processes that
regulate synaptic function. Recent evidence has suggested that protein homeostasis, i.e.
maintaining proper synaptic protein levels, is important for synaptic function and plasticity
(Cajigas et al., 2010). Consistent with the role of protein synthesis in ASD, several studies have
reported many genes that are risk factors for ASD involve the ubiquitin proteasome system that
regulates protein degradation (Glessner et al., 2009). The role of the proteasome system in ASD
is most directly demonstrated in Angelman syndrome, as mutations in UBE3A, an E3 ubiquitin
ligase, are thought to be responsible for this disorder (Kishino et al., 1997). Ubiquitination
involves activating enzymes (E l), conjugating enzymes (E2), and ligases (E3). Ligation of
ubiquitin to a protein directs it to be degraded, and substrate specificity is usually provided by
the E3 ligases (Hochstrasser, 1995). Interestingly, a major target of Ube3a in neurons is Arc and
deletion of Ube3a results in increased Arc levels at the synapse (Greer et al., 2010). Thus,
alterations in synaptic protein synthesis and degradation associated with ASD may converge on
the same protein targets.
The proteasome system is also required for the induction of mGluR-LTD and rapid
degradation of FMRP is thought to be a potential mechanism for the de-repression of protein
synthesis downstream of mGluR5 activation (Hou et al., 2006). Furthermore, proteasome
activation has also been shown to regulate a form of mTOR-dependent local translation (Briz et
al., 2013). This suggests that there is a reciprocal relationship between mRNA translation and
protein degradation - dysregulating one may lead to compensatory changes in the other. Rather
than there being an optimal level of synaptic protein synthesis per se, it may be that proper
synaptic function requires an optimal level of proteins at the synapse, which can be disrupted by
altering either translation or degradation. Compensatory changes in the proteasome system in
response to alterations in protein synthesis, or vice versa, may be just as crucial to the
pathophysiology of ASD as the primary dysfunction itself.
Just as coordination between translation and degradation is required for optimal protein
levels at the synapse, proper synaptic function also involves the coordination between pre-
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synaptic and post-synaptic processes. Studies of neurexins and neuroligins have demonstrated
that coordinated pre- and post-synaptic function is crucial for proper synaptic transmission, and
that this coordination may be disturbed in ASD. Several studies have shown that many FMRP
targets encode presynaptic proteins (Bassell and Warren, 2008; Brown et al., 2001; Darnell et al.,
2011), and axonal projections and presynaptic function are altered in Fmr1 KO mice (Bureau et
al., 2008; Hanson and Madison, 2007). The results from a recent study using a novel high
throughput cross-linking immunoprecipitation (HITS-CLIP) assay to identify FMRP targets is
particularly illuminating (Darnell et al., 2011). Over 800 mRNA binding targets of FMRP were
identified and interestingly, presynaptic targets for FMRP were found to be just as numerous as
postsynaptic targets. The TSC1/2 complex has been shown to regulate axon formation as well,
and there are aberrant axonal projections and abnormal growth cone collapse in Tsc21- mice
(Choi et al., 2008). This suggests that presynaptic disruptions are also likely to contribute to the
pathogenesis of both FX and TSC. In fact, several proteins related to axonal growth and synapse
formation have now been identified as potential risk factors for ASD (Alarcon et al., 2008;
Morrow et al., 2008; Wang et al., 2009; Weiss et al., 2009).
While the evidence for local protein synthesis in axons or axon terminals in the mature
nervous system is still sparse, recent studies have demonstrated that during early axon
development and synapse formation local protein synthesis plays an important role in pathway
and target selection (Akins et al., 2009; Jung et al., 2012). Thus, dysregulation of local protein
synthesis may disrupt presynaptic development as well as postsynaptic plasticity, with the
combination resulting in the altered synaptic function and connectivity characteristic of ASD.
Furthermore, mRNA profiling of regenerating sensory axons has revealed that the accumulation
of specific mRNAs in axons can be increased or decreased in response to different ligands
(Willis et al., 2007). Therefore, the protein population of pre-synaptic inputs may be
bidirectionally modifiable in a similar manner as post-synaptic inputs.
5.5 Synaptic dysfunction in relation to the autistic phenotype
Genetic and molecular studies have made great strides in identifying synaptic dysfunction
as a common pathology in ASD, and this has led to potential therapeutic targets. However,
connecting this synaptic pathology to the complex behavioral phenotypes of ASD remains a
significant challenge. We have demonstrated that there is an optimal range of protein synthesis
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for synaptic function and that deviations too far in either direction are detrimental. While this in
itself may not be entirely surprising, the fact that these bidirectional alterations can lead to
similar cognitive and behavioral dysfunction was certainly unexpected. This suggests a
convergence of these opposing alterations on a common function or process, and highlights the
need to examine circuit-level disturbances that may unify these opposing synaptic disruptions.
The work in this thesis has focused on the hippocampus because it is a model system for
the study of synaptic plasticity and essential for memory and cognition. However, disruptions
associated with autism are by no means limited to this area. Indeed, alterations in synaptic
plasticity are present in many brain regions in the Fmr1 KO mouse (Pfeiffer and Huber, 2009).
A recent intriguing study demonstrated that specifically deleting Tsc1 in the cerebellum resulted
in several social behavior deficits, demonstrating the importance of this brain area to the autistic
phenotype (Tsai et al., 2012). Many genes implicated in autism have complex expression
patterns and therefore may have different effects on different brain regions. An extreme example
is Angelman syndrome, where the UBE3A gene is maternally imprinted resulting in a very
discrete deletion pattern (Kishino et al., 1997). Thus, disruption of the genes associated with
ASD may occur in a complex temporal and spatial pattern, which likely contributes to the
heterogeneity of the autistic phenotype.
It is tempting to speculate that certain regions may be involved with specific aspects of
the ASD phenotype, for example: the hippocampus and cognitive/learning deficits; the striatum
and stereotyped behavior; the amygdala and emotional responsiveness; the cerebellum and
motor/gait disruption; and primary cortical areas and aberrant sensory processing. However,
uncovering the social brain has remained elusive. It is likely that coordinated activity between a
network of brain regions is required for the interpretation of complex stimuli that underlies social
interaction.
Cognitive and executive functions are thought to rely on the coordinated interactions of a
large number of neurons that are distributed within and across different specialized brain areas.
Neurophysiological studies have demonstrated that local synchronization of high frequency brain
oscillations within a brain area, and global synchrony between brain regions, may be important
for this coordination (Uhlhaas and Singer, 2006). It is interesting to speculate that alterations in
the synchronization of neural activity may impair communication between brain regions, and it
has been suggested that decreased functional connectivity between brain areas may contribute to
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the cognitive and behavioral deficits associated with ASD (Geschwind and Levitt, 2007).
Supporting this notion, numerous human studies using fMRI and MEG have found altered
synchrony in the brains of people with autism, (Cherkassky et al., 2006; Damarla et al., 2010;
Just et al., 2004; Khan et al., 2013; Villalobos et al., 2005). Interestingly, alterations in neuronal
synchrony have recently been recapitulated in several mouse models of ASD (Penagarikano et
al., 2007; Zhang et al., 2008), which will allow for dissection of the underlying cellular process
that may contribute to this disruption in functional connectivity.
Alterations in the ratio of cellular excitation to inhibition (E/I balance) is thought to
regulate neural synchrony (Sohal et al., 2009; Yizhar et al., 2011), and it has been suggested that
disruption in E/I balance may a common pathology in ASD (Gogolla et al., 2009; Rubenstein,
2010; Rubenstein and Merzenich, 2003). Indeed, a recent study has demonstrated that enhancing
the E/I ratio in the cortex of mice is sufficient to both alter neuronal oscillations and disrupt
social behavior, demonstrating a connection between these processes (Yizhar et al., 2011).
Many mouse models of ASD exhibit alterations to excitatory and/or inhibitory synaptic strength
(Dani et al., 2005; Etherton et al., 2009; Gibson et al., 2008; Gkogkas et al., 2013; Tabuchi et al.,
2007). Interestingly, many of the mutations that disrupt synaptic protein synthesis also result in
changes in cellular excitation (Bateup et al., 2011; Gibson et al., 2008; Gkogkas et al., 2013),
suggesting that alterations in synaptic protein synthesis can lead to changes in connectivity and
vise versa.
The maintenance of a healthy E/I balance requires synaptic strength to be maintained
within an optimal functional range. Above we discussed the possibility that the proteins
dysregulated in ASD may provide an architecture for maintaining this functional range. Thus,
disrupting the balance of synaptic protein synthesis in either direction may lead to an imbalance
in the E/I ratio, subsequently disrupting functional connectivity between brain regions and
impairing the cognitive processes required for complex behaviors like language and social
interaction. A more thorough examination of E/I balance and neural synchrony in animal models
of ASD, and their relation to previously defined synaptic alterations, is required to determine
how synaptic dysfunction may be related to the behavioral phenotypes associated with ASD.
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5.6 Concluding remarks
Two technical advances have been instrumental in advancing our understanding of the
pathophysiology of ASD: (1) large-scale genomic sequencing that has identified potential risk
factors for the disorder; and (2) genetic engineering that has allowed researchers to model these
genetic disruptions in animals. The last decade has seen a marked increase in data addressing the
genetic nature of ASD and literally hundreds of genes have been identified as potential risk
factors (Abrahams and Geschwind, 2008; Betancur, 2011). These studies have provided a
framework for identifying the molecular pathways that may be associated with ASD.
Furthermore, they have provided targets that can be modeled in animal systems in order to
determine the molecular and cellular underpinnings of ASD.
This thesis directly compared animal models of ASD resulting from distinct genetic
mutations with the motivation of finding an underlying connection in the molecular and cellular
basis of ASD. The data presented here has demonstrated that synaptic protein synthesis,
particularly downstream of mGluR5 activation, may be a common pathology in ASD.
Specifically, we have shown that there are bidirectional deviations in synaptic protein synthesis
in the mouse models of FX and TSC, the two leading inherited causes of ASD (Figure 3.6a).
However, there are several additional animal models of ASD that have disruptions in the ERK
and mTOR pathways. It will be illuminating to determine where these other models of ASD lie
on this axis of synaptic protein synthesis (Figure 5.1).
Based on the results described here, animal models characterized by excessive mTOR
signaling, like those with Pten mutations, would be predicted to display a similar phenotype to
the Tsc2*/- mice. Conversely, those characterized by excessive ERK signaling, like the NF1J/-
mouse, would phenocopy Fmr1 KO mice. If alterations in synaptic protein synthesis and LTD
are indeed found in other animal models of ASD, it would provide further evidence that this is a
shared synaptic disruption in ASD and will elucidate potential therapeutic strategies.
Interestingly, decreasing ERK signaling with the Ras inhibitor lovastatin has been shown to be
beneficial in both the NF1]/~ (Li et al., 2005) and Fmr1 KO mice (Osterweil et al., 2013).
Likewise, rapamycin treatment has been shown to reverse several cellular and behavioral
phenotypes in both Tsc2*/- and Pten+/- mice (Ehninger et al., 2008a; Zhou et al., 2009). It will be
informative to determine the effect of mGluR modulation in these other animal models to
determine the scope of this therapeutic approach.
l148
Chapter 5 - Implications and future directions
While germ line mutations in ASD-related genes best model the human disorders, it is
difficult to distinguish between synaptic disruptions that cause altered brain function and those
that are consequences of altered brain development in these animal models. While both are
important for understanding disease pathophysiology, it is likely that treatments targeting the
primary pathogenic cause(s) of synaptic dysfunction will be more efficacious. A case in point
may be the excessive mTOR signaling that has been demonstrated under certain conditions in the
Fmr1 KO mouse. While this would suggest that inhibition of mTOR is a potential therapy for
FX, the results presented here suggest the contrary, as a disease characterized by excess mTOR
activity (the Tsc21- mouse) displayed opposite phenotypes from the Fmr1 KO mouse.
Furthermore, increasing mTOR signaling by decreasing Tsc2 levels in the Fmr] KO mice
ameliorated both synaptic and behavioral phenotypes.
It is important to exercise caution when attempting to translate cellular phenotypes in
animal models into clinical therapies. Two things must be considered. First, while acute
manipulation of ASD associated genes may not replicate the disorder as well as germ line
mutations, it is still a useful tool for dissociating the primary pathogenic deficits from secondary
or compensatory consequences. To this end, acute deletion of Fmr1 has been shown to result in
exaggerated LTD, and acute re-expression of FMRP rescues this exaggeration in the Fmr1 KO
mouse (Zeier et al., 2009). Acute deletion of Tsc1 has likewise been shown to result in deficient
LTD (Bateup et al., 2011).
Secondly, the consequences of any cellular or molecular phenotypes in animal models of
ASD should be validated at the behavioral level before extrapolating to drug therapies.
However, it is important to remember that a mouse brain is not a human brain. Deletions of
ASD-associated genes in mice are not likely to lead to the same cognitive phenotypes as they do
in humans. Despite this, it is likely that these disruptions will have some effect on animal
behavior, making behavioral examination still important, particularly for determining the
potential efficacy of treatments. Moreover, though the behavioral manifestations in animal
models of ASD may not recapitulate the phenotypes seen in humans, it is likely that the effect of
these mutations at the cellular and circuit levels will be similar. Determining how synaptic
dysfunction may converge at the circuit and system levels, guided by the knowledge gained from
genetic and molecular studies, is required to develop a complete understanding of
pathophysiology of ASD.
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WT
Angelman?
Synaptic protein synthesis
Figure 5.1 - Defining an axis of synaptic pathophysiology in autism. The research in this
thesis has indicated that an optimal synaptic function requires a narrow and tightly regulated
level of synaptic protein synthesis, and that deviations of protein synthesis in either direction can
impair function. Here we have demonstrated that impaired functions in FX caused by excessive
local protein synthesis can be corrected by a negative allosteric modulator (NAM) of mGluR5.
On the other hand, impaired function in TSC caused by reduced local protein synthesis can be
restored by an mGluR5 PAM. Future studies will be required to determine the extent to which
dysregulated synaptic protein synthesis is associated with other models of ASD and the
effectiveness of mGluR modulators in ameliorating synaptic and behavioral disruptions in these
animal models.
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